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According to the most recent clinical diagnostic criteria published by the Movement Dis-
orders Society in 2015, Parkinson’s disease (PD) is primarily diagnosed by the presence of 
at least three cardinal motor manifestations: bradykinesia, rigidity and rest tremor.1 It is the 
second-most common neurodegenerative disease, roughly twice as prevalent in men than 
women, and affects approximately 1-3% of individuals above 60 years of age.2, 3 Its prevalence 
is expected to grow substantially as the incidence of PD increases steeply at higher age and 
people are increasingly exposed to environmental toxins (a known risk factor).4 James Par-
kinson already described the bradykinesia and rest tremor of PD in his essay on the ‘Shaking 
Palsy’, while also stating “the senses and intellects being uninjured”.5 Now, more than two 
centuries later, research has shown that this statement is incorrect: PD causes a plethora of 
non-motor features including autonomic and olfactory dysfunction, sleep disorders, psychiat-
ric disorders and cognitive impairment.2 While the presence of non-motor features does not 
formally add to the diagnostic criteria of PD, these features are highly common,6 are associat-
ed with additional disease burden7 and can even precede the onset of the motor symptoms.8 
There are large inter-individual differences in symptomatology and while individuals with PD 
can often successfully manage their symptoms for a long time, the capricious disease course 
prompts uncertainty about individual prognosis.
The exact cause of PD is still unknown. The typical motor symptoms – but also some of the 
non-motor symptoms – are due to dysfunction in dopamine-dependent circuits linking the 
basal ganglia, thalamus and cortex, caused by loss of dopamine-producing cells in the sub-
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stantia nigra that project towards the striatum.9 Neuronal death in PD is associated with Lewy 
pathology that follows an ascending pattern through the brain. In early, premotor stages of 
PD, this process starts deep in the brainstem (i.e., dorsal nucleus of the vagus nerve).10 Re-
cent findings have suggested that the pathology even originates from the gut,11, 12 potentially 
explaining the gastrointestinal and autonomic symptoms that often precede motor features. 
The disease slowly ascends through the brain reaching associative and primary neocortical 
areas in final stages of the disease, negatively impacting the brain on as close as all imagin-
able levels. As yet, these pathological hallmarks are not identifiable in-vivo and a definitive 
PD diagnosis can only be made post-mortem. The widespread pathology associated with PD, 
affecting multiple neurotransmitter systems and brain atrophy, is a sensible explanation for 
the fact that PD is not only a movement disorder, but also significantly affects the intellect. 
Cognition and cognitive decline in Parkinson’s disease
Epidemiology of cognitive impairment in PD. ‘Injury of the intellects’ – or rather, cognitive 
impairment – is already present in about 15-24% individuals with newly-diagnosed PD13-15 and 
becomes apparent in virtually every patient at some stage of the disease. Cognitive impair-
ment with spared, independent activities of daily living is often categorized as ‘mild cognitive 
impairment’ (PD-MCI).16, 17 PD-MCI is considered a precursor of dementia, predicts cognitive 
decline and is diagnosed in about 27% of PD patients without dementia.16, 18 The decline of 
cognitive function is relatively modest in the earliest stages of PD and can react adequately to 
commencing dopamine therapy, but accelerates as the disease progresses.19 
Ultimately, the large majority of PD patients will develop PD dementia (PD-D) – clinically de-
fined as severe cognitive impairment in multiple domains with a significant impact on daily 
functioning.20 Famous prospective studies such as the Sydney multi-center study (20-y fol-
low-up) and Norwegian studies by the Aarsland group (8-12-y follow-up) support this notion by 
reporting cumulative PD-D prevalences of 60-83% in surviving participants.21-23 The point prev-
alence of PD-D is approximately 30% with an estimated average of ten years until the onset 
of PD-D.20, 24 Risk factors for cognitive decline in PD include clinical and demographic factors, 
such as older age,25-27 male sex,26, 27 more severe motor symptoms,26 psychotic symptoms28 
and REM sleep behavior disorder.27 Other neuroimaging and genetic markers include slowing 
of oscillatory brain activity,29, 30 decreased caudal dopaminergic deficits,30 and carrying at least 
one apolipoprotein E gene (APOE) ε2 or ε4 allele.31 
The cognitive profile of PD. The cognitive impairments associated with PD are generally 
observed in the executive function domain (i.e., inhibition and switching, working memory 
and sustained and selective attention),32 and on mental speed, episodic memory and visuo-
spatial function.33, 34 The cognitive profile of PD is typically seen as a ‘subcortical’ syndrome, 
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SPECT is a nuclear imaging method used to 
record the gamma rays that are emitted by 
intravenously administered radioactive tracers. 
Specific tracers can be attached to substances 
that bind to (specific) receptors, transporters 
or enzymes. In PD, the radiotracer 123I-N-ω-flu-
oropropyl-2β-carbomethoxy-3β-(4-iodophenyl)
nortropane (123I-FP-CIT) is frequently used in PD 
as it has high affinity for the dopamine trans-
porter in striatal areas and can as such provide 
a reliable estimate of the nigrostriatal dopamine 
system integrity. Figure 1a shows an axial slice 
of a SPECT scan in a healthy participant, with 
high intensity binding in striatal areas (caudate 
nucleus and putamen) suggesting adequate 
integrity of the nigrostriatal dopaminergic path-
ways.
Box 1 Neuroimaging methodology
Magnetic resonance imaging (sMRI) portrays 
the anatomy of the brain using a magnetic field 
that makes protons in the body emit energy, 
which is picked up by the MRI device. Func-
tional MRI (fMRI) is a specific MRI sequence that 
images the hemodynamic response of brain ar-
eas by using a blood-oxygen-level-dependent 
(BOLD) contrast, which is thought to reflect the 
energy use of brain cells. Task-related fMRI par-
adigms map brain activity during task perfor-
mance, which is often contrasted to a baseline 
condition. For example, the brain activity during 
performance of a planning task is contrasted 
with a simple counting task to identify brain 
areas responsible for the execution of the spe-
cific task. Resting-state procedures measure 
spontaneous brain activity at rest to determine 
functional connectivity: the temporal coherence 
of the BOLD signal in two (or more) brain re-
gions. At rest, the spontaneous activity of the 
brain is organized in large-scale networks of 
brain areas that are synchronously active or at 
rest. Figure 1b shows a widely-accepted sev-
en-network parcellation of the human cortex 
by Yeo and colleagues, that we used in our 
analyses.70
Figure 1b Parcellation of the human cerebral 
cortex on the basis of resting-state networks.
Dark purple: visual; blue: somatomotor; red: de-
fault mode; orange: frontoparietal; green: dorsal 
attention; light purple: ventral attention.
Figure 1a Axial slice of a SPECT scan in a 
healthy individual.
Single-photon emission computed tomography (SPECT)




The brain can be viewed as a network 
(‘graph’) of brain regions (‘nodes’) with recipro-
cal connections (‘edges’; see Figure 1c). This 
complex network approach can be applied to 
structural and functional neuroimaging data 
and thus transcends the imaging modality. 
The analysis of graphs ranges from analysis 
of nodal characteristics to the global topology 
of the graph (see Figure 1d). Nodal charac-
teristics for example include the number of 
connections that a certain brain region has: 
the degree. Global topology can for instance 
be objectified by its efficiency or clustering. 
The global efficiency of a network quantifies 
the integration of information processing in 
the network; if all nodes are connected, inte-
gration is maximal. However, as this would not 
be cost-effective, biological graphs are often 
organized into sub-networks, or modules, that 
are densely intra-connected and sparsely in-
ter-connected. This balance between integra-
tion and segregation is called a ‘small-world 
organization’. Complex network analysis has 
the advantage of analyzing the full information 
of the brain network and its indices have reli-
able behavioral associations.71
Functional magnetic resonance imaging (fMRI)
Figure 1c Schematic image of the brain as a 





Figure 1d Graphic representation of a graph 
with nodes and edges. Networks tend to be 
clustered, into modules. Shorter average paths 
between nodes indicate higher efficiency 
(acknowledgment: J.F. Stormmesand).
Box 1 Neuroimaging methodology
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with predominantly the aforementioned deficits combined with relatively intact language and 
praxis function.33, 35 Notably, in the episodic memory domain PD significantly differs from more 
cortically based diseases such as Alzheimer’s disease: the ability to learn and recollect is gen-
erally slightly less impaired – but still significantly affected – and recognition memory remains 
relatively intact.36 
This typical profile is, however, too simplistic as individuals with PD show considerable in-
ter-individual heterogeneity in the specific impairments and their onset, severity and rate of 
decline.37-40 While cognitive heterogeneity in PD is widely accepted, there is no consensus 
on the cognitive profiles yet. One hypothesis proposes that patients with mainly executive 
dysfunction have a more favorable disease course compared with patients that show ‘poste-
rior cortical’ deficits, i.e., mnemonic, visuospatial and semantic fluency deficits, reminiscent of 
Alzheimer’s disease.41 Patients that have the non-tremor-dominant subtype of PD42 or postural 
instability and gait dysfunction43 are suggested to experience more severe cognitive impair-
ment and have a worse prognosis compared with patients with the tremor-dominant subtype 
(see Table 1).43 More detailed studies are needed to unravel the cognitive profiles of PD, as 
the variability in expression and rate of progression of cognitive impairments in PD complicate 
accurate diagnosis and provoke significant uncertainty for individuals diagnosed with PD.
Neuroimaging and PD-related cognitive impairment. Neuroimaging studies have provided 
comprehensive knowledge about the neural deficiencies associated with PD-related cogni-
tive impairment. Studies have first focused on the influence of dopaminergic disruption on 
cortico-striato-thalamo-cortical (CSTC) circuits because of the significance of the dopamine 
system in the motor symptomatology of PD. The attention has broadened to other aspects of 
neurodegeneration, including gray matter atrophy, structural and functional connectivity, and 
– more recently - the topology of the brain as a complex network (for a brief description of 








Poor response to dopamine replacement therapy
Mild non-motor symptoms 
Relatively low risk of developing PD-D
Postural instability and gait dysfunction
Fast disease progression
More severe non-motor symptoms
Relatively high risk of developing PD-D
Late-onset with rapid disease progres-
sion
Rapid disease progression
Relatively spared cognitive function
This table shows a suggested overview of clinical (motor) subtypes of PD and their clinical and cognitive 
correlates that are frequently reported.44, 45 Still, there is no consensus on this division and it only partly 
explains the complex and heterogeneous clinical picture of PD.
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neuroimaging methodologies, see Box 1). A schematic overview of important neural changes 
associated with cognitive impairment in PD is shown in Figure 2.
Neuronal cell death in the substantia nigra pars compacta leads to dopamine deficiencies that 
are associated with dysfunction of large-scale brain networks, including cortico-subcortical 
circuits and frontoparietal and default mode networks.46, 47 Communication in the cortico-stria-
to-thalamo-cortical (CSTC) circuits, which encompass connections between (pre-)frontal brain 
regions, the striatum and the thalamus, is impaired in PD. The executive function deficits in PD 
are likely related to associative CSTC circuit disruption, as this disruption leads to hypo-exci-
tation of the dorsolateral prefrontal cortex.47, 48 In addition, other cognitive deficits in inhibitory 
functions and motivation are associated with CSTC circuits connecting the orbitofrontal cortex 
and anterior cingulate cortex to more ventral parts of the striatum.49, 50 Experimental studies 
have indeed shown that the degeneration of the striatal dopamine system in PD, specifically 
parts that are connected with ‘associative’ prefrontal brain areas, correlate with cognitive 
dysfunction.51-53 Task-based functional MRI studies in these mainly dopamine-regulated areas 
have additionally suggested that in early stages of PD compensatory regional hyper-activity 
of frontal brain regions seems to sustain intact function,54, 55 but with more pronounced pathol-






Figure 2 A schematic overview of neuroimaging findings related to cognitive dysfunction in PD. In green, 
the associative part of the cortico-striato-thalamo-cortical loop is shown, with projections from the substan-
tia nigra (SN) to striatal and thalamic areas. In yellow, frontoparietal connections are shown with emphasis 
on the importance of the dorsolateral prefrontal cortex and inferior parietal cortex. In these areas, PD 
patients, compared with healthy controls, showed functional brain alterations during task performance and 
rest. The red areas show cortical brain regions that show atrophy already in early stages of PD.
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Deficiencies in other neurotransmitter systems, including acetylcholine,58 serotonin59 and 
noradrenaline,60 are prevalent in PD. Degeneration of the cholinergic system is significant 
in PD and can even surpass degeneration as observed in Alzheimer’s disease.61 Cholinergic 
dysfunction is associated with attention deficits, fluctuations in vigilance, visuospatial im-
pairment and memory deficits.62 The noradrenergic deficiencies mainly relate to attention 
deficits.62 While serotonergic deficits are present in PD and amongst others relate to motor 
complications and affective symptoms in PD, there is still little research on their role in cogni-
tive impairment.63
Magnetic resonance imaging (MRI) studies have yielded evidence that there is progressive 
atrophy along the continuum of cognitive decline in PD, with subtle early-stage cortical thin-
ning in parietal and temporal regions – even preceding cognitive decline – to diffuse marked 
atrophy in final stages of the disease, also affecting hippocampal and amygdalar volumes.64, 65 
Intrinsic functional brain networks , that are dependent on multiple neurotransmitter systems, 
encompass reliable and clinically relevant patterns of functional brain communication and 
show deficits in PD. The default mode network – the most frequently studied resting-state 
network that is related to self-referential processing – is disrupted in PD.66, 67 Moreover, poorer 
cognitive function is associated with reduced segregation of the default mode network with 
‘task-positive’ networks, i.e., the frontoparietal and salience networks.68, 69 
Graph analysis is a relatively novel method to study the brain at the macroscopic level as a 
large network of brain regions (nodes) and connections (edges). The topology of the brain, 
i.e., the organization and arrangement of the brain network, can be quantified by measures 
of e.g. integration and segregation that are shown to be reliably associated with behavior.72, 
73 Cognitive impairment in PD is associated with decreased efficiency of the network,74, 75 re-
organization of highly connected brain regions,74, 76 more random network organization,77 and 
decreased strength of nodal connections.78 
All in all, cognitive decline is highly prevalent in PD and is associated with neurotransmitter 
deficiencies, ascending atrophy and disruption of brain networks. Cognitive decline can 
cause significant worry in individuals that are diagnosed with PD. The associated mental bur-
den for the patients and their caregivers and the increasing health care costs79, 80 emphasize 
the importance of accurate diagnosis, reliable prognosis, and the development of adequate 




Treatment options of cognitive decline in PD
Pharmacological treatment options. Levodopa, the gold standard for the treatment of mo-
tor symptoms,2 targets cortico-striato-thalamo-cortical circuits and can thereby improve the 
mental slowing and rigidity that is often seen in newly diagnosed individuals with PD.19 Studies 
have, however, also shown adverse effects of levodopa on other (executive) functions such 
as reversal learning, because of a hypothesized dopaminergic ‘overload’ in relatively unaf-
fected striatal regions.81, 82 Currently, the acetylcholinesterase inhibitor rivastigmine is the only 
evidence-based treatment for dementia in PD.19, 83, 84 It is accepted by the U.S. Food and Drug 
Administration specifically for PD-D and included in the Dutch multidisciplinary guidelines for 
the treatment of PD-D. Still, there is individual heterogeneity in the response to rivastigmine84 
and it can have considerable side-effects.83 The focus of pharmacological management of 
cognitive impairment is broadening to earlier stages of PD with one large randomized con-
trolled trial showing potential of the acetylcholinesterase inhibitor donepezil,85 whereas other 
agents, like monoamine oxidase B inhibitors, do not seem efficacious.86, 87 PD patients often 
already take substantial amounts of medication for both PD- and aging-related health issues, 
which complicates adequate symptom management.88, 89 Non-pharmacological treatment 
options would therefore provide an interesting alternative.
Non-pharmacological interventions. The latest Dutch multidisciplinary guidelines for the 
treatment of cognitive dysfunction in PD list cognitive training (CT) as an intervention to con-
sider based on meta-analytic findings.90 CT is a component of neuropsychological rehabili-
tation with the focus on improving cognitive impairment or adapting to cope with it. Physical 
exercise and non-invasive brain stimulation are other non-pharmacological treatment options 
for cognitive impairment in PD.91 These non-pharmacological interventions are thought to 
make use of (positive) neuroplasticity to enhance the resilience of the brain and may thus be 
able to improve cognitive function and delay decline.92, 93 
Results from several small studies support the potential of these therapeutic modalities,90, 
94-98 but to date no robust evidence from large-scale trials is available. Aggregated findings 
from small clinical studies have indicated that CT can have small to moderate positive effects 
on cognitive function.90 Two studies have even suggested that CT may delay cognitive de-
cline.99, 100 These effects mimic positive findings in multiple sclerosis,101 Alzheimer’s disease,102 
and traumatic brain injury.103, 104 The evidence is, however, mainly based on small studies with 
methodological limitations. Besides, there is considerable debate on the ‘far transfer’ of CT 
effects,105 as there is – as of yet – little evidence for positive effects on function in activities of 
daily life.100, 106-109
CT is hypothesized to induce neuroplastic effects that may compensate or restore brain 
damage, even in elderly people, where neuroplasticity is likely reduced. Neuroplastic effects 
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due to cognitive engagement are widely accepted: for example, food-storing birds show 
hippocampal growth during autumn and winter potentially as a consequence of storing food 
and the cognitive demands related to it (e.g., remembering the hiding spots).110 A well-known 
example in humans is the ‘London taxi driver effect’, an observational study that showed 
larger posterior hippocampi in London taxi drivers, presumably caused by repeated training 
because of the exceptional navigational requirements of their work.111 Ever since, studies have 
tried to extrapolate these effects to CT in healthy and clinical populations.
In PD, exploratory neuroimaging studies revealed that CT paradigms can enhance functional 
connections within cognitive resting-state networks112, 113 and alter functional activity during 
in-scanner task performance.112, 114 Studies in other neurodegenerative diseases and healthy 
aging have additionally reported that CT is associated with increases in cortical thickness,115, 
116 brain region volume,117, 118 cerebral blood flow,119-121 structural connectivity,119, 122 and structural 
and functional brain topology.115, 123-125 It is therefore likely that CT can affect cognitive function 
and alter the brain’s structure and function, yet evidence from robust, large-scale randomized 
clinical trials is lacking. Moreover, the exact underlying mechanisms of the observed effects 
are still largely unknown.
Thesis aims
In this thesis, we aimed 1) to improve our understanding of (the heterogeneity of) cognitive 
impairment in PD and 2) to investigate a non-pharmacological intervention for its treatment. 
We used clinical (primarily neuropsychological) assessments to profile cognitive impairment in 
PD and applied neuroimaging methods to gain more insight in the underlying neural network 
processes. The first part of this thesis presents two studies that aimed to assess cognitive 
impairment and its heterogeneity in a cohort of PD patients that were elaborately assessed 
at the Amsterdam UMC (location VUmc) movement disorders outpatient clinic. In the second 
part of this thesis, we present studies we undertook to obtain more insight into the efficacy 
and working mechanisms of CT. By means of the studies described in this thesis we aimed to 
answer the following research questions.
What are the clinical subtypes of cognitive dysfunction in PD? In chapter 2, our research goal 
was to study the cognitive heterogeneity and its association with neuropsychiatric symptoms 
in a cohort of PD patients from the Amsterdam UMC (location VUmc) movement disorders 
outpatient clinic. Earlier studies on the heterogeneity of PD already provided valuable infor-
mation about motor symptom subtypes or a ‘dual-syndrome’ model of cognitive impairment. 
We used a data-driven analysis method to evaluate the clinical heterogeneity of a combina-
tion of motor symptoms, neuropsychological function and neuropsychiatric symptoms. 
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What is the contribution of striatal dopamine and extra-striatal serotonin integrity to cognitive 
impairment in PD? To gain more insight in the involvement of the dopaminergic and seroto-
nergic systems in PD-related cognitive impairment, we analyzed the association between 
the integrity of these neurotransmitter systems and cognitive function in the same cohort of 
patients (chapter 3). We hypothesized a positive association between striatal dopamine in-
tegrity and executive function and attention, and a positive association between thalamic and 
hippocampal serotonin integrity, and memory and attention. We used Single Photon Emission 
Computed Tomography (SPECT) combined with the radiotracer 123I-N-ω-fluoropropyl-2β-car-
bomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT). This radiotracer combined with SPECT 
can provide a proxy for dopaminergic integrity mainly in striatal areas. In extra-striatal areas, 
this imaging technique can be used to assess integrity of the serotonin system by its affinity 
for the serotonin transporter in extra-striatal areas such as the thalamus and hippocampus.
What is the effect of cognitive training on cognitive function in PD? As there is increasing 
evidence from small, sub-optimally designed trials for the efficacy of CT in PD, yet evidence 
from large, robustly designed trials is lacking, we performed a randomized clinical trial to an-
swer this research question: the COGnitive Training In Parkinson Study (COGTIPS). In chapter 
5, we present the design of this trial involving 140 PD patients with significant subjective cog-
nitive complaints. Chapter 6 describes the results of the primary and secondary clinical RCT 
outcomes. Seventy participants in this study underwent eight weeks of home-based, online 
cognitive training, three times per week for 45 minutes. We compared this group to seventy 
participants that received an active control intervention, to control for non-specific cognitive 
activity and test-retest effects. We hypothesized that CT 1) would improve executive function, 
2) would decrease subjective cognitive complaints, and 3) effects would persist after six-
months follow-up.
What are the effects of cognitive training on brain network function and its topology? In 
chapter 4, we provide a systematic overview of studies that used fMRI to assess function-
al changes induced by CT in healthy aging and neurodegenerative diseases. As cognitive 
decline in healthy aging and neurodegenerative diseases are both associated with marked 
brain network changes, we summarized the effects of CT in this context. We additionally 
aimed to assess whether the effects of CT are dependent on the study population – i.e., dis-
ease-specificity – and whether different CT programs would induce differential effects – i.e., 
intervention-specificity. In Chapter 7, we present the effects that our COGTIPS CT program 
had on brain network connectivity and topology. A subset of the full COGTIPS population, 
i.e., 80 participants, underwent resting-state fMRI. We hypothesized that CT would 1) enhance 
anti-correlations between cognitive resting-state networks, 2) enhance efficiency of the brain 
network and 3) increase the segregation within the network. 
23
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In chapter 8, we integrate the findings of the studies we performed and discuss the scientific 
and clinical implications of our study results. In addition, we discuss our studies’ limitations 
and make recommendations for future research.
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Abstract
Background. Parkinson’s disease (PD) is a highly heterogeneous disease, in which motor 
symptom subtypes are often-described. While it is recognized that motor, cognitive and affec-
tive neuropsychiatric symptoms negatively influence the patients’ quality of life, it is currently 
unknown how these symptoms contribute to phenotypic subtypes. The objective of this study 
was to assess subtypes of motor, cognitive and affective symptoms in PD.
Methods. A hierarchical cluster analysis was conducted on clinical data of 226 PD patients 
screened at the VU University Medical Center using comprehensive assessment of cognitive, 
affective and motor symptoms. Subsequent linear discriminant analyses were conducted to 
investigate discriminating constructs between clusters. 
Results. The cluster analysis yielded four clusters: (1) a young-age (59.9 years), mildly affected 
cluster (N = 86), (2) an old-age (72.3 years) cluster with severe motor and non-motor symp-
toms (N = 15), (3) a cluster (age 64.7 years) with mild motor symptoms, below-average execu-
tive functioning and affective symptoms (N = 46) and (4) a cluster (age 64.8 years) with severe 
motor symptoms, affective symptoms and below-average verbal memory (N = 79). 
Conclusions. Cluster 1 and 2 seem to represent opposite ends of the PD disease stages. 
Patients in clusters 3 and 4 had similar age, educational level and disease duration but differ-
ent symptom profiles – we therefore suggest that these clusters represent different pathways 
of disease progression, presumably with distinct underlying pathology localization. Future 
research on the neuropathophysiological characteristics of these two clusters and monitoring 
of disease progression is required.
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Introduction
In the past fifteen years, there has been increased interest in identifying subtypes of Parkin-
son’s disease (PD) and understanding the heterogeneity in clinical symptoms.1, 2 Data-driven 
studies in longitudinal cohorts have identified subtypes of PD,3, 4 even in the early stages of 
the disease.5 Studies into subtypes of cognitive and neuropsychiatric symptoms in PD are 
scarce, however, despite a large variability in the presence of cognitive and neuropsychiatric 
disorders in PD.2, 6, 7 Furthermore, these symptoms have a particularly high impact on patients’ 
quality of life.8 Although cognitive status and neuropsychiatric symptoms are greatly inter-
twined in the general population,9 the exact relation between these symptoms in PD has still 
be to unraveled. Only an association between psychotic symptoms and the presence of more 
severe global cognitive dysfunction, including memory impairment has been reported fre-
quently.7, 10, 11
Previous studies have distinguished varying clusters. In general, neuropsychiatric symptoms 
seem to be more prevalent in the non-tremor-dominant subtype of PD.12 A cluster analysis on 
cognitive characteristics reported three clusters with increasing severity of cognitive impair-
ment, varying from no or minimal impairment to cognitive impairment across most cognitive 
domains.13 Two patterns of executive dysfunction – i.e. attentional control versus abstract 
reasoning – were identified by Kudlicka and colleagues in patients with mild to moderate PD 
(Hoehn and Yahr stages I-III).14 In addition, a subgroup with specifically attention, visuospatial 
and logical memory impairment was distinguished from a subgroup with general impaired 
cognition and a PD dementia subgroup by Liepelt-Scarfone and colleagues.15 However, these 
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studies did not assess the relationship between cognitive subtypes and neuropsychiatric 
symptoms.
Given the limitations described above, our aim was to identify symptom profiles in PD patients 
using a data-driven approach, that not only includes the motor characteristics but also de-
tailed information on cognitive functioning and neuropsychiatric symptoms. We aim to relate 
profiles of specific cognitive deficits to neuropsychiatric symptoms, principally affective symp-
toms (i.e. anxiety and depression). 
Methods
Patients. For the analyses described in this report, we used data obtained in 226 consec-
utive patients who were referred to the outpatient clinic for movement disorders of the VU 
University Medical Center (Amsterdam, The Netherlands) between May 2008 and June 2014. 
As part of routine clinical practice patients were assessed using a clinical neurological exam-
ination, an elaborate neuropsychological assessment, and neuropsychiatric and behavioral 
questionnaires. Patients were diagnosed clinically with idiopathic PD by movement disorders 
specialists (H.B. & E.F.). Inclusion criteria were 1) diagnosis of idiopathic PD according to the 
United Kingdom Parkinson’s Disease Society Brain Bank criteria, 2) written informed con-
sent of the patient to use their clinical data for scientific purposes, and 3) a complete set of 
neurological, neuropsychological, and neuropsychiatric variables after imputation selected 
for cluster analysis (see Statistical Analysis). This study was approved by the medical ethical 
committee of the VU University Medical Center.
Measurement Instruments. Some measurements were used for the clustering procedure and 
some for post-hoc analyses only. Multicollinearity, ceiling performances, limited variation in 
scores and non-continuous measurement scale impaired the ability to include more measures 
in the cluster analysis (see Statistical analysis for more detail).  
Cluster analysis measurements: Measurements used in the cluster analysis assessed motor 
symptoms, cognitive function, and affective symptoms. Neuropsychological instruments were 
administered by trained neuropsychology students or professionals. Motor symptom severity 
was assessed in the “ON” medication state (if applicable) by trained residents in neurology 
using the Unified Parkinson’s Disease Rating Scale (UPDRS)-III. Neuropsychological tasks 
assessed a wide range of cognitive domains. Global cognitive functioning: Mini-mental State 
Examination (MMSE). Executive functions/working memory: the Stroop interference measure 
(color-word task time corrected for color-only time), the Trail Making Task (TMT) task B time 
corrected for task A time (B | A), and the backwards digit span subtest of the Wechsler Adult 
Intelligence Scale (WAIS)-III. Episodic memory: the 15-minute delayed recall of a 15-word list 
learning task (15WT – Dutch version of the Rey Auditory Verbal Learning Test). The Beck Anx-
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iety Inventory (BAI) for anxiety symptoms was the only neuropsychiatric symptom measure in 
the cluster analysis.
Post-hoc analyses measurements: Disease duration was computed by subtracting the subjec-
tive age at disease onset - the age at which the patient first noticed signs of motor symptoms 
related to PD, retrospectively - from age at testing. Educational level was measured by the 
Dutch ‘Verhage’ education scale, which ranges from 1 (minimum; primary school not finished) 
to 7 (maximum; university education and higher). Disease stage was measured by the Hoehn 
& Yahr (H&Y) scale. The UPDRS was divided in three averaged subscores: a tremor score 
(item 16, 20, and 21), a hypokinesia/rigidity score (item 22 and 31) and a postural instability/
gait disorder (PIGD) score (item 13, 14, 15, 29, and 30).12 Dopaminergic medication use was 
transformed to the ‘levodopa equivalent daily dosage’ (LEDD), as described elsewhere.16 
Neuropsychological measures used for post-hoc analyses are described in the Supplemen-
tary material. Depressive symptoms were measured by the Beck Depression Inventory (BDI). 
In addition, we screened for psychotic symptoms and impulse control impairment, using the 
Scales for Outcomes in Parkinson’s Disease – Psychiatric Complications (SCOPA-PC). Sleep 
disorders were assessed by the SCOPA-SLEEP – item B1 to B5 assessed nighttime sleep 
quality and item D1 to D6 assessed daytime sleepiness. Autonomic symptoms were measured 
by the SCOPA-AUT. Finally, the activities of daily living (ADL) were measured using the UPDRS 
part II and the Schwab and England ADL Scale. Statistical analyses were performed using 
Statistical Package for the Social Sciences (SPSS) version 20.0 (SPSS, Chicago, Il, USA). 
Questionnaires were completed by the patient prior to the examination, if necessary with help 
from the informal caregiver. BAI score > 12 and BDI score > 14 were considered clinically rele-
vant. An MMSE ≤ 24 was considered indicative of cognitive impairment. 
Statistical Analysis. Cognitive measures were adjusted for sex, age and/or educational level, 
and transformed to t- or percentile scores, using the Dutch norms by Schmand, Houx and De 
Koning (2012). A summary of the corrected variables with an overview of the qualitative de-
scription of norm scores is provided in Table S1 of the Supplementary material. BAI, BDI, SCO-
PA-SLEEP daytime sleepiness and SCOPA- AUT item 1-21 scores were imputed if 1/6 or less 
of the items were missing using the average score of valid questionnaire items. Cases were 
excluded from analysis if more than 1/6 of the items was missing. The sex-specific items (item 
22-25) and the item concerning medication (item 26) of the SCOPA-AUT were not included in 
the imputation due to different answer scales within these items. Variables were checked for 
normality. Skewed distributions were transformed, if necessary, using a square root transfor-
mation.
We conducted a hierarchical cluster analysis (HCA) on cognitive, affective and motor symp-
toms. The adjusted cognitive measures, BAI, UPDRS-III and MMSE were transformed to 
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z-scores to equalize the unit of measurement across variables within the HCA. We used the 
squared Euclidean distance measure, with Ward’s clustering method of minimal variance, ren-
dering good clustering qualities. The number of clusters was determined by 1) the ‘best cut’ 
dendrogram output, 2) the ‘elbow’ in the scree plot and 3) the ecological value of the cluster 
solution. The HCA included the Stroop interference measure, TMT task B time corrected for 
task A time, Digit span backwards from the WAIS-III, Dutch RAVLT – delayed recall condition, 
MMSE, UPDRS-III and BAI. Multicollinearity within several neuropsychological measures (i.e. 
TMT subtasks, Stroop subtasks, fluency), ceiling performances (i.e. RCFT), and limited range 
(i.e. BADS) limited the inclusion of more neuropsychological measures in the HCA. Due to 
the mutual independency assumption of the HCA and the high correlation between BDI and 
BAI, no measure of depression was included in the HCA. SCOPA-PC scores cannot be ade-
quately used as continuous measure, also displayed a small range, and were for these two 
reasons not included in the HCA. We conducted a linear discriminant analysis (LDA) in order 
to assess which variables could discriminate between clusters and how much variability these 
explained. The MMSE violated the normality assumption and was therefore eliminated from 
the LDA. Moreover, a second LDA was used to analyze the discriminative value of variables 
not included in the HCA. Analyses of variance (ANOVAs), Kruskall-Wallis tests or Chi-square 
tests were used to describe differences between the clusters on the remaining variables not 
included in the HCA. Differences were considered significant if they fell below an α of 0.05. 
Following ANOVA tests, we used Hochberg’s GT2 procedure for unequal sample sizes to 
correct for multiple comparisons and the Bonferroni method following Kruskall-Wallis and Chi-
square tests. 
Results
Demographic and descriptive characteristics. In 75 patients, missing data were replaced by 
imputation. The final sample consisted of 226 PD patients (mean age: 63.4 ± 10.2 years; fe-
male: 35.8%; H&Y median: stage 2). A comparison of patients that were included with patients 
that were excluded is given in Table S2 in Supplementary material. Further demographic char-
acteristics are shown in Table 1.
Clustering procedure and LDA. The hierarchical cluster analysis identified four clusters 
(Table 1). The behavioral characteristics of the four clusters are illustrated in four compilation 
scores in Figure 1: the Stroop interference measure, Trail making task part B | A and Digit span 
backwards (“Executive function / working memory impairment”); the RAVLT direct and de-
layed recall subtests (“Verbal memory impairment”); the BAI and BDI scores (“affective symp-
toms”); the UPDRS-III motor score (“Motor symptoms”). 
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Table 1 Demographic and clinical characteristics of the four clusters. In the right column, the statistical signi-
ficance of the group comparisons is shown.
Variable Total Cluster 1 Cluster 2 Cluster 3 Cluster 4 P value
Number of patients N (%) 226 86 (38.1) 15 (6.6) 46 (20.4) 79 (35.0)
Female % 35.8 34.9 20.0 54.3d 29.1c .0183
Age M ± SD 63.4 ± 10.2 59.9 ± 10.2b-d 72.3 ± 9.8a,d 64.7 ± 9.2a 64.8 ± 9.5a,b .0001
Age at onset M ± SD 58.0 ± 11.2 54.9 ± 11.4b 66.3 ± 11.9a 58.9 ± 10.5 59.2 ± 10.3 .0011












Education median (range) 6 (1-7) 6 (1-7) 5 (2-7) 5 (3-7) 6 (1-7) .069
2
H&Y M ± SD 2.1 ± .6 1.8 ± .6b,d 2.3 ± .5a 2.0 ± .5d 2.3 ± .5a,c .0001
     Stage 0 N 1 1 0 0 0
     Stage 1 N 24 19 0 5 0
     Stage 1.5 N 17 9 1 5 2
     Stage 2 N 104 39 7 18 40
     Stage 2.5 N 51 12 3 12 24
     Stage 3 N 20 5 4 2 9
     Stage 4 N 3 0 0 0 3
LEDD†
     - total median (N) 450 (111) 450 (42) 603 (10) 330 (21) 425 (38) .3122
     - non-LD median (N) 225 (45) 200 (17) 240 (7) 225 (7) 213 (14) .8722
     - LD median (N) 375 (100) 375 (38) 400 (9) 300 (19) 338 (34) .9022
     - COMT % 4.8 1.7 0.6 0.8 1.7 .7994
     - MAOB % 5.6 2.0 0.7 0.8 2.3 .8074
Unmedicated % 50.4 51.2 33.3 52.3 51.9 .5933
1Univariate ANOVA; 2Non-parametric Kruskal-Wallis H Test; 3Pearson’s Chi-Square Test; 4Fisher’s Exact Test. †Medicated 
patients. 
Significant differences on the α = .05 level are shown in bold. Post-hoc testing: aSignificantly different from Cluster 1 on 
the α = .05 level; bSignificantly different from Cluster 2 on the α = .05 level; cSignificantly different from Cluster 3 on the α 
= .05 level; dSignificantly different from Cluster 4 on the α = .05 level. 
Abbreviations: COMT = Catechol-0-methyl transferase inhibitor; MAOB = Monoamine oxidase B inhibitor; H&Y = Hoehn & 
Yahr; LD = Levodopa; LEDD = Levodopa Equivalent Daily Dosage.
Due to the small size of cluster 2, an LDA with cluster 1, 3 and 4 (N = 211) was conducted, 
resulting in two discriminant functions. The two discriminant functions together explained 
74% of the variance in the clusters and differentiated significantly between clusters: Λ = .267, 
χ2(12) = 271.1, p < .001. Using the two discriminant functions, 83.9% of the cases could be clas-
sified correctly, significantly higher than classification through chance (Press’s Q = 242.7, p < 
.01). The first function explained 53% of the variance in the clusters and the second function 
explained 21%. As illustrated in Figure 2, motor (UPDRS-III) and affective (BAI) symptoms dis-
criminated cluster 1 from cluster 4. The Z-score of cluster 3 on the first function was neither 
negative nor positive, due to high BAI scores but low UPDRS-III scores. The TMT part B | A (r = 
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.71), the Stroop card III | II measure (r = .43) and the Digit span backwards (r = .37) discriminat-
ed cluster 1 and 4 from cluster 3. A second LDA, using variables that were not included in the 
HCA, resulted in two discriminating functions that explained 29% of the variance in the clus-
ters (see Table S3 and Figure S1 in Supplementary Material). 
Symptom clusters. Table S4 (in Supplementary material) displays the clinical characteristics of 
the four clusters. 
Cluster 1 (N = 86; age: 59.9 ± 10.2 y) consisted of young-age PD patients – compared to clus-
ter 2, 3 and 4 – with an early disease stage and a young subjective age at disease onset. 
Patients in this cluster had intact neuropsychological functioning and had no evidence of 
affective symptoms. Furthermore, motor symptoms in these patients were relatively mild, as 
compared to cluster 2 and 4. 
Patients in cluster 2 (N = 15; age: 72.3 ± 9.8 y) were relatively older at the time of diagnosis 
and testing as compared to cluster 1, 3 and 4. These patients were in a later disease stage 
and had severe motor and affective symptoms. The PIGD motor subscore was significantly 
higher compared to cluster 1. Neuropsychological assessment indicated disorders in multiple 


















Figure 1 Radar chart containing four domains of neuro(psycho)logical and neuropsychiatric symptoms. 
Data points indicate the mean Z-score of the cluster on the four domains. Z-scores are transformed as 
such, that lower Z-scores indicate less symptom severity, whereas high Z-scores indicate more severe 
symptoms.
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MMSE scores of 24 or lower, indicative of PD dementia. In contrast, only 1 patient (in cluster 1) 
outside cluster 2 scored MMSE ≤ 24.
Cluster 3 (N = 46; age: 64.7 ± 9.2 y) contained a relatively high proportion of female patients. 
The mean age at time of testing as well as the (subjective) age of disease onset were similar 
to those in cluster 4, and were positioned between those of cluster 1 and 2. Patients in cluster 
3 were in an early disease stage and had mild motor symptoms compared to cluster 2 and 4. 
Patients in this cluster scored relatively low on executive functioning. Furthermore, patients 
experienced clinically significant affective symptoms. 
Cluster 4 (N = 79; age M: 64.8 ± 9.5 y) consisted of a relatively low proportion of female pa-
tients. The disease stage was high compared with cluster 1 and 3, and patients in this cluster 
had more severe motor symptoms compared with cluster 1 and 3 – on all motor subscores. 
Verbal memory of these patients was relatively low, while executive functioning, working 
memory, language function, and measures of attention and mental speed were unaffected. 
The patients experienced clinically significant affective symptoms. 
Figure 2 Discriminating functions between the three clusters in the LDA. Cluster centroid coordinates 
represent standardized mean scores of the clusters on function 1 and 2. Tables: the correlation between 
the LDA variables and the discriminating functions. Bold: important discriminating variables (r > .3). Stroop III 
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The objective of this study was to map heterogeneity in the clinical profile of PD using cluster 
analysis, focusing on the affective and cognitive symptoms. The present cluster analysis in a 
large sample of PD patients with a large heterogeneity of clinical characteristics resulted in 
four clusters of patients. 
Patients in cluster 1 and 2 had antipodal clinical profiles with respect to age, subjective age at 
disease onset and overall symptom severity. Cluster 1 and 2 were characterized by an early 
and late age at disease onset, respectively, in agreement with earlier data-driven studies.4 The 
clinical profile of these clusters have been described previously in two systematic reviews in 
clinical PD subtypes.4, 17 Patients in cluster 3 and 4 had similar age, subjective age at disease 
onset and affective symptoms, but distinct motor and cognitive symptom profiles. The char-
acteristics of the patients in cluster 3 – below-average executive function, affective symptoms 
and mild motor symptoms – are in accordance with an earlier cluster analysis.18 Furthermore, 
this subgroup with isolated executive dysfunction has been reported in earlier non-data-driv-
en studies.6, 19 Executive dysfunction is frequently associated with frontal lobe dysfunction, 
specifically impairment of the dorsolateral prefrontal cortex and interconnected cortical and 
subcortical brain regions.20 We hypothesize that cluster 3 characteristics are induced by 
dopaminergic deficits in the associative cortico-striato-thalamo-cortical (CSTC) circuit, that is 
known to play a role in executive functioning20 and affective symptoms 21, 22 symptoms in PD.
In contrast, cluster 4 is characterized by relatively high motor symptom severity that has 
previously been associated with decreased putaminal dopamine transporter availability, an 
in vivo marker for the integrity of the striatal dopamine system.23 Furthermore, studies in the 
CamPaIGN cohort24 have previously linked a similar cognitive profile as that of our patients in 
cluster 4 – i.e. below-average verbal memory performance but relatively intact executive func-
tions – to posterior cortical cholinergic dysfunction. These posterior dysfunctions24 and se-
vere motor symptoms in the early disease stage of PD25 have been identified as a risk factor 
for PD dementia. Furthermore, decreased hippocampal volume could – additionally – under-
lie cluster 4 cognitive characteristics, given its association with episodic memory impairment 
in PD.26
A previous review from the CamPaIGN study group postulated the ‘dual syndrome hypothe-
sis’,27 referring to two discernable cognitive profiles in PD patients: dysfunction in frontal-stria-
tal dopaminergic circuits underlying a dysexecutive cognitive profile versus posterior cortical 
cholinergic dysfunction that underlies visuospatial, semantic and mnemonic impairments. In 
accordance with the dual syndrome hypothesis and earlier data-driven studies, we hypothe-
size that cluster 3 and 4 represent different pathways of PD progression. Cluster 1 represents 
a group with a young age at onset, mild symptom severity cluster, while cluster 2 consists of 
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older patients with more severe motor and non-motor symptoms. The majority of patients in 
cluster 2 showed signs of  PD dementia – conclusions from neuropsychological assessments 
indicated that one patient met criteria for dementia, five patients were in between of mild cog-
nitive impairment and dementia, and six patients had mild cognitive impairment.
Although cluster 3 and 4 did not have distinct neuropsychiatric profiles based on the available 
measures, we hypothesize that such distinctions might have been present. Impulse control 
disorders (ICD) symptoms in PD are associated with decreased dopamine transporter binding, 
predominantly in the caudate nucleus.28 Given the speculated dopaminergic deficits in the 
associative CSTC circuit in cluster 3, these patients may have, or later develop, symptoms of 
ICD. In contrast, psychotic symptoms in PD are commonly associated with attention and epi-
sodic memory dysfunction.29 These symptoms are therefore expected to be more prevalent in 
cluster 2 and 4. Posterior cortical cholinergic dysfunction could underlie these clusters’ clin-
ical profiles. If replicated and further supported by nuclear imaging studies, this might have 
the clinical implication that acetylcholinesterase inhibitors may be an interesting additional 
treatment for these PD subtypes, even in the early stages of the disease. Figure 3 illustrates 
the hypothesized relationship between the four clusters identified in the present study as a 
starting point for future studies. 
At the time of the study, none of the patients showed ICD or psychotic symptoms accord-
ing to the SCOPA-PC. However, the SCOPA-PC is a screening instrument and not sensitive 
to subclinical psychiatric symptoms.30 We were unable to include multiple neuropsychiatric 
measures in the cluster analysis due to cluster analysis assumptions. Whereas the UPDRS-III 
was taken in the ON-state, it might be that the neuropsychological assessment was taken in a 
suboptimal dopaminergic state due to dopamine fluctuations during the day. However, since 
this applied to all patients on dopaminergic medication, it has had minimal influence on the 
cluster formation. The patients excluded from analyses due to missing data were significantly 
different from patients included in the analyses (see Table S2 in Supplementary material). 
Characteristics of the excluded patients were comparable to cluster 2 patient characteristics; 
possibly these patients were less physically and/or mentally able to undergo the extensive 
neuropsychological or questionnaire assessments. The reported cluster solution awaits repli-
cation in an independent sample. Future research may focus on the relationship between the 
cognitive heterogeneity and neuropsychiatric symptoms in more detail, and on its impact on 
disease course. Follow-up measurement of neuropsychiatric symptoms in this same cohort 
may help us to test some of the previously described hypotheses (see Figure 3). The use of 
neuroimaging may shed light on possible pathophysiological differences between clusters. 
Since this study was cross-sectional, the proposed model about the temporal relationship 
between the four clusters warrants testing using a longitudinal design.
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In conclusion, using a data-driven approach we distinguished four clusters based on clinical 
PD symptoms. Two clusters were identified with similar age, disease stage and disease dura-
tion, yet distinct motor symptom severity and pattern of cognitive dysfunction. In the present 
study, no differences occurred in neuropsychiatric profile between these clusters. Longitudi-
nal studies using elaborate cognitive and neuropsychiatric assessment could shed more light 
on their reciprocal influence and their predicting value for treatment allocation and disease 
prognosis. 
Figure 3 Hypothesis of differences in disease progression, as illustrated by the four identified clusters. In 
cursive: hypothesized differences in neuropsychiatric symptom profile.
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Supplementary Methods
Neuropsychological measures used in post-hoc analyses - Executive functioning: letter fluen-
cy, and the Rule Shift Cards (BADS-RS) and Key Search (BADS-KS) subtests of the Behavioural 
Assessment of the Dysexecutive Syndrome (BADS). Attention and mental speed: the forwards 
digit span subtest of the WAIS-III, the Stroop card I and II, and the TMT part A. Language: cat-
egory fluency. Episodic memory: the direct reproduction total score, and recognition subtask 
of the 15WT and the delayed recall of the Rey Complex Figure Test (RCFT). Visuoconstructive 




























Function 1 - Attention/memory, motor function,













Figure S1 Discriminating functions between the three clusters in the LDA of variables not included in the 
cluster analysis. Cluster centroid coordinates represent standardized mean scores of the clusters on func-
tion 1 and 2.
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Table S1 Summary of cognitive measures that were corrected for age, gender and/or education level. A 




Age Gender Education level
Stroop card I + + t-score
Stroop card II & III + + + t-score
Stroop interference + + + t-score
TMT part A + + t-score
TMT part B + + + t-score
TMT B corrected for A + + + t-score
Digit span + t-score
Category fluency + + t-score
Letter fluency + t-score
15WT recall + + + t-score
RCFT copy + percentile score
Abbreviations: 15WT = 15 Words Task; RCFT = Rey Complex Figure Task; TMT = Trail Making Task
Table S2 Comparison between patients included in cluster analysis, and patients excluded due to missing 
data.
Variable Included in HCA Excluded from HCA P value
Number of patients N (%) 226 128
Female % 35.8 39.8 .5603
Age mean (SD) 63.4 70.2 <.0011
Age at onset mean (SD) 58.0 62.4 <.011
Disease length (years) median (range) 3 (0-20) 5 (0-24) <.0012
Education level median (range) 6 (1-7) 5 (1-7) <.0012
UPDRS-III mean (SD) 24.6 34.2 <.0011
MMSE median (range) 29 (19-30) 25 (6-30) <.0012
1Univariate ANOVA; 2Mann-Whitney U Test; 3Pearson’s Chi-Square Test.
Significant differences on the α = .05 level are shown in bold.
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Table S3 Discriminant variables in second LDA including variable correlations per discriminant function. 
Variables are sorted by importance per function. In bold: important discriminating variables (r > .3).
Function 1 Function 2
Stroop card I* - .577 - .061
H&Y stage .540 - .219
15WT direct recall* - .487 .190
BDI .426 .193
SCOPA-AUT† .379 .011
SCOPA-SLEEP nighttime sleepiness† .300 .046
UPDRS-II ADL† .258 - .180
TMT part A*† - .248 - .107
Category fluency*† - .235 .099
Letter fluency*† - .155 .097
Age† .152 .149
Digit span forwards*† - .060 - .053
BADS rule-shift task (time) .154 .907
SCOPA-SLEEP daytime sleepiness† .065 - .089
*t-score; †Variable not included in model, due to too low F value for inclusion.
Abbreviations: H&Y = Hoehn & Yahr; 15WT = 15 Words Task; SCOPA = Scale for Outcomes of Parkinson’s 
Disease; UPDRS = Unified Parkinson’s Disease Rating Scale; TMT = Trail Making Task; BDI = Beck Depres-
sion Inventory; BADS = Behavioural Assessment of the Dysexecutive Syndrome.
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Table S4 Cluster means on the variables of the four clusters. 
Variables included in HCA
Variable Total Cluster 1 Cluster 2 Cluster 3 Cluster 4 P value
Stroop interference* 50.8 52.8b,c 44.6a,d 45.2a,d 51.7b,c <.001
TMT B corrected for A* 48.4 52.0b-d 27.8a,c,d 38.1a,b,d 48.5a-c <.001
Digit span backward* 53.0 58.0b-d 42.1a,d 47.0a 50.4a,b <.001
15 WT delayed recall* 44.0 47.5b,d 31.2a,c,d 44.0b 40.5a,b <.001
MMSE† 28.1 28.8b 23.7a,c,d 28.2b 28.2b <.001
BAI†,‡ 13.7 9.5c,d 16.9 17.6a 15.4a <.001
UPDRS-III‡ 22.9 18.1b,d 31.9a,c 19.9b,d 33.1a,c <.001
Variables not included in HCA
Variable Total Cluster 1 Cluster 2 Cluster 3 Cluster 4 P value
Stroop card I* 44.7 48.1b,c,d 29.7a,c 43.0a,b 42.6a,b <.001
Stroop card II* 43.8 46.9b,c,d 28.7a 42.3a 42.0a <.001
TMT part A* 47.6 49.4b,c,d 36.7a,c,d 44.4a,b 48.2a,b <.01
COWAT* 49.4 52.0b 32.8a,c,d 50.3b 47.3b <.001
Category fluency* 49.7 51.5b 36.3a,d 49.7 48.8b <.01
Digit span forward* 52.6 55.5c 47.0 48.9a 51.3 <.05
15WT direct recall* 42.8 46.4b,d 25.5a,c,d 43.7b 39.4a,b <.001
RCFT copy total† 33.4 34.4b,c 29.9a 33.0a 33.0 <.001
RCFT delayed recall total 19.5 21.0c 17.9 16.7a 19.0 <.05
BADS rule shift cards (time) ‡ 42.6 40.2b,c 56.2a,d 48.7a 41.1b <.01
BADS key search† 11.5 12.1b 8.0a,d 10.6 12.0b <.001
BDI†,‡ 11.0 7.7c,d 14.0 13.5a 12.5a <.001
SCOPA-psychiatric complications†,‡ 1.0 .7b 2.2a 1.2 1.2 <.01
UPDRS subscores
  Tremor .46 .39d .58 .34d .59a,c <.01
  Hypokinesia/rigidity 1.1 .89d 1.2 .94d 1.5a,c <.001
  PIGD .61 .43b,d .91a .61 .74a <.001
SCOPA-daytime sleepiness†,‡ 10.1 8.7b-d 12.9a 10.6a 10.7a <.001
SCOPA-autonomic‡ 33.9 31.3b-d 38.3a 36.2a 35.8a <.01
UPDRS-II ADL‡ 9.2 7.7b,d 11.8a 9.1 11.2a <.01
Schwab & England scale† 87.6 92.7b,d 82.3a 86.9d 83.3a,c <.001
* normalized t-scores. 
†non-parametric Kruskall-Wallis H-test. Unless otherwise specified, differences are tested using ANOVA. 
‡Lower score indicates less symptom severity. 
Post-hoc testing: aSignificantly different from Cluster 1 on the α = .05 level; bSignificantly different from Clus-
ter 2 on the α = .05 level; cSignificantly different from Cluster 3 on the α = .05 level; dSignificantly different 
from Cluster 4 on the α = .05 level. 
Abbreviations: 15WT = 15 Words Test; ADL = Activities of Daily Living; BADS = Behavioural Assessment for 
the Dysexecutive Syndrome; BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory; COWAT = 
Controlled Oral Word Association Test; MMSE = Mini Mental State Examination; PIGD = Postural Instability/
Gait Disorder; RCFT = Rey Complex Figure Test; SCOPA = Scales for Outcomes in Parkinson’s Disease; 
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Abstract
Background. Parkinson’s disease (PD) affects the integrity of the dopamine and serotonin 
system, and is characterized by a plethora of different symptoms, including cognitive impair-
ments of which the pathophysiology is not yet fully elucidated.
Objectives. Investigate the role of the integrity of the dopaminergic and serotonergic system 
in cognitive functioning in early-stage PD using Single Photon Emission Computed Tomogra-
phy (SPECT) combined with the radiotracer 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-io-
dophenyl)nortropane (123I-FP-CIT).
Methods. We studied the association between cognitive functions and dopamine transporter 
(DAT) availability in the caudate nucleus and putamen - as a proxy for striatal dopaminergic 
integrity – and serotonin transporter (SERT) availability as a proxy for serotonergic integrity in 
the thalamus and hippocampus using bootstrapped multiple regression. One-hundred-and-
twenty-nine (129) PD patients underwent a 123I-FP-CIT SPECT scan and a neuropsychological 
assessment. 
Results. We showed a positive association between DAT availability in the head of the cau-
date nucleus and the Stroop Color Word Task - card I (reading words; β = .32, p = .001) and 
a positive association between DAT availability in the anterior putamen and the Trail Making 
Test part A (connecting consecutively numbered circles; β = .25, p = .02). These associations 
remained after adjusting for motor symptom severity or volume of the region-of-interest and 
were most pronounced in medication-naïve PD patients. There were no associations between 
cognitive performance and SERT availability in the thalamus or hippocampus. 
Conclusions. We interpret these results as a role for striatal dopamine – and its PD-related 
decline – in aspects of processing speed. 
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Introduction
Cognitive impairments are common in Parkinson’s disease (PD), with cognitive impairment 
already present in up to twenty-five percent of patients around the time of diagnosis.1, 2 Tasks 
that require cognitive flexibility, (divided) attention or that are time-sensitive are especially 
affected in PD.1, 3 Furthermore, up to eighty percent of patients will eventually develop PD 
dementia (PDD).4 The incidence of cognitive impairments increases steadily with progression 
of the disease which implies a role of the spreading PD pathology in its etiology. Indeed, the 
severity of post-mortem cortical Lewy body pathology has been shown to be associated with 
increased cognitive impairments.5 
The integrity of dopaminergic projections can be approximated in vivo by measuring the 
availability of striatal presynaptic dopamine transporters (DAT) using radiotracers, such as 
123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) in combina-
tion with single photon emission computed tomography (SPECT). Using such radiotracers, 
studies have shown lower striatal DAT binding, indicative of more dopamine denervation,6 in 
PD patients with cognitive impairments compared with those without.7-9 DAT availability is also 
associated with cognitive performance7, 10-12 and task-related brain activation.13, 14 Dopamine is 
the primary modulator of the cortico-striato-thalamo-cortical (CSTC) circuits.15 Especially within 
the associative CSTC circuit, involving connections between the striatal regions and prefron-
tal cortex, dopamine deficiencies are associated with cognitive impairments.7, 8, 10-12
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Other neurotransmitters are also involved in cognition, such as acetylcholine and sero-
tonin.16-19 These neurotransmitters also play a role in the pathophysiology of PD but has so 
far received less scientific attention.20-22 The radiotracer 123I-FP-CIT has, in addition to its high 
affinity for the DAT, also modest affinity for the serotonin transporter (SERT). Due to the differ-
ential expression patterns of DAT and SERT, 123I-FP-CIT binding in the striatal regions predom-
inantly reflects DAT availability, while 123I-FP-CIT binding in extrastriatal regions, such as the 
hippocampus and (hypo)thalamus, represents SERT availability.23 A single 123I-FP-CIT SPECT 
scan can therefore be used to simultaneously measure DAT and SERT availability, as demon-
strated previously.24-26 
The SERT-rich hippocampus and thalamus are important brain regions for memory and for 
executive functions, attention and (working) memory, respectively.27-30 Patients with dementia 
with Lewy bodies (DLB) showed reduced 123I-FP-CIT SPECT binding in the thalamus compared 
with both PD patients and healthy controls.31 Although DLB is characterized by severe cogni-
tive deficits and thought to share an underlying pathophysiology with PD, the clinical signif-
icance of this finding is currently unclear. In non-PD samples, no relationship was observed 
between SERT availability and cognitive performance in young adult healthy participants 
with normal cognition,32 while another found reduced SERT availability in patients with mild 
cognitive impairment (MCI) in various brain regions, including the thalamus, that correlated 
with worse memory performance.33 This correlation was not observed in cognitively normal 
controls, suggesting that associations with SERT are only observed under pathological condi-
tions.33 
In this study we investigated the association between striatal DAT and extrastriatal SERT 
availability and cognitive function in PD patients to provide further evidence that monoamine 
deficiencies are related to PD-related cognitive impairments. Based on previous research we 
hypothesized a positive association between cognitive performance, in particular executive 
functions, attention and working memory, and striatal DAT availability, specifically in the cau-
date nucleus.7, 8, 10-12 Based on the study by Smith and colleagues33 in patients with MCI we 
hypothesized a positive correlation between thalamic and hippocampal SERT availability and 
cognitive performance in PD, specifically memory and attention. 
Patients and methods
Participants. PD patients were selected from a database of consecutive cases that visited 
the outpatient clinic for movement disorders of the neurology department of the Amsterdam 
UMC, location VU University Medical Center (Amsterdam, The Netherlands) between May 
2008 and February 2017. Overlapping samples derived from this cross-sectional database 
have also been used for previous investigations into non-motor symptoms of PD ( e.g. 14, 24, 34, 
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35). Diagnosis of PD was established by movement disorder specialists according to the UK 
PD Society Brain Bank criteria.36 Diagnosis was confirmed in 89% of the included patients 
after at least two year follow-up. The others were lost to follow-up. Patients were eligible for 
this study when they were administered a 123I-FP-CIT SPECT scan, a T1-weighted magnetic res-
onance imaging (MRI) scan and a neuropsychological assessment. Patients in our center are 
administered these scans and the assessment as part of the diagnostic work-up. We excluded 
patients on selective serotonin reuptake inhibitors (SSRIs), because SSRIs can displace 123I-FP-
CIT from the DAT and SERT.23 See Figure 1 for a flowchart. In accordance with the Declaration 
of Helsinki, all included patients gave written informed consent to use their clinical and neuro-
imaging data for scientific purposes, and the study was approved by the local medical ethics 
committee. 
Clinical and neuropsychological measures. We evaluated motor symptom severity with the 
Unified PD Rating Scale, section III (UPDRS-III).37 Patient that were on dopamine replacement 
therapy were measured in their ‘ON’ phase during all assessments and the SPECT scan. For 
these patients we calculated the levodopa equivalent daily dose (LEDD) to standardize the 
medication dosages.38 Severity of depressive symptoms was assessed using the Beck De-
pression Inventory (BDI). We scored education level according to the Dutch Verhage scale39 
that ranges from 1 - primary school not finished, to 7 – university or higher. We administered 
the Mini-mental state examination (MMSE),40 as a measure of global cognition. 
The neuropsychological assessment comprised the Stroop Color Word Test (SCWT), the Trail 
Making Test (TMT), the digit span subtest of the Wechsler Adult Intelligence Scale (WAIS)-III, 
the Dutch version of the Rey Auditory Verbal Learning Test (RAVLT) and the delayed recall 
of the Rey Complex Figure Test (RCFT). These neuropsychological tests were performed to 
assess a range of cognitive functions: 1) executive functions: we used the SCWT color-word 
card (SCWT-III) time corrected for color-only card (SCWT-II) time as a measure of interference 
control. The TMT task B time corrected for task A time was used as a measure of set-shifting; 
2) attention and processing speed: we used the time on the word reading card of the SCWT 
(SCWT-I) and the time on the TMT card A (TMT-A; connecting consecutively numbered circles) 
as measures of attention and processing speed. We used the total score on the forward digit 
span of the WAIS-III as a measure of attention; 3) working memory: the WAIS-III backward digit 
span score was used as a measure of working memory; 4) episodic memory: verbal episodic 
memory was measured with the delayed recall score of the RAVLT. We measured visuospatial 
episodic memory with the delayed recall of the RCFT. We did not include the SCWT-II as a 
separate measure of attention and processing speed in our analyses as this was highly cor-
related with the SCWT-I. Likewise, we did not use the direct recall score of the RAVLT as sep-
arate measure in our analyses given the high correlation with the delayed recall score. The 
RAVLT recognition trial was excluded from the analyses due to ceiling effects. All neuropsy-
chological assessments were performed within two weeks of the 123I-FP-CIT scan. All scores 
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on the neuropsychological tests were converted to standardized T-scores (with a mean of 50 
and standard deviation of 10) or percentiles to adjust for age, sex and/or educational level, 
using the appropriate Dutch norm scores.41 See Table 1. 
123I-FP-CIT SPECT–image acquisition and pre-processing. 123I-FP-CIT was intravenously ad-
ministered in a dose of approximately 185 MBq (specific activity >185 MBq/nmol; radiochemi-
cal purity >99%; produced as DaTSCAN™ according to good-manufacturing-practices criteria 
at GE Healthcare, Eindhoven, The Netherlands). All images were obtained within 3-4 hours 
after injection conforming to Darcourt et al. (2010).42 123I-FP-CIT has an affinity of Ki = 3.5 nM 
for DAT and Ki= 10 nM for SERT.43 We obtained static images for 30 minutes using a dual-head 
gamma camera (E.Cam; Siemens, Munich, Germany) with a fan-beam collimator. The images 
were reconstructed as described earlier,44 with a Chang’s attenuation correction of 0.15 and 
subsequently reoriented to the anterior-posterior commissure plane in Statistical Parametric 
Mapping 12 software (SPM 12; Wellcome Trust Centre for Neuroimaging, London, UK).
Regions of interest. We used FreeSurfer 6.0 (Athinoula A. Martinos Center for Biomedical 
Imaging, Boston, MA, USA) with default settings to individually segment Regions of interest 
(ROIs) from 3D T1-weighted MRI scans. These T1-weighted scans were acquired at different 
MRI systems at Amsterdam UMC (location VUmc). See the supplementary material for the 
scan parameters. We selected the bilateral striatal caudate head and putamen (DAT regions) 
and the bilateral extrastriatal hippocampus and thalamus (SERT regions) as our ROIs. The 
putamen was divided into an anterior and posterior part by a line perpendicular to the anteri-
or commissure. Similarly, the head of the caudate nucleus was constrained to voxels anterior 
to the anterior commissure. All ROIs were visually inspected for segmentation errors (see 
results). 
123I-FP-CIT SPECT and T1 co-registration and analysis. 123I-FP-CIT SPECT scans were co-reg-
istered with the T1-weighted scans using a previously established method24 in SPM 12. Briefly, 
hyper-intense FreeSurfer segmentations of the striatal regions were superimposed on the 
original T1-weighted scans to create a common landmark in both the MRI and 123I-FP-CIT 
SPECT scan to allow co-registration based on this mutual spatial information. We calculated 
binding ratios per subject for each of the striatal and extrastriatal ROIs using the bilateral Crus 
II of the cerebellum (excluding the vermis) in the automated anatomical labelling (AAL) atlas as 
a reference (REF). Binding ratios were calculated according to: [(ROI – REF) / REF]. Consistent 
with previous studies,24, 25, 35, 44 we did not perform partial volume correction.
Statistics. Analyses were performed in SPSS 22 (IBM Corp, Armonk, NY, USA). Distributions 
of the variables were inspected using histograms, Q-Q plots, and Kolmogorov-Smirnov tests. 
We describe demographics and clinical characteristics using means and standard deviations, 
unless indicated otherwise. 
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To investigate the association between 123I-FP-CIT binding and cognitive performance we per-
formed hierarchical multiple regression. Because of the natural decline in 123I-FP-CIT binding 
with aging, age was entered in the first block of the hierarchical multiple regression analysis. 
In the second block, age, sex and education adjusted scores on our cognitive tests were 
simultaneously entered in the regression model to investigate the association with 123I-FP-
CIT binding in the three DAT-rich striatal regions (caudate head and anterior and posterior 
putamen) and SERT-rich thalamus and hippocampus. 
We investigated the relation between executive functions, processing speed, attention and 
working memory and 123I-FP-CIT binding in the head of the caudate nucleus, anterior putamen 
and posterior putamen. Although we did not expect strong associations between cognitive 
performance and 123I-FP-CIT binding in the posterior putamen – which is mainly involved in 
motor functions – we performed this association as an internal control. All available cognitive 
test outcomes were fed into the regression model of the thalamus, because the thalamus 
seems vital for all cognitive processes.45 Memory tests were fed into the regression model 
with hippocampal 123I-FP-CIT binding. This analysis scheme is also outlined in Table 1. To 
determine the neuropsychological measures that needed to be modelled with 123I-FP-CIT 
binding in the different ROIs and limit the number of tests we applied a backward selection 
procedure as previously described.34 It is also generally accepted that there is a large over-
lap between processes underlying executive functions, attention and working memory46 and 
the tests designed to measure it, providing additional credence to first perform a backward 
selection procedure. For the caudate head and anterior and posterior putamen the following 
cognitive tests were initially entered into the second step of the model (age was entered in 
the first step): SCWT-I, TMT-A, SCWT interference score, TMT set-shifting score, digit span 
backward and digit span forward. For the thalamus we additionally entered the delayed recall 
sore on the RAVLT and RCFT. 123I-FP-CIT binding in the hippocampus was modelled with the 
delayed recall sore on the RAVLT and RCFT only (Table 1). Predictors (i.e. neuropsychological 
test scores) were removed one-by-one from the model if their regression coefficient (β) fell 
short of our statistical threshold (i.e. p>0.05). Age always remained in the model regardless 
of significance. The model was re-evaluated after removal of the predictor and repeated until 
all remaining predictors had a p<0.05. This process was performed for each of the five ROIs 
separately, resulting in a maximum of five final models that needed to be statistically evalu-
ated (see results). The final regression models were bootstrapped using 1000 iterations and 
we report bias corrected and accelerated (BCa) confidence intervals and P values (Pbca) for a 
more robust estimate of the association. 
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All assumptions of multiple regression analyses were assessed and met. We corrected the 
final models for multiple comparisons with Simple Interactive Statistical Analysis (SISA; http://
www.quantitativeskills.com/sisa/calculations/bonhlp.htm), an online tool that uses the mutual 
correlation coefficient between variables (binding ratios in our bilateral ROIs; striatal rmean = 
0.81) to adjust the statistical threshold and allows a less stringent correction than, e.g. Bon-
ferroni. For the striatal ROIs this resulted in a statistical threshold (Pcorr) of Pcorr<0.043. As a 
sensitivity analysis, we additionally added UPDRS-III or dopaminergic medication status to the 
third step of the models to adjust for these possible confounding variables and performed 
the regression analyses in the group of medication-naïve PD patients (N = 85). To exclude the 
possible influence of ROI volume we lastly added FreeSurfer-based volume as a nuisance 
covariate to the third step of the final models. 
Results
Group characteristics. There were 233 PD patients with a 123I-FP-CIT SPECT and T1-weight-
ed MRI scan. Of those, a total of 99 were excluded (see flowchart in Figure 1) leaving 134 PD 
patients for analysis. Five additional patients had to be excluded due to segmentation failures 
in FreeSurfer. The final sample thus consisted of 129 PD patients (36.4% female) with a mean 
age of 65.3(± 10.8). The majority of PD patients  (75.2%) had a Hoehn & Yahr stage of ≤2. See 
Table 2 for further sample characteristics. See Figure 2 for rainbow plots of the performance 
on the different neuropsychological tests.
Table 1 Cognitive tests per domain and associations with regions of interest.
S T H Cognitive domain Cognitive test Outcome measure
Executive 
functions SCWT
Interference score – time on color-word card 
corrected for time on color naming 
TMT Set-shifting score – time on part B corrected for time on part A
Working 
Memory Digit span – backwards Total correct
Attention Digit span - forwards Total correct
SCWT – card I Time
TMT – part A Time 
Episodic 
memory RAVLT (verbal memory) Delayed recall total score
Rey complex figure test 
(visuospatial memory) Delayed recall total score
Abbreviations: S = striatal regions (caudate, anterior putamen and posterior putamen), T = thalamus, H = 
hippocampus; SCWT = Stroop Color Word Task, RAVLT = Rey Auditory Verbal Learning Test, TMT = Trail 
Making Test.
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Backward selection procedure. Based on the backward selection procedure the final regres-
sion models that needed to be statistically evaluated were the caudate head with SCWT-I and 
the anterior putamen with SCWT-I and TMT-A. No final models were evaluated for the posteri-
or putamen, and the extrastriatal thalamus and hippocampus (all βs with p>0.05). 
Association between 123I-FP-CIT SPECT and cognitive functioning. Performance on SCWT-I 
(word reading) showed a significant association with mean 123I-FP-CIT binding in the bilateral 
caudate head (β = .32, Pbca = .001; Figure 3a) and anterior putamen (β = .18, Pbca = .033; see 
Table 3). 123I-FP-CIT binding in the anterior putamen additionally showed a positive association 
with performance on TMT-A (drawing lines between consecutively numbered circles; β = .25, 
Pbca = .02; Figure 3b). Adding markers for disease severity (UPDRS-III or Hoehn & Yahr stage) 
or duration (subjective disease duration), severity of depressive symptoms (BDI) or medication 
status had no effect on the association between SCWT-I and 123I-FP-CIT binding in the bilateral 
caudate head or between TMT-A and 123I-FP-CIT binding in the anterior putamen, although the 
association between 123I-FP-CIT binding in the anterior putamen and SCWT-I performance was 
no longer significant after adding UPDRS-III (β = .15, Pbca = .06), Hoehn & Yahr stage (β = .15, 
Pbca = .07), BDI (β = .17, Pbca = .06) or subjective disease duration (β = .12, Pbca = .17). 
When performing the analyses in the subgroup of medication-naïve PD patients (N=85) the 
associations between SCWT-I performance and 123I-FP-CIT binding in the anterior putamen 
was no longer significant (β = .18, Pbca = .08), while the association between SCWT-I perfor-
mance and 123I-FP-CIT binding in the caudate head (β = .36, Pbca =.001) and TMT-A with 123I-FP-
CIT binding in the anterior putamen (β = .33, Pbca = .02) remained and even showed a slight 
increase in strength. Adding volume of the bilateral ROI as a nuisance covariate had no effect 
on the significance of these associations. 
Figure 1 Flowchart of the excluded patients in this study.
233 PD patients with a 
T1-weighted MRI and 
123I-FP-CIT scan Exclusion
3 technical difficulties during scan
60 missing data on 
neuropsychological tests
5 too large interval between scan and 
neuropsychological tests
1 gross brain pathology on MRI
26 drugs that affect 123I-FP-CIT 
binding
4 diagnostic conversion at follow-up134 patients available 
for analyses
129 patients in final
sample
5 failed Freesurfer segmentation
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N patients (% female) 129 (36.8)
Age (years) 65.3 ± 10.8
UPDRS-III 22.6 ± 9.7
BDI (N = 123) 11.5 ± 7.7
Education level (in %)
  2 1.6
  3 7.0
  4 16.3
  5 24.0
  6 22.5
  7 28.7
H&Y stage (in %) N = 128
  1 17.8
  1.5 2.3
  2 55.0
  2.5 19.4
  3 4.7
Subjective disease duration 
(years)* 3.0 ± 3.9
MMSE 28.3 ± 1.7
DRT (yes/no) 44/85
LEDD (mg/day) 266.9 ± 918.0
Cognitive tests Mean ± SD [range]Ψ Percentage impaired†
Stroop-I 45.2 ± 9.8 [15-68] 4.6%
Stroop interference 49.9 ± 9.2 [22-71] 1.5%
TMT-A 45.6 ± 10.8 [10-73] 8.3%
TMT set-shifting 46.9 ± 11.2 [6-68] 6.9%
Digit Span – Forwards 51.8 ± 11.6 [19-78] 3.1%
Digit Span – Backwards 51.7 ± 10.7 [32-89] 0.0%
RAVLT – delayed recall 42.8 ± 11.2 [18-70] 12.9%
Rey figure – delayed recall 30.4 ± 26.9 [10-100] 0.0%
Education level was scored according to the Dutch classification system of Verhage (1964) that ranges from 
1 - primary school not finished, to 7 - university or higher. * measured from the first sign of motor symptoms. 
ΨAll neuropsychological tests were converted to Dutch norm scores to correct for age, sex and/or edu-
cation level, see supplements. Scores are presented as T-scores, except the Rey Figure – delayed recall 
(percentile). † Impairment was defined as >2 SD below the mean of the Dutch norm scores. Abbreviations: 
UPDRS-III: Unified Parkinson’s disease Rating Scale part III (motor symptom severity), H&Y = Hoehn & Yahr, 
MMSE = Mini-Mental State Examination, DRT = dopamine replacement therapy, LEDD = Levodopa Equiva-
lent Daily dose, BDI = Beck Depression Inventory.
Table 2 Sample characteristics.
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Finally, because neuropsychological data was missing for N=2 on TMT-B and N=10 on RCFT 
– which may have impacted the backward selection procedure – we additionally performed 
the backward selection procedure in the subsample with full neuropsychological data (N=118). 
This had no effect on the final models that needed to be evaluated, nor their statistical signif-
icance.
Figure 2 Rainbow plot showing the performance of our sample on the various neuropsychological tests. 
Scores were converted to standardized T-scores (with a mean of 50 and standard deviation of 10) or per-
centiles to adjust for age, sex and/or educational level, using the appropriate Dutch norm scores.41 Abbrevi-
ations: SCWT-I: Stroop Color Word Task card I, TMT A: trail making task part A, TMT SS: trail making task set 
shifting score, RAVLT: Rey Auditory Verbal Learning Task, RCFT: Rey Complex Figure Task., att = attention, 
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Table 3 Associations between [123I]FP-CIT binding and cognitive performance.
ROI Model B (SE) 95% CI (BCa) Beta Pbca
Caud Age -0.014 (0.004) -0.022, -0.005 -.309 .001
SCWT-I 0.015 (0.004) 0.009, 0.022 .312 .001
A-Put Age -0.005 (0.004) -0.013, 0.003 -.112 .237
SCWT-I 0.009 (0.004) 0.001, 0.017 .186 .038
TMT-A 0.010 (0.005) 0.002, 0.020 .233 .032
For each ROI, age was entered in model 1. Only the results of model 2 are shown here. Abbreviations: 
CAUD = caudate nucleus, A-PUT = anterior putamen, SE = standard error, CI= confidence interval, BCa 
= bias corrected and accelerated, SCWT-I = Stroop task card I (reading the words of the colors), TMT-A 





In this study we investigated the association between striatal and extrastriatal 123I-FP-CIT 
binding and cognitive performance in a large sample of early-stage PD patients. Using boot-
strapped multiple regression analysis our main finding was that age-adjusted 123I-FP-CIT bind-
ing in the head of the caudate nucleus and anterior putamen were positively associated with 
cognitive performance on the SCWT card I and TMT card A, respectively. These associations 
remained even after additional correction for markers of disease severity (UPDRS-III, Hoehn 
& Yahr stage or disease duration) or ROI volume and when the analyses were performed in 
a subset of medication-naïve PD patients (N = 85). Additional post-hoc analysis showed that 
123I-FP-CIT binding in both the left and right caudate head or anterior putamen contributed 
approximately equally to the reported associations (data not shown). No associations were 
found with SERT availability in the thalamus or hippocampus and cognitive performance. 
Extensive prior studies have implicated the head of the caudate nucleus and anterior 
putamen in cognitive processes. Both striatal subregions are involved in the associative 
CSTC circuit15 that consists of connections between the basal ganglia, thalamus and multiple 
prefrontal, parietal and temporal brain regions involved in cognitive control.47, 48 The TMT-A 
is a measure of visual search and visuomotor speed.49, 50 SCWT-I can be seen a measure of 
attention and processing speed.51 Because these associations remained significant after ad-
Figure 3 Scatter plots of the associations between cognitive performance and striatal dopamine transpor-
ter availability. A) positive association between performance on Stroop card I (reading words) and dopa-
mine transporter availability in the caudate head. B) positive association between performance on the trail 
making task part A (connecting consecutively numbered circles) and dopamine transporter availability in 
the anterior putamen. The black trend line and grey confidence interval are based on the full sample. The 
red dots in the plot represent the medication-naïve Parkinson patients (N=85). FP-CIT binding is residuali-
zed for age. Values on the x axis represent standardized T-scores (see methods).
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justing for disease severity and duration, these associations are less likely the result of PD-re-
lated decreases in hand speed or speech tempo. Although attention may also be a common 
denominator of both the TMT-A and SCWT-I, the digit span forward task –a pure attention 
task– did not explain enough variance to survive the selection procedure. The results are 
therefore less likely to be related to attention. Instead they may point towards a role of PD-re-
lated degeneration of dopamine projections towards the head of the caudate nucleus and 
anterior putamen in a slowing of processing speed; a fundamental cognitive ability. Of note is 
that the reported associations were most pronounced in the unmedicated sample, in which 
the deficiencies of the dopaminergic system leading to slowing of processing speed are not 
alleviated by dopaminergic medication. 
Previous studies have generally shown an association with (higher-order) executive functions, 
using either an aggregated score from a neuropsychological screening battery7 or composite 
scores of individual tests.10, 11 Based in part on these studies and others,13, 14, 52, 53 we also ex-
pected DAT availability in the head of the caudate nucleus and anterior putamen to be related 
to executive functions. At first glance, our results therefore seem inconsistent with our hy-
pothesis and prior research. Nevertheless, because processing speed is a cognitive process 
that drives executive functions54, 55 and both the SCWT and TMT were part of the executive 
measures of previous studies, it could be that these results are at least partly explained by the 
shared variance with this fundamental cognitive ability. Indeed, multiple studies have shown 
an association between dopamine signalling and processing speed in non-PD samples,56, 57 
although we cannot completely rule out a role for an attentional component. The dissociation 
between an association of the SCWT-I and TMT-A with the head of the caudate nucleus and 
anterior putamen, respectively (after correcting for markers of disease severity) may have 
something to do with the fact that the SCWT-I is a verbal task and the TMT-A requires manual 
execution. At this point, however, this remains speculative. 
In contrast to our hypothesis based on previous research,7, 10-12 there was no association be-
tween executive functions and striatal DAT availability. This might be due to methodological 
differences. In contrast with the current study, previous studies have not always accounted 
for age during their analysis of the 123I-FP-CIT binding. Because DAT availability declines with 
natural aging, the guidelines of the European Association of Nuclear Medicine (EANM) rec-
ommend adjusting for age to avoid overinterpretation.42 In fact, when Siepel and colleagues 
adjusted their results for age, their association between 123I-FP-CIT binding and executive 
functions was no longer significant.10 Furthermore, SSRIs are frequently used in PD24, 58 and 
significantly increase the quantification of DAT availability by 123I-FP-CIT.23 In our study we 
excluded all PD patients on SSRIs for this reason (approximately 10%; see flowchart), while 




Because of the moderate affinity of 123I-FP-CIT binding for SERT, we also investigated the re-
lationship between cognition and 123I-FP-CIT binding in the thalamus and hippocampus. Our 
backward selection procedure, however, did not produce a final model for statistical evalu-
ation. Previous studies using a radiotracer that is selective for SERT, i.e. [11C]-DASB, showed 
lower SERT availability in cortical, limbic and thalamic regions in MCI patients compared with 
healthy controls and a negative correlation between cortical SERT availability and memory 
performance.33 In PD, MMSE scores were negatively associated with [11C]-DASB binding in 
the caudate, but this was based on a metaregression analysis.22 Based on these results we 
hypothesize that 123I-FP-CIT may not be sufficiently sensitive to investigate the relationship 
between the serotonergic system and cognitive functions, even though it was sufficiently 
sensitive to find a relationship with other PD-related symptoms.24, 25 A study that specifically 
examines the relation between cognition and SERT using a selective radiotracer in PD is 
therefore warranted. 
Strengths of this study include the large sample size, comprised largely of drug-naïve PD pa-
tients, the diverse set of cognitive tests used, and the wide range in cognitive assessments. 
Furthermore, we performed sensitivity analyses to verify the robustness of the results and 
excluded patients on drugs that may influence 123I-FP-CIT binding. A limitation of the study is 
that we did not use a radiotracer that is selective for SERT, which may have hampered our 
ability to detect an association between SERT availability and cognitive function. Furthermore, 
because not all patients performed two neuropsychological tests per cognitive domain, we 
were unable to classify their cognitive status according to the relevant diagnostic criteria for 
PD-MCI level II59 and no information was available on impairment in daily life to establish PD 
dementia.60
The absence of a healthy control group also impeded us from determining the specificity of 
our results for PD. The pathophysiology of PD therefore merely provides a good opportunity 
to study how (pathological) variation in DAT availability is related to cognitive ability. 
In conclusion, using 123I-FP-CIT SPECT in a large sample of early-stage PD patients, we 
observed a positive association between striatal DAT availability and performance on the 
SCWT-I and TMT-A, likely reflecting processing speed. These results support a role of PD-re-
lated dopamine degeneration in this fundamental cognitive ability.
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Abstract
Cognitive training (CT) is an increasingly popular, non-pharmacological intervention for im-
proving cognitive functioning in neurodegenerative diseases and healthy aging. Although 
meta-analyses support the efficacy of CT in improving cognitive functioning, the neural mech-
anisms underlying the effects of CT are still unclear. We performed a systematic review of 
literature in the PubMed, Embase and PsycINFO databases on controlled CT trials (N > 20) in 
aging and neurodegenerative diseases with pre- and post-training functional MRI outcomes 
up to November 23rd 2018 (PROSPERO registration number CRD42019103662). Twenty arti-
cles were eligible for our systematic review. We distinguished between multi-domain and sin-
gle-domain CT. CT induced both increases and decreases in task-related functional activation, 
possibly indicative of an inverted U-shaped curve association between regional brain activity 
and task performance. Functional connectivity within ‘cognitive’ brain networks was consis-
tently reported to increase after CT while a minority of studies additionally reported increased 
segregation of frontoparietal and default mode brain networks. Although we acknowledge 
the large heterogeneity in type of CT, imaging methodology, in-scanner task paradigm and 
analysis methods between studies, we propose a working model of the effects of CT on brain 
activity and connectivity in the context of current knowledge on compensatory mechanisms 
that are associated with aging and neurodegenerative diseases.
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Introduction
In recent years, cognitive training (CT) has become increasingly popular as a treatment for 
cognitive dysfunction and decline. CT is a behavioral, non-pharmacological treatment that 
has a history of more than a century but has regained interest in the past two decades.1 Its 
scope nowadays ranges from alleviating cognitive dysfunction in neurodegenerative diseas-
es, in which pharmacological treatment options have limited efficacy,2, 3 to improvement of 
cognitive abilities in cognitively intact individuals see e.g., Shah et al.4 The recent popularity 
of CT has evoked substantial debate and criticism from the scientific community regarding its 
efficacy and validity,5-8 at least partly due to the growth of commercial companies promising 
to enhance mental fitness or cure cognitive dysfunction in an aging society by offering online 
‘brain training’ products without scientific basis.
Meta-analyses of studies in multiple neurodegenerative diseases support the efficacy of CT 
to improve cognitive function.9-12 Even more so, CT has been shown to delay cognitive decline 
in both healthy adults and patients with Parkinson’s disease (e.g., 13-15). This indicates that CT 
may have a neuroprotective effect that counteracts or delays age- and disease-related de-
generation of the brain and is reminiscent of the “use it or lose it” principle.16, 17
The aim of CT through ‘process-based’ or ‘drill’ training is, as generally opposed to cognitive 
strategy training, to improve cognition through repeated engagement of cognitive processes 
using one or more challenging and preferably adaptive tasks – analogous to physical training. 
Stimulation of neuroplasticity and thereby enhancement of cognitive reserve is thought to 
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represent the underlying neurobiological mechanism.18, 19 Neuroplasticity refers to the brain’s 
ability to undergo structural and functional alterations by altering neurotransmission, synap-
togenesis and neurogenesis from birth to old age.20 Research in rodents has indicated that 
training-induced neuroplasticity entails changes in dendritic spine formation rate,21 cortical 
spine density22 and synapse potentiation23 (for a review see Abraham, 2008),24 and also neu-
ral changes such as hippocampal synaptic connectivity in animal models of neurodegenera-
tive diseases.25
In humans, non-invasive neuroimaging techniques are an elegant way to map neural alter-
ations in response to CT, but so far there is no agreement on how CT alters the aging brain 
at this macroscopic level. This review seeks to provide a systematic overview of reported 
changes in brain activity and connectivity induced by process-based CT, measured by func-
tional magnetic resonance imaging (MRI). As integration of information in large-scale brain 
networks is increasingly thought to be essential for successful cognition,26, 27 we aim to de-
scribe results in the context of the human brain connectome. This systematic review aims to 
answer the following questions: what is the influence of the trained domain (e.g., single-do-
main versus multi-domain, working memory versus attention) on alterations of brain activity 
and connectivity? Do these alterations specifically involve certain brain networks? Are the 
mechanisms of effect of CT dependent on the target study population?
Insight into the neural mechanisms of CT across neurodegenerative diseases and healthy 
elderly, and across training packages is warranted to further optimize the efficacy of CT. We 
hypothesize that CT-induced changes in brain activity and connectivity are dependent on 
the type of CT, and that these changes occur predominantly in brain networks important for 
the specific cognitive domain that is trained. We first summarize the existing literature for 
multi-domain and single-domain CT separately. In the final section, we evaluate and integrate 
the reviewed studies, and provide recommendations for future research. 
Methods
Study selection and screening. We performed a systematic literature review following Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, http://www.pris-
ma-statement.org/) guidelines on records published in the PubMed, Embase and PsycINFO 
databases up to November 23rd 2018. We registered the review protocol with the PROSPERO 
International Prospective Register of Systematic Reviews of the University of York (registration 
number: CRD42019103662). The search terms were defined as a combination of “cognitive 
training” and related terms and “neuroimaging” and related terms. Additionally, we added 
exclusion terms based on our eligibility criteria. An overview of the literature search terms is 
provided in Supplementary material 1. We also added studies from reference lists of studies in 
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our literature search (i.e., snowball method). Records were first independently screened (TvB, 
CV) for eligibility and disagreement was re-evaluated to consensus.
Eligibility criteria were 1) randomized and non-randomized controlled trials on process-based 
CT, 2) in a human population of patients suffering from neurodegenerative diseases or 
healthy elderly (defined as a mean age of 60 years or older), 3) with neuroimaging data be-
fore and immediately following CT, 4) with functional magnetic resonance imaging (fMRI, i.e., 
resting-state and/or task-related) as reported outcome measure, and 5) with a minimal total 
sample size of 20 participants to enhance reliability of single-study results. Eligibility criterion 
2 was retrospectively adjusted and therefore deviates from the PROSPERO review protocol: 
the minimal age for healthy participants was increased from 30 to 60 years in order to in-
clude studies specifically in the aging healthy elderly sample. One study that was originally 
included (Clark et al. 2017) was for this reason excluded from the synthesis. Exclusion criteria 
were combination treatments, such as CT combined with physical activity. As the popularity 
of process-based CT is increasing, there is also considerable debate on the efficacy and 
working mechanism, as described in the Introduction. Cognitive strategy training studies were 
therefore not eligible for this review in order to improve our understanding of –specifically– 
process-based training, to enhance comparability in a heterogeneous research field. 
We only considered reports written in English. Potentially eligible records were screened in 
full-text based on the aforementioned criteria and excluded records were assigned an exclu-
sion label. Eligible records were included in the systematic review.
While meta-analytic methods such as activation likelihood estimation and seed-based d map-
ping28, 29 are highly suitable to define agreement across multiple neuroimaging studies, we did 
not perform such a meta-analysis as the correspondence in study methods, analysis methods, 
seed regions or regions-of-interest used, and in-scanner tasks was insufficient and did not 
adhere to recent neuroimaging meta-analysis recommendations.30 Additionally, as there al-
ready was significant heterogeneity in fMRI study methodology and to ensure comparability 
of results, we focused on studies using this neuroimaging modality and did not include other 
modalities (e.g., positron emission tomography, magnetoencephalography) as well.
Data extraction and assessment. We extracted data of participant demographics and inter-
vention characteristics, including sample size, age, domain of CT, control group type (active 
of passive) and number of hours trained. We classified interventions as multi-domain or sin-
gle-domain CT. We extracted the specific domain that single-domain interventions focused 
on (i.e., cognitive control, inhibition, processing speed and working memory). Concerning 
the fMRI outcome, we extracted the imaging modality (resting-state or task-related fMRI), the 
analysis method and seed region or region-of-interest (ROI) applied. We extracted the re-
ported regions of CT-related alterations, including directionality of effect, outcome measure, 
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coordinates of the anatomical brain locations (if specified) and correlations with behavioral 
outcomes (when applicable). Talairach coordinates were converted to Montreal Neurological 
Institute (MNI) coordinates using Wake Forest University PickAtlas in Statistical Parametric 
Mapping.31, 32 We used BrainNet Viewer to visualize results.33 Extracted training-induced 
changes in brain function are relative to a control condition (i.e., the interaction-effect) unless 
otherwise specified in this paper.
To get an overview of how CT influenced brain network function, we assigned neural network 
labels to extracted coordinates of neural alterations using the atlases of cerebral, cerebellar 
and striatal parcellation studies of which the default mode network (DMN), frontoparietal 
network (FPN), and dorsal and ventral attention network (DAN and VAN) play a large role in 
facilitating cognitive functions (see Box 1).34-36 We used the widely accepted 7-network topol-
ogy for neocortical areas as described in the Yeo and colleagues paper,36 the Buckner and 
colleagues paper37 for cerebellar network organization, the paper by Choi and colleagues38 
for striatal areas, and classified the hippocampus as a DMN region.39, 40
Quality assessment. We assessed the quality of individual studies by a National Institutes of 
Health standardized quality assessment tool of controlled intervention studies (https://www.
nhlbi.nih.gov/health-topics/study-quality-assessment-tools, see Supplementary material 2). 
Criteria involved clear trial description, randomization procedure, allocation concealment, 
blinding, no baseline differences between groups, low drop-out rate and difference in drop-
out between groups, high protocol adherence, similar simultaneous treatments (e.g., treat-
ment-as-usual), outcome measure quality, sufficient power, pre-specified analyses, and inten-
Box 1 Resting-state ‘cognitive’ networks
Default mode network (DMN) - Essential regions of the DMN are the medial pre-
frontal cortex and posterior cingulate cortex (PCC). This network is characterized 
by activity in the absence of external cognitive demand. The DMN is thought to be 
involved in integration of memory, self-monitoring and theory of mind.41-43
Frontoparietal network (FPN) - Important FPN regions are the dorsolateral prefrontal 
cortex (dlPFC) and the posterior parietal cortex. This network is also often referred 
to as the central executive network, and its activity is anti-correlated with DMN ac-
tivity. The FPN has previously been described as a “multi-demand network”,44 and 
its activity is important for goal-directed cognitive tasks, including working memory, 
planning, judgment and decision-making.45, 46 Relative to other brain networks, the 
FPN shows strong within- as well as between-network connectivity, reflecting the 
heterogeneous functions it encompasses.47
Dorsal attention network (DAN) & ventral attention network (VAN) - Lastly, two at-
tention networks can be distinguished that follow a dorsal route (DAN) or a ventral 
route (VAN). The DAN consists of important regions in the intraparietal sulcus and 
frontal eye field, and it is mainly important for voluntary, goal-directed attention ori-
entation 35, 48-50. The VAN directs attention stimulus-driven – that is, when identifying 
salient stimuli 35, 48, 50-52. The VAN is therefore also referred to as the “salience net-
work” 51, 53. Crucial VAN regions are the anterior insula and dorsal anterior cingulate 
cortex. 
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tion-to-treat analysis. The neuroimaging analysis quality was additionally assessed by a clear 
description of neuroimaging protocol and analyses, correction for motion and multiple com-
parisons correction. We coded trials as ‘Poor’ if they adhered to <10 criteria, ‘Fair’ if they ad-
hered to 10-13 criteria and ‘Good’ if they adhered to >13 criteria. Records were independently 
assessed by TvB and CV and disagreement was re-evaluated to consensus. As the final sam-
ple size was low, we did not exclude studies from this review based on the quality.
Results
Study selection. The literature screening resulted in 1760 records through PubMed, 1058 
records through Embase and 707 records through PsycINFO. Of these, 1300 records were du-
plicates and five records were non-English. A total of 2220 records were screened of which 
98 full-text articles were reviewed. Twenty full-text articles met the inclusion criteria and were 
included in this systematic review. An overview of the excluded records that underwent full-
text review, including the main reason for exclusion, is provided in Supplementary material 3. 
A flow diagram of the screening process according to PRISMA guidelines (www.prisma-state-
ment.org) is provided in Figure 1. 
Figure 1 Flow diagram of the screening process according to PRISMA guidelines.
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Study characteristics. Eight studies included healthy elderly,54-61 three studies included indi-
viduals with mild cognitive impairment (MCI),62-64 one study was performed in Alzheimer’s dis-
ease (AD),65 six in multiple sclerosis (MS),66-70 and one study was performed in Parkinson’s dis-
ease (PD).71 One study included AD and MCI patients, and healthy elderly.72 The sample size 
varied from twenty68, 69 to 54 participants.57 Fourteen studies assessed the neural effects of 
multi-domain training54-57, 62, 64, 66-72 and six studies assessed the effects of single-domain train-
ing.58-61, 63, 65 A description of the interventions and re-coding to single- or multi-domain training 
is supplied in Supplementary material 4. The amount of training hours varied from ten61 to 78 
hours.62 The majority of studies (i.e., n = 13) compared CT effects to an active control group,55, 
57, 60-65, 67, 70-73 six studies applied a passive control group54, 56, 58, 66, 68, 69 and one study compared 
CT to both an active and a passive control group.59 All studies used randomization except for 
three studies that were not described to be randomized55, 58, 67 and two studies that were un-
clear on randomization.63, 64 Detailed study characteristics are shown in Table 1.
Quality assessment. Table 2 shows the quality assessment results. We classified the Diez-Ci-
rarda et al. paper71 after re-evaluation as ‘Good’ as the main RCT aspects were present and 
clearly reported on, and we classified the Lin et al. paper63 after re-evaluation as ‘Fair’ as both 
the blinding and the randomization procedure were not reported on. A major limitation across 
most studies was the lack of blinding for participants and/or for assessors. The sample size 
was generally low without clear power calculations to support the sample size, probably due 
to the exploratory nature of the studies. In general, the neuroimaging methodology was clear-
ly reported on. Concerning competing interests, in the study by Diez-Cirarda and colleagues,71 
two co-authors were reported to be copyright holders of the studied intervention. Three 
studies did not report on competing interests.55, 60, 68 The other studies reported to have no 
competing interests. 
Results of individual studies. The results of individual studies and methodological details are 
summarized in Table 1. The results are divided into studies on multi-domain training and sin-
gle-domain training. A graphical presentation of the findings is shown in Figure 2. 
Multi-domain training: In healthy elderly. In healthy elderly, multi-domain training increased 
functional connectivity of the posterior cingulate cortex (PCC) with other DMN regions54, 55 and 
within-network connectivity of the FPN and salience network.54 Cao and colleagues54 addi-
tionally reported an increased training-related anti-correlation between the DMN and FPN. 
In the same dataset, Luo and colleagues56 showed increased laterality of the left FPN –an 
increased confinement of the FPN to the left hemisphere– after CT, which was interpreted as 
an increase in information processing efficiency. Li and colleagues57 assessed brain entropy 
in this dataset comparing the multi-domain training with an additional single-domain training 
and an active control condition (for a detailed description of entropy measures, see Li et al.).57 
Both the multi-domain and single-domain training counteracted the age-related increase in 
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Table 2 Assessment of individual studies on trial and neuroimaging quality.
A. Trial Quality Assessment B. Neuroimaging quality assessment
Overall as-
sessment
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Cao et al. 2016 Y Y Y N Y Y N N N NA Y Y CD Y Y Y Y Y Y Fair
Luo et al. 2016 Y Y Y N Y Y N N N NA Y Y CD Y Y Y Y Y Y Fair
De Marco et al. 2016 N NR NR N NR Y Y Y NR NA Y NR CD N Y Y NR Y Y Poor
Li et al. 2016 Y Y Y N Y Y N N N NA Y Y CD Y Y Y NR Y Y Fair
De Marco et al. 2018 N N NR NR NR Y N N Y Y Y N CD NR Y Y NR Y Y Poor
Suo et al. 2016 Y Y NR Y Y Y Y Y Y Y Y Y Y Y Y Y NR Y Y Good
Barban et al. 2017 Y Y Y NA Y Y Y NR NR Y Y NR CD NR Y Y Y Y Y Fair
Diez-Cirarda et al. 
2016 Y Y NR N Y Y Y Y Y Y Y Y Y Y Y Y NR Y Y Good
De Giglio et al. 2016 Y Y Y N Y CD Y NR NR Y Y N CD Y Y Y Y Y Y Fair
Bonavita et al. 2015 N NR NR NR NR CD Y NR NR Y Y NR CD NR Y NR NR Y Y Poor
Parisi et al. 2014 Y Y NR Y Y Y Y Y NR Y Y N CD Y Y Y NR Y N Fair
Filippi et al. 2012 Y Y NR Y Y Y Y Y NR Y Y N CD Y Y Y NR Y Y Good
Cerasa et al. 2013 Y Y Y Y Y Y Y Y NR Y Y N CD Y N Y NR Y Y Good
Campbell et al. 2016 Y Y Y N N Y Y Y Y Y Y NR Y Y N Y NR Y Y Fair
Kim et al. 2017 N N NR NA NR Y Y Y NR NR Y NR CD Y Y Y NR Y Y Poor
Kuhn et al. 2017 Y Y Y NR NR Y Y Y NR NR Y Y CD Y Y Y NR Y Y Fair
Ross et al. 2018 Y NR Y Y Y Y Y N Y Y N NR CD Y Y Y NR Y Y Fair
Lebedev et al. 2018 Y Y NR Y NR Y N Y NR N Y NR CD Y Y Y Y Y N Fair
Lin et al. 2016 Y NR NR N Y Y Y Y Y Y Y Y CD Y Y Y NR Y Y Fair
Huntley et al. 2017 Y Y NR N N Y Y Y NR NR Y Y Y Y Y Y NR Y NR Fair
Quality assessment criteria (see Supplementary material 2 for elaborate description): 1 = randomized (controlled) trial; 2 = adequate random-
ization; 3 = concealed treatment allocation; 4 = participant and assignment provider blinding; 5 = assessor blinding, 6 = similar group baseline 
characteristics; 7 = drop-out ≤ 20%; 8 = differential drop-out ≤ 15%; 9 = high protocol adherence; 10 = no other interventions; 11 = valid and 
reliable assessments; 12 = sufficient sample size; 13 = prespecified outcomes and analyses; 14 = intention-to-treat analysis; 15 = clear neuroim-
aging protocol; 16 = motion-corrected functional images; 17 = equal group motion parameters; 18 = clear neuroimaging analyses; 19 = multiple 
comparison correction. Trials were coded ‘Poor’ if they adhered to <10 criteria, ‘Fair’ at 10-13 criteria and ‘Good’ at > 13 criteria. Abbreviations: 
CD = cannot determine; N = no; NA = not available; NR = not reported; Y = yes.
whole-brain asynchrony and decrease in spontaneous brain activity. Additionally, the multi-do-
main training significantly reduced the age-related decrease in lateralization of entropy mea-
sures, while single-domain training did not. 
Multi-domain training: In neurodegenerative diseases. Five studies applied a specific 
multi-domain training (i.e., ‘RehaCom’) in individuals with MS with variable length (12-36 hours). 
Using independent component analysis on resting-state fMRI scans, RehaCom training in-
creased resting-state functional connectivity within the DMN, mainly in the posterior, parie-
to-occipital DMN regions,67 which correlated with a lower post-treatment interference on the 
Stroop task. Another study showed that RehaCom led to increased or stable resting-state ac-
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tivity fluctuations of salience network, FPN, and DMN areas relative to decreased fluctuations 
in the control group.69 In this study, task-related activation of the dorsolateral prefrontal cortex 
(dlPFC) and PCC during the interference condition of the Stroop task was also increased, 
correlating with performance on a working memory task (paced auditory serial addition test), 
but no information was provided on the direction of these specific correlations. On the same 
dataset, Parisi and colleagues68 reported increased resting-state functional connectivity be-
tween the anterior cingulate cortex (ACC) and inferior parietal lobe after RehaCom training 
that was related to improved performance on a working memory task. 
RehaCom training in MS induced increased task-related activation during a working memory 
task of a temporo-parietal region,70 and in the superior parietal and posterior cerebellar lobe; 
the latter correlated positively with post-training Stroop interference task performance (lobe 
Figure 2 Overview of the findings of all included studies, irrespective of population or training type, that 
reported coordinates of brain regions with CT-induced alterations. Each dot represents a single alteration 
in activity (panel A) or connectivity (in which both the seed and connected region are displayed; panel B). 
In panel B, the seed and connected regions are classified by resting-state network parcellation according 
to 36, 37, 38 to illustrate within- and between-network connectivity changes. The side views show intra-hemis-
pheric connections. Details about these studies are listed in Table 1. Abbreviations – FPN: frontoparietal 
network; DMN: default mode network; VAN: ventral attention network; DAN: dorsal attention network; SMN: 
somatomotor network; n.a.: no network assigned.
A: task-related activity
FPN DMN VAN DAN limbic SMN visual n.a.
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VI).73 After a 12-week follow-up period, task-related activity of the temporal-parietal and ad-
ditional frontal and prefrontal regions was still higher compared with the control group.70 A 
different multi-domain training paradigm in MS resulted in increased resting-state functional 
connectivity between the thalamus seed and the PCC, precuneus and lateral parietal cortex, 
and decreased connectivity between the thalamus and the left dlPFC, the vermis, and bilater-
al cerebellar cortical regions.66
In patients with amnestic MCI, multi-domain training decreased functional connectivity of the 
superior frontal gyrus and ACC with the PCC, a core area of the DMN, but increased con-
nectivity of the hippocampus with the superior frontal gyrus.62 Another multi-domain training 
increased the within-DMN connectivity in MCI patients,64 but did not alter connectivity within 
the FPN or visual network. The study from Barban et al.72 in MCI patients reported decreased 
functional connectivity of the medial superior frontal gyrus with the DMN after multi-domain 
training and –using network-based statistics analysis74– decreased connectivity within a 
subnetwork consisting of subcortical areas, the cerebellum, and temporal and occipital ar-
eas. They additionally reported increased betweenness centrality, i.e., the importance of a 
particular brain area in long-range network communication,75 of the orbitofrontal cortex, and 
decreased betweenness centrality of the cerebellar vermis. Conversely, in the same study 
multi-domain training in AD patients increased the spatial extent of the DMN, increased the 
functional connectivity of the network-based statistics subnetwork and increased between-
ness centrality of the ACC. The authors therefore concluded that multi-domain training had 
different effects on the brain in MCI and AD, despite similar cognitive improvements. It must 
be noted, however, that MCI patients improved mainly on memory tasks while AD patients 
showed an improvement in attention. 
In PD patients, an integrative multi-domain training resulted in increased resting-state func-
tional connectivity between the left inferior temporal lobe and bilateral dlPFC and increased 
activation of the left middle temporal lobe during a memory task.71 
Multi-domain training: Synthesis of results. Results from multi-domain training studies co-
herently suggest that it counteracts age-related or disease-related network dysfunction by 
increasing the within-network connectivity –predominantly reported in the DMN– and the 
degree of anti-correlation between networks, in particular between the FPN and DMN, which 
has been related to better cognitive functioning.45, 76, 77 Studies on within-DMN connectivity 
alterations in MCI and AD patients showed mixed results, however, with both increased and 
decreased connectivity in this resting-state network. CT increased task-related activity across 




Single-domain training: In healthy elderly. Processing speed/attention training induced de-
creased activation in the anterior insula and supplementary motor area during an in-scanner 
‘useful field of view’ task61 – a visual processing speed and attention task.78 This reduction in 
brain activation was significantly different compared with no-contact controls, while no train-
ing-induced activation differences were found relative to an active control group. In this study, 
resting-state functional connectivity of areas that showed activation during the task at base-
line increased significantly after the experimental training compared with both control groups. 
Kuhn and colleagues59 compared inhibition training to 1) multi-domain training on a mobile 
application and 2) a passive control condition, and found decreased activation of the right 
inferior frontal gyrus/anterior insula during an in-scanner stop-signal task after inhibition train-
ing only, although this effect did not reach significance in the interaction model (i.e., relative 
to the control groups). A cognitive control training increased activation of right frontoparietal 
regions and the left anterior insula during an interference control task.58 These results were 
associated with cognitive performance improvement, mainly on the Stroop color-word inter-
ference task. Working memory training increased brain-network segregation during an n-back 
and a visuospatial reasoning task as shown by increased whole-brain modularity and reduced 
connectivity between the FPN and both the DMN and sensorimotor network after training.60 
Interestingly, before training modularity was positively associated with working memory 
performance, but not with the complex reasoning task. The authors argued that the working 
memory training potentially induced an increased modular organization that is beneficial for 
specific abilities such as working memory, but deleterious for complex cognitive tasks. 
Single-domain training: In neurodegenerative diseases. In amnestic MCI patients, a visu-
ospatial speed of processing training resulted in increased resting-state functional connec-
tivity within the DMN,63 while increased FPN connectivity did not differ significantly from the 
active control group. An adaptive WM training in early AD resulted in decreased averaged 
post-training activity of the right dlPFC and left parietal cortex.65
Single-domain training: Synthesis of results. Single-domain training paradigms increased 
functional connectivity w1ithin networks and reduced connectivity between networks, similar 
to connectivity alterations after multi-domain training, but only two studies performed func-
tional connectivity analyses. These paradigms additionally induced reductions in task-related 
activations in both healthy elderly and an MCI population, which is generally interpreted as an 
increased efficiency of neural resources needed for the task at hand.79, 80 Reduced activation 
may additionally be related to the fact that the content of the single-domain CT was identical61, 
65 or highly similar59 to the in-scanner task, thus inducing practice effects. Accordingly, one 
study that used an in-scanner task that was dissimilar to the CT found increased training-re-
lated activity.58 The quality rating of this study was, however, poor so these results should be 
interpreted with caution.
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Discussion 
This paper systematically reviews studies that investigated the influence of CT through 
repeated cognitive engagement (i.e., process-based training) on task-related activity and 
resting-state functional connectivity using fMRI in both healthy populations and neurodegen-
erative diseases. Our results show that all investigated CT paradigms led to changes in brain 
activation during task performance and resting-state functional connectivity. There are three 
main conclusions to our research questions that can be drawn from this literature overview: 
1) CT induced both increases and decreases in task-related activity, mostly in fronto-parietal 
brain areas, without a clear influence of the targeted cognitive domains; 2) multi-domain CT 
was consistently reported to counteract dysfunctional connectivity patterns in cognitive brain 
networks that are generally associated with aging or neurodegenerative diseases; 3) method-
ological heterogeneity between studies limits our ability to statistically compare findings and 
study disease- or training-specific neural alterations. Below we consider the implications of 
our findings and critically discuss methodological issues to guide future research.
Task-related activation studies: training-induced improvement in increased neural effi-
ciency, or increased effort. The majority of single-domain studies and four multi-domain CT 
studies assessed training-induced alterations in task-related brain activation. We observed 
that alterations were most frequently reported in frontoparietal areas, probably driven by 
the fact that the FPN was a network of interest in most studies (see Limitations and rec-
ommendations for future research section). Three single-domain studies found decreased 
task-related activity after CT,59, 61, 65 while one single-domain study and all multi-domain studies 
found increased task-related activity.58, 69-71, 73 These results of both increased and decreased 
activity are in line with a meta-analysis in healthy elderly that similarly reported on functional 
activity alterations predominantly in areas of the FPN.81 A review on working memory train-
ing in healthy populations reported predominantly post-training regional activity decreases, 
while increased activity was more scarcely reported.82 An interesting distinction was found 
in one study that the review described, reporting decreased post-CT activity in young adults 
but increased activity in elderly suggesting different processes of plasticity.83 Another similar 
review in healthy populations also reported both increased and decreased brain activity after 
CT, possibly related to task selectivity, improved efficiency or more automatic processing due 
to CT.84 We hypothesize that either training-induced neural efficiency or neural effort can ac-
count for the bi-directionality of the results, although in-scanner task characteristics may also 
be relevant.
Decreased task-related activity after training suggests an increase in efficiency, i.e., reduced 
use of neural resources. This result was described only in healthy elderly samples and fits 
well with the literature on compensatory mechanisms of increased neural resource use to 
uphold ‘normal’ cognitive task performance in healthy aging.85-88 It is generally accepted 
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that aging-related decline in brain ‘fitness’ due to, for example, decreased within-network 
connectivity, increased neural noise, or dedifferentiation of task-positive and task-negative 
neural networks is compensated for by mechanisms such as regional over-activation, a pos-
terior-to-anterior shift in brain activity, and decreased asymmetry of hemispheric activity.89-91 
Our results may therefore indicate that the increased efficiency after single-domain training 
reverses age-related compensatory mechanisms of increased neural effort while maintaining 
cognitive performance (illustrated by (1) in Figure 3, panel A and B). 
Four studies in patients with PD or MS reported an increase in post-training activity during 
task performance. This seems to reflect an increase in neural effort, which is in contrast with 
the increase in efficiency as described above – but may be related to differences between 
Figure 3 Working model. A) The inverted U-shaped association between regional brain activity during 
task performance and task load. Aging and neurodegenerative diseases lead to a shift of the curve to 
the left, while CT seems to induce the opposite, illustrated by the horizontal arrows. Consequently, at the 
same task load different neural resources are needed/used. B) The association between task-related brain 
activity and network connectivity and modularity at increasing age or disease stage. The arrows indicate 
the suggested effect of CT at different stages of aging or disease. Both in panel (A) and (B), (1) indicates 
training-induced hypo-activity associated with neural efficiency: either a) tasks with lower demand can be 
performed more efficiently through cognitive training (panel A), or b) CT (partially) restores compensatory 
hyper-activity that is associated with early stages of aging and neurodegenerative diseases to a more 
‘healthy’ state (panel B); (2) indicates that CT leads to hyper-activity that is associated with increased effort 
and which is needed to successfully fulfill a task with a high cognitive demand. 
cognitive function
aging and increasing neurodegenerative disease stage
within network connectivity


























The effects of cognitive training on brain network activity and connectivity in aging and 
neurodegeneative diseases: a systematic review
healthy and non-healthy populations. Theories on compensatory mechanisms with healthy 
aging assume that significant neural remodeling occurs, while at the behavioral level per-
formance remains relatively unimpaired.90 This mechanism has also been described in early 
stages of neurodegenerative diseases in which task performance is still comparable to age-
matched healthy controls.92-95 Indeed, in a recent study, working memory CT showed similar 
task-related activity decrease in healthy adults and a population of early-stage cognitively 
healthy MS patients.96 Cognitive performance in MS and PD patients is, however, generally 
impaired97, 98 and compensatory mechanisms as described above may at later disease stage 
no longer be sufficient for these patients. Indeed, task-related neural activity is hypothesized 
to follow an inverted U-shaped curve both in healthy adults and elderly subjects,91 in patients 
suffering from MS99 and neuropsychiatric disorders,100 so that when task demands become 
too high, compensatory hyperactivity fails resulting in relative hypo-activity and impaired 
performance. In the reviewed studies on MS and PD patients, we hypothesize that –as base-
line cognitive performance was impaired in these studies– training resulted in a shift of the 
U-shaped curve to the right thus counteracting the relative hypo-activity at baseline, and 
improved performance (illustrated as (2) in Figure 3). There is, however, no information on the 
baseline cognitive performance of the MS and PD samples relative to healthy controls.
Differences in task demand and familiarity may also have impacted the observed outcomes. 
In accordance with the literature on compensatory brain processes,85, 91 variation in task load 
difficulty between task-related fMRI studies may have induced different results with less 
demanding fMRI tasks such as a digit span task65 inducing increased efficiency of neural re-
sources, while complex tasks such as the multi-source interference task58 induced increased 
brain activity. Moreover, some studies using fMRI task paradigms that were also part of the CT 
paradigm, e.g., in Huntley et al.65  and Ross et al.61, reported post-training activity decreases, 
while studies using an fMRI task that was less similar to the tasks being trained (such as in the 
multi-domain training studies) showed increased post-training activity. In line with theories of 
neural efficiency85 and neural scaffolding,86 this may indicate increased neural efficiency by 
familiarity of the task paradigm –i.e., having repeatedly performed one specific task– or in-
creased scaffolding by being able to address compensatory neural resources, respectively.
Counteracting age- or disease-related neural network dysfunctions. The brain is organized 
into several segregated functional and structural networks that facilitate the execution of com-
plex functions.35, 53, 101 Aging and neurodegenerative diseases lead to reductions in the con-
nectivity within networks and decreased segregation of (i.e., increased connectivity between) 
these networks.102-106 Our review shows that relative to a control condition, CT consistently 
induced neural alterations that counteracted these age- and disease-related connectivity pat-
terns. This was particularly evident for studies on multi-domain training. First, CT increased in-
tra-network functional connectivity. This effect was most frequently reported within the DMN, 
but also for the FPN, DAN/VAN connectivity and in functional connectivity of the hippocampus 
86
Chapter 4
and thalamus. Additionally, CT enhanced the degree of network segregation, evident from 
increases in the anti-correlation between task-negative (i.e., DMN) and task-positive networks 
(FPN or DAN), or a training-induced increase in whole-brain modularity. Enhanced segregation 
is associated with better cognitive functioning in the network literature.106
Two reports specifically addressed age-related neural alterations and described a long-term 
effect of CT on resting-state fMRI-derived indices of neural network laterality56 and brain 
entropy,57 even a year after training. Similarly, a recent study in patients with MCI found in-
creased spontaneous regional brain activity during resting-state.107 Taken together, the results 
thus seem to indicate a restorative effect of CT on aging and neurodegeneration-induced 
changes in neural network organization (see Figure 3, panel B). This seems mainly applicable 
to multi-domain training. It should be noted that only a single study enrolled both a healthy 
and a non-healthy population; it therefore remains speculative whether CT indeed restores 
brain network connectivity of patients with neurodegenerative diseases to healthy control 
levels.
Limitations and recommendations for future research. The main shortcoming of the re-
viewed literature is the heterogeneity in type of training, imaging methodology, in-scanner 
task paradigm and analysis method, which did not allow us to do statistical comparisons 
through meta-analyses. The reviewed studies all show that CT induces changes in brain ac-
tivity and connectivity that are not localized to specific brain regions. Our systematic review 
therefore does not seem to confirm an earlier reported assumption that neural alterations 
are specific to a particular type of CT82 – although there are some general differences be-
tween multi- and single-domain training. It remains, however, unclear if any population- or 
training-specific effects exist. There is a significant body of literature on functional activity and 
connectivity changes after strategy-based CT that show similar findings as the results from 
this review. For instance, mnemonic strategy CTs increased activity of fronto-parietal and tem-
poral regions in individuals suffering from MCI and increased functional connectivity within 
cognitive networks in healthy elderly.108-112 These studies were, however, beyond the scope of 
this review. An additional issue impacting the results of this review is that there is a likelihood 
of publication bias given the lack of negative results in this review sample. 
Future research should focus on statistically comparing training packages and types, popula-
tion-specific CT effects and quantify publication bias. Likewise, our quality assessment iden-
tified several low-powered, non-blinded, or non-randomized studies, which substantiates the 
need for future studies with unified CT paradigms and analysis methods to enhance compara-
bility. The use of healthy control samples could additionally highlight differential effects of CT 
on healthy and non-healthy populations and shed light on possible restorative effects that CT 
might induce. One recently published study in a small group of individuals with MS 
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showed for example that hyper-activation relative to healthy controls at baseline was partially 
normalized after CT.113
An important methodological limitation of the reviewed studies is the fact that the majority 
of studies focused on alterations of the activity or connectivity of a single or only a few brain 
regions using ROI- or seed-based approaches. As a consequence, the selection of the ROI 
or seed determines the observed patterns and (slight) shifts in location may already lead to 
different results.114 Moreover, ROI- or seed-based approaches are based on the assumption 
that cognitive functions are related to discrete brain regions and thus focus on just a piece 
of the puzzle.115 By exclusively focusing on particular ROIs or seed regions, other potentially 
interesting and meaningful brain activity and connectivity patterns might have been missed. 
Neural correlates of CT were, for example, reported mainly in cognitive brain networks, but 
the majority of the ROIs or seed regions were located within these networks which biases the 
reported effects. As higher-order cognitive functions typically require the integration of multi-
ple brain processes by having large-scale networks interact dynamically, instead of relying on 
independent, localized processes,26, 27, 46 whole-brain, integrative approaches are indispens-
able in the assessment of neural CT correlates.
Improvements in computational power in neuroimaging and its analyses have led to a net-
work approach that can grasp the complexity of behavior including cognitive functions.26, 116, 
117 In neuroscience, neural network topology and dynamics are strongly correlated with cog-
nitive functions.118-120 An example of an integrative approach is offered by a single study in this 
review that used modularity as a graph theoretical measure to assess neural network segre-
gation after CT.60 The results of this study confirm the findings from seed-based connectivity 
studies in this review of CT-induced enhanced task-positive versus task-negative network 
segregation during task performance. It has further been advocated that to really understand 
the neural correlates of executive functioning –and by extension the working mechanism 
of CT– one needs to study the dynamic and flexible engagement of brain networks.121 Inter-
actions between brain regions constantly change during task execution, a process called 
dynamic network reconfiguration, which is dependent on task demands.121-123 Converging 
evidence of both integrative and targeted approaches may in the end lead to a better under-
standing of how CT alters brain function.
Lastly, although most studies show that CT is able to induce either clinical cognitive improve-
ment or lead to changes in brain activity and/or connectivity, few studies report on an actual 
association between CT-induced alterations in brain function and the change in neuropsy-
chological measures. Yet, from a clinical perspective, it is essential to demonstrate these 
associations between neural alterations and improvement on neuropsychological measures 
and, even more so, in measures of everyday function. Furthermore, the organization of brain 
networks may serve as a predictive biomarker for treatment response to facilitate personal-
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ized CT programs (i.e., precision medicine). Multiple studies in neurological and psychiatric 
populations have shown that the individual variation in pre-training brain morphological and/
or network characteristics, e.g., brain modularity or cortical volume, is related to the variability 
in CT-induced cognitive improvement.124-129 In addition, neural activation and functional con-
nectivity after CT reportedly predict the persistence of neuropsychological and behavioral 
improvement at follow-up testing.130-132
Conclusion. There is convincing evidence that cognitive process-based training alters brain 
activation and connectivity patterns. CT-induced changes occur mainly in neural networks 
important for cognitive function and seem to counteract dysfunctional activation and connec-
tivity patterns associated with aging and neurodegenerative diseases, either indicative of a 
restorative or compensatory process – or a combination thereof. In order to improve our un-
derstanding of CT-induced neural alterations and the associated cognitive improvement, we 
advocate a network view of the brain to better comprehend the complex, dynamic changes 
in the brain induced by training. It is essential to harmonize the methodology and improve 
trial quality to increase comparability between studies and ultimately enable quantitative me-
ta-analyses. Knowledge of how CT alters the brain network and how this relates to cognitive 
improvement may ultimately improve CT efficacy and accelerate individualized cognitive 
training programs.
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Supplementary material 1 – Overview of structured literature search
Three components were added in the literature search, i.e. a combination of “cognitive train-
ing” and related terms, “neuroimaging” and related terms, and exclusion terms based on our 
eligibility criteria. The search strategy below was used in PubMed and translated to PsycINFO 
and Embase.
 › Cognitive training component
“cognitive training”[tiab] OR “attention training”[tiab] OR “working memory training”[tiab] OR 
“memory training”[tiab] OR “strategy training”[tiab] OR “processing speed training”[tiab] OR 
“speed-of-processing training”[tiab] OR “multitasking training”[tiab] OR “multi-tasking train-
ing”[tiab] OR “cognitive rehabilitation”[tiab] OR “attention rehabilitation”[tiab] OR “working 
memory rehabilitation”[tiab] OR “memory rehabilitation”[tiab] OR “strategy rehabilitation”[tiab] 
OR “processing speed rehabilitation”[tiab] OR “speed-of-processing rehabilitation”[tiab] OR 
“multitasking rehabilitation”[tiab] OR “multi-tasking rehabilitation”[tiab] OR “cognitive inter-
vention”[tiab] OR “attention intervention”[tiab] OR “working memory intervention”[tiab] OR 
“memory intervention”[tiab] OR “strategy intervention”[tiab] OR “processing speed interven-
tion”[tiab] OR “speed-of-processing intervention”[tiab] OR “multitasking intervention”[tiab] 
OR “multi-tasking intervention”[tiab] OR “cognitive enhancement therapy”[tiab] OR “attention 
enhancement therapy”[tiab] OR “working memory enhancement therapy”[tiab] OR “memory 
enhancement therapy”[tiab] OR “strategy enhancement therapy”[tiab] OR “processing speed 
enhancement therapy”[tiab] OR “speed-of-processing enhancement therapy”[tiab] OR “multi-
tasking enhancement therapy”[tiab] OR “multi-tasking enhancement therapy”[tiab] OR “cogni-
tive stimulation”[tiab]
 › Neuroimaging component
network*[tiab] OR brain[tiab] OR neural*[tiab] OR “magnetic resonance imaging”[tiab] OR fM-
RI[tiab] OR MRI[tiab] OR connectivity[tiab] OR neurofunctional[tiab] OR structural[tiab] OR func-
tional[tiab] OR neuroimaging[MeSH]
 › Exclusion criteria components
a. Not: psychotherapy[tiab] OR “cognitive behavioral therapy”[tiab] OR “acceptance and 
commitment therapy”[tiab] OR mindfulness[tiab] OR meditat*[tiab] OR “transcranial mag-
netic stimulation”[tiab] OR TMS[tiab] OR “transcranial direct current stimulation”[tiab] OR 
tDCS[tiab] OR “deep brain stimulation”[tiab] OR DBS[tiab] OR “electroconvulsive therapy-
”[tiab] OR ECT[tiab] OR magnetoencephalo*[tiab] OR electroencephalo*[tiab]
b. No animal studies: Not: animals[Mesh] NOT humans[Mesh]
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c. Adult studies: Not: (“Adolescent”[Mesh] OR “Child”[Mesh] OR “Infant”[Mesh] OR adoles-
cen*[tiab] OR child*[tiab] OR schoolchild*[tiab] OR infant*[tiab] OR girl*[tiab] OR boy*[tiab] 
OR teen[tiab] OR teens[tiab] OR teenager*[tiab] OR youth*[tiab] OR pediatr*[tiab] OR pae-
diatr*[tiab] OR puber*[tiab]) NOT (“Adult”[Mesh] OR adult*[tiab] OR man[tiab] OR men[tiab] 
OR woman[tiab] OR women[tiab])
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1. Was the study described as randomized, a randomized trial, a randomized clini-
cal trial, or an RCT?
2. Was the method of randomization adequate (i.e., use of randomly generated 
assignment)?
3. Was the treatment allocation concealed (so that assignments could not be 
predicted)?
4. Were study participants and providers blinded to treatment group assignment?
5. Were the people assessing the outcomes blinded to the participants’ group 
assignments?
6. Were the groups similar at baseline on important characteristics that could 
affect outcomes (e.g., demographics, risk factors, co-morbid conditions)?
7. Was the overall drop-out rate from the study at endpoint 20% or lower of the 
number allocated to treatment?
8. Was the differential drop-out rate (between treatment groups) at endpoint 15 
percentage points or lower?
9. Was there high adherence to the intervention protocols for each treatment 
group?
10. Were other interventions avoided or similar in the groups (e.g., similar back-
ground treatments)?
11. Were outcomes assessed using valid and reliable measures, implemented 
consistently across all study participants?
12. Did the authors report that the sample size was sufficiently large to be able to 
detect a difference in the main outcome between groups with at least 80% pow-
er?
13. Were outcomes reported or subgroups analyzed pre-specified (i.e., identified 
before analyses were conducted)?
14. Were all randomized participants analyzed in the group to which they were 
originally assigned, i.e., did they use an intention-to-treat analysis?
Neuroimaging quality assessment
15. Was the neuroimaging protocol clearly described?
16. Were functional images corrected for motion?
17. Were motion parameters equal between groups?
18. Were the neuroimaging analyses clearly described?
19. Did the authors correct for multiple comparisons by using corrected P values?
Quality Rating (Good, Fair, or Poor)
Rater #1: Rater #2:
Additional Comments (If POOR, please state why): 
*CD, cannot determine; NA, not applicable; NR, not reported
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Supplementary material 3 – Overview of excluded studies  
after full-text review
Reason of exclusion:
4. No neurodegenerative disease/healthy elderly population (N=37)1-37
5. No pre- and post-CT fMRI assessment (N=12)38-49
6. No process-based cognitive training intervention (N=18)50-67
7. Combination intervention (N=4)68-71
8. Sample size < 20 (N=3)72-74
9. No control group (N=4)75-78
Supplementary material 4 –  Description of the study interventions 
and re-coding of CT type to single-domain or multi-domain training
Study Intervention description Re-coding
Cao et al. 
2016 CT
Multi-domain cognitive training targeting memory, reasoning 
and problem-solving. Multi-domain
Control Wait-list. Passive
Luo et al. 
2016 CT
Multi-domain cognitive training targeting memory, reasoning 
and problem-solving. Multi-domain
Control Wait-list. Passive
De Marco et 
al. 2016 CT
Cognitive training with semantic retrieval, logical reasoning, 
proper names retrieval and speed of processing tasks, and a 
single-trial final exercise.
Multi-domain
Control A daily regime of intense social interactions. Active
Li et al. 2016 CT
Multi-domain cognitive training targeting memory, reasoning 




Control Lectures about healthy living every two months. Active
De Marco et 
al. 2018 CT
Cognitive training with semantic retrieval, logical reasoning, 
proper names retrieval and speed of processing tasks, and a 
single-trial final exercise.
Multi-domain
Control A daily regime of intense social interactions. Active
Suo et al. 
2016 CT
Multi-domain training with fourteen exercises focusing on mem-
ory, working memory, speed of processing, executive function 
and attention.
Multi-domain
Control Watching documentary clips and answering simple questions about these. Active
Barban et al. 
2017 CT
Cognitive training including memory, executive function, atten-
tion, reasoning and ‘other’ domain exercises. Multi-domain
Control Name and numeric value entry. Active
Diez-Cirarda 
et al. 2016 CT
Cognitive training including attention, memory, language, exec-
utive function and social cognition components. Multi-domain
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Study Intervention description Re-coding
Control Occupational therapy (drawing, reading news, constructing) Active
De Giglio et 
al. 2016 CT
Cognitive training including memory, attention, visuospatial 
processing and calculation games. Multi-domain
Control No intervention. Passive
Bonavita et 
al. 2015 CT
Cognitive training including attention and concentration, plan 
a day, divided attention, reaction behavior and logical thinking 
sessions.
Multi-domain
Control Newspaper reading and explaining the content Active
Parisi et al. 
2014 CT
Cognitive training including attention, information processing 
and executive function components. Multi-domain
Control No intervention. Passive
Filippi et al. 
2012 CT
Cognitive training including attention, information processing 
and executive function components. Multi-domain
Control No intervention. Passive
Cerasa et al. 
2013 CT
Cognitive training including several attention ability and infor-
mation processing tasks. Multi-domain
Control Visuomotor coordination reaction time task. Active
Campbell et 
al. 2016 CT
Cognitive training divided in three modules focusing on work-
ing memory, visuospatial memory and divided attention. Multi-domain
Control No intervention. Passive
Kim et al. 
2017 CT Cognitive training using five tasks of cognitive control. Single-domain
Control No intervention. Passive
Kuhn et al. 
2017 CT Cognitive training using an inhibition game. Single-domain
Control Both a mobile cognitive training application or no intervention. Active and passive
Ross et al. 
2018 CT
Useful field of view training focusing on diverse attention func-
tions. Single-domain
Control
Both a complex paper-and-pencil training targeting higher level 




al. 2018 CT Cognitive training using four tasks of working memory. Single-domain
Control Perceptual speed training. Active
Lin et al. 
2016 CT
Cognitive training using five tasks focusing on vision-based 
speed of processing. Single-domain
Control Online crosswords, Sudoku and solitaire games. Active
Huntley et al. 
2017 CT Cognitive training of adaptive digit span recall using chunking. Passive
Control Non-adaptive digit sequence of three digits. Active
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Abstract
Background. Cognitive dysfunction is highly prevalent in Parkinson’s disease (PD) and a large 
proportion of patients eventually develops PD-related dementia. Currently, no effective treat-
ment is available. Cognitive training is effective in relieving cognitive dysfunctions in several 
–neurodegenerative– diseases, and earlier small-scale trials have shown positive results for 
PD. In this randomized controlled trial, we assess the efficacy of online home-based cognitive 
training, its long-term effects, as well as the underlying neural correlates in a large group of 
PD patients. 
Methods. In this double-blind randomized controlled trial we will include 140 non-dement-
ed patients with idiopathic PD that experience significant subjective cognitive complaints. 
Participants will be randomized into a cognitive training group and an active control group. 
In both groups, participants will individually perform an online home-based intervention for 
eight weeks, three times a week during 45 minutes. The cognitive training consists of thirteen 
games that focus on executive functions, attention and processing speed with an adaptive dif-
ficulty. The active control comprises three games that keep participants cognitively engaged 
without a training component. Participants will be subjected to extensive neuropsychological 
assessments at baseline and after the intervention, and at six months, one year and two years 
of follow-up. A subset of participants (40 in each treatment condition) will undergo structural 
and functional magnetic resonance imaging. The primary outcome of this study is the perfor-
mance on the Tower of London task. Secondary outcomes are objective and subjective cog-
nitive functioning, conversion to PD-related mild cognitive impairment or dementia, functional 
and structural connectivity and network topological indices measured with magnetic reso-
nance imaging. None of the outcome measures are part of the cognitive training program. 
Data will be analyzed using multivariate mixed-model analyses and odds ratios.
Discussion. This study is a large-scale cognitive training study in PD patients that evaluates 
the efficacy in relieving cognitive dysfunction, and the underlying mechanisms. The strengths 
of this study are the large sample size, the long follow-up period and the use of neuroimaging 
in a large subsample. The study is expected to have a low attrition and a high compliance rate 
given the home-based and easily-accessible intervention in both conditions. 
Trial registration. ClinicalTrials.gov ID NCT02920632. Registered September 30, 2016.
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COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of homebased, 
online cognitive training on cognition and brain networks in Parkinson’s disease
Background
Background and rationale. Cognitive impairments are among the plethora of non-motor 
symptoms associated with Parkinson’s disease (PD).1, 2 Approximately 25% of PD patients suf-
fer from significant cognitive impairments already at the time of diagnosis,3, 4 and up to 80% 
eventually develop PD dementia (PD-D).5, 6 Moreover, compared with people without PD, pa-
tients with PD have up to 5.9 times the risk to develop dementia.7 Cognitive impairments have 
a negative impact on performing the activities of daily living8, 9 and are an important modulator 
in the development of neuropsychiatric symptoms, including psychosis.10, 11 Degeneration 
of dopaminergic and non-dopaminergic systems is one of the alleged causes of cognitive 
impairments12, 13 and have therefore been targets for pharmacological treatments. Although 
these drugs have modest temporary effects on cognitive symptoms by improving the atten-
tional capacity, they have no proven efficacy in preventing further cognitive decline in PD.14, 
15 Hence, non-pharmacological treatment options must be considered as an alternative treat-
ment for alleviating cognitive dysfunction in PD.
Cognitive training in PD: the gap in knowledge. Cognitive training (CT) was developed after 
the first brain tumor resections and traumatic brain injury treatment during the World Wars,16 
but is currently applied in numerous neurological and psychiatric diseases. Meta-analyses 
have confirmed its efficacy in relieving cognitive dysfunction in Alzheimer’s disease,17 mild 
cognitive impairment (MCI),18 schizophrenia,19 and traumatic brain injury.20, 21 Furthermore, a 
recent meta-analysis in PD yielded positive results of CT mainly in relieving ‘frontal’ cognitive 
dysfunction (i.e. executive dysfunction, and working memory and psychomotor speed impair-
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ment).22 This meta-analysis, however, included only seven randomized controlled trials (RCTs), 
with a maximum sample size of 73 PD patients.23 Consequently, the authors called for larger 
trials in PD populations – a conclusion that had earlier been stated in a systematic review24 – 
although the results cautiously implied cognitive training to be efficacious. 
The potential of cognitive training to preserve and protect. Two study protocols have 
recently been published, describing a cognitive training intervention in PD.25, 26 Both inter-
ventions are specifically aimed at patients who have already developed PD-related MCI26 or 
PD-D,25 respectively. However, neural changes have been demonstrated early on in cogni-
tively preserved PD:27-30 at this stage compensatory local hyperactivity seems to counteract 
the progressive buildup of PD pathology that threatens global brain network function.31, 32 At 
a later disease stage, this compensatory mechanism gradually fails and ultimately leads to 
brain-wide network failure and cognitive dysfunction.33-35 An early-stage intervention to boost 
the compensatory phase during this window of opportunity is imperative to try and preserve 
cognitive functions and protect patients from cognitive decline (for a working model, adapted 
from Gerrits,36 see Figure 1).
Cognitive training may induce reorganization of structural and functional networks in the 
brain: it has been proposed that CT leaves a ‘footprint’ on the brain, that prepares the brain 
for better and faster processing.37 Multiple studies have provided evidence that CT can in-
duce reorganization of the brain network infrastructure. For example, patients with amnestic 
MCI showed post-CT normalization of within- and between-network connectivity38, 39 that cor-
related with improved performance on memory tasks.39 In addition, CT can alter resting-state 
networks in multiple sclerosis,40-42 normalize task-related activity in patients with schizophre-
nia,43, 44 and enhance functional connectivity37, 45, 46 and cerebral blood flow37 in healthy elderly. 
Figure 1 Working model of local compensatory brain activity (in yellow) that preserves intact 
cognitive functioning (in blue) but fails at later disease stage, while global brain network integrity gradually 
degenerates (in green). Dashed lines illustrate the hypothesized effects that CT may have on local and 














performance failure of compensation
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online cognitive training on cognition and brain networks in Parkinson’s disease
To date, only a few reports have focused on the underlying neural alterations after CT in PD47-
49 in small and mainly exploratory studies (N = 10-30). Results were mixed, showing increased 
functional connectivity,48 increased local activation,47, 48 but also decreased local activation49 in 
comparison with controls. 
In this study we aim to assess the efficacy of CT in a large sample of PD patients using a lon-
gitudinal design. Moreover, we aim to establish working mechanisms of CT by visualizing the 
within- and between-network changes that occur during training and to use the pre-treatment 
network topology, combined with the demographic and clinical characteristics, to predict who 
will profit most from CT. 
Methods and design
Study objectives. In this study protocol we present COGTIPS – the “COGnitive Training In 
Parkinson Study”. The main research questions of this project are 1) What is the short-term 
and long-term effect of CT on objective and subjective cognitive functioning in PD? and 2) 
What are the neural mechanisms underlying the effect of CT in PD? 
The study objectives of the COGTIPS study involve assessing an easily-accessible, home-
based cognitive function training in individuals with mild subjective cognitive complaints in 
PD. Our primary objective is to assess the efficacy of an online CT program (compared to an 
active control condition) on executive functions. Our secondary objectives are to evaluate CT 
compared with an active control condition (AC) on 1) the efficacy on relieving subjective cogni-
tive complaints; 2) the durability of the effect after six months, one year and two years; 3) the 
rate of conversion to PD-MCI and PD-D after one year and two years; 4) the effect on brain 
network efficiency and connectivity. Furthermore, we aim to identify baseline brain network 
characteristics that predict treatment outcome.
Based on previous literature on CT in PD and other neurodegenerative diseases, we hypoth-
esize that compared with an active control condition 1) CT alleviates cognitive –mainly execu-
tive– dysfunction in PD patients, 2) CT relieves subjective cognitive complaints in daily-life, 3) 
the CT effect endures for up to two years after finishing the intervention, and reduces the risk 
of conversion to PD-MCI and PD-D, and 4) CT improves brain network efficiency and connec-
tivity.
Study design and setting. COGTIPS is a monocenter phase-III randomized controlled trial 
that will enroll one-hundred-and-forty (140) PD patients. To assess the superiority of the online 
CT compared with an AC, participants are randomly appointed to either of the conditions in a 
1:1 fashion (70 versus 70). Eighty participants (i.e. 40 in each condition) will undergo pre- and 
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post-training neuroimaging to assess CT-specific effects on functional and structural connec-
tivity. This study was approved by the VU University Medical Center Medical Ethical Commit-
tee and this protocol is reported in accordance with SPIRIT guidelines (see SPIRIT checklist in 
the online additional file 2).50
The COGTIPS study will be performed at the Amsterdam University Medical Centers (Am-
sterdam UMC), location VUmc, an academic hospital with expertise in movement disorders 
located in Amsterdam, the Netherlands. We will enroll Dutch-speaking PD patients that have 
shown their interest in participation through 1) the outpatient clinic for movement disorders of 
the Amsterdam UMC, or community or academic hospitals in the area, 2) the PD patient asso-
ciation (“Parkinson Vereniging”), 3) advertisements in media like the Parkinson Magazine and 
national newspapers, 4) advertisements on participant recruiting websites such as ‘Parkinson-
Next’ and ‘Hersenonderzoek.nl’, and 4) a database of PD patients that have previously shown 
interest in online cognitive training. 
Eligibility criteria. Participants will be included on the basis of the presence of subjective 
cognitive complaints. We will focus on mild-to-moderate disease stage PD patients with mild 
cognitive complaints, to ensure that these patients are still within the ‘window of opportunity’. 
An overview of the inclusion and exclusion criteria is depicted in Table 1.
Pre-screening, screening and baseline assessment. PD patients that have shown interest in 
participating in COGTIPS will first undergo pre-screening for which they are required to sign 
informed consent and send this back by mail or E-mail. Pre-screening consists of a self-ad-
ministered cognitive screening and questionnaires that are filled out at home (i.e. Self-admin-
istered Gerocognitive Examination),51 and a phone interview. Patients are asked whether they 
are interested in participating in the subgroup that will undergo neuroimaging and if so, are 
screened for contraindications. After positive pre-screening, eligible patients are invited for an 
intake measurement.
At intake, patients will sign informed consent for participation in COGTIPS. They first undergo 
face-to-face screening of cognitive dysfunction by the Montreal Cognitive Assessment,52, 53 
motor impairment by the Unified Parkinson’s Disease – Rating Scale part III,54 psychotic symp-
toms by the Schedule for Assessment of Positive Symptoms – PD,55 depressive symptoms by 
the Beck Depression Inventory56 and impulse control disorders (ICDs) by an ICD criteria inter-
view. Eligible patients will undergo the baseline assessment (‘T0’) which comprises an exten-
sive neuropsychological assessment, structured interviews and questionnaires. A sub-popu-
lation will undergo magnetic resonance imaging. Neuroimaging data will be acquired at the 
Amsterdam UMC, location VUmc, on a Discovery* MR750 3.0T MRI scanner (General Electric, 
Milwaukee) with a 32-channel head coil. We will obtain structural imaging (i.e. T1 and diffusion 
tensor imaging) and functional resting-state imaging. See Supplementary material for the scan 
109
COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of homebased, 
online cognitive training on cognition and brain networks in Parkinson’s disease
parameters. All assessments are performed by study members that are blinded for the treat-
ment condition. The screening and baseline assessment will be performed during a single 
visit to the Amsterdam UMC, location VUmc.  
Participant timeline. Figure 2 shows a global overview of the time schedule. A detailed de-
scription of the participant visits and assessments is shown in Table 2.
Table 1 Overview of inclusion and exclusion criteria.
Inclusion criterion Measured with Defined by
Significant subjective cognitive complaints Parkinson’s Disease Cognitive 
Functional Rating Scale
Score > 3
Mild to moderate disease stage Hoehn & Yahr disease stage Score < 4
Access to computer or tablet with access to Internet. 
Capability to use keyboard and computer mouse
Phone interview -
Signed informed consent - -
General exclusion criterion Measured with Defined by
Indication for dementia syndrome Self-administered Gerocognitive 
Examination
Score < 14
Montreal Cognitive Assessment Score < 22
Current drug- or alcohol abuse CAGE AID-interview Score > 1
Inability to undergo extensive neuropsychological 
assessments or eight weeks of home-based cogni-
tive intervention
- -
Moderate to severe depressive symptoms Beck depression inventory > 18
Presence of one or more impulse control disorders ICD criteria interview Positive screening
Psychotic symptoms. Benign hallucinations with 
insight are not an exclusion criterion
Schedule for Assessment of 
Positive Symptoms – PD
Positive screening
Traumatic brain injury Phone interview Cerebral contusion with 
1) loss of consciousness 
for > 15 minutes and 2) 
posttraumatic amnesia 
> 1 hour
Exclusion criterion for participation in magnetic 
resonance imaging
Measured with Defined by
A space occupying lesion Assessment by radiologist -
Significant vascular abnormalities Assessment by radiologist Fazekas > 1
Severe claustrophobia
MRI safety screening question-
naire Positive screening
Presence of metal in the body (e.g. pacemaker, neu-
rostimulator)
Pregnancy
Difficulty with, or shortness of breath during 60 min-
utes of lying still
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Condition allocation and instructions. Following a positive screening for eligibility, a non-blind-
ed study member will allocate the participant to either the CT or AC condition. Participants will 
be consecutively assigned to either the CT or AC condition on the basis of a randomization 
sequence. The randomization sequence is generated in Microsoft Excel by using comput-
er-generated random numbers. We will use stratified randomization in which two strata will be 
generated according to education level. Vocational education level (or lower) defined as an 
education level of 5 or lower according to a Dutch classification system,57 which is compara-
ble to 11 or less years of education.58 High education level is defined as level 6 or 7 according 
to the Verhage classification system, which is comparable to 12 or more years of education. 
A non-blinded study member will provide instructions to the participant concerning the log-in 
procedure for the training, the various training components, and the duration and frequency 
of training. After instructions, the participant will be asked to fill out a questionnaire concern-
ing the patients’ expectations and credibility regarding the intervention.59 Participants will 
additionally receive a hand-out with instructions to take home.  
Eight-week intervention period. After the baseline assessment, participants may directly start 
with the 8-week intervention. A detailed description of the CT and AC interventions is provid-
ed below. Compliance will be monitored automatically and will be checked weekly. During the 
intervention, patients will receive biweekly questionnaires to ensure compliance and check 
for questions and problems performing the intervention. Non-blinded study members will 
follow-up on potential problems by phone. 
Post-intervention assessments. After 24 intervention sessions, patients are invited for the 
post-intervention assessment. This assessment will be scheduled as close as possible to the 
last training session. Participants will first evaluate the intervention with a non-blinded study 
member. Directly afterwards, participants will undergo a post-intervention assessment (‘T1’). 
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This assessment comprises a neuropsychological assessment and questionnaires (see Ta-
ble 2). One team member (TB) will be de-blinded after the last T1 visit. All assessments after 
baseline will make use of parallel versions of neuropsychological tasks, if possible. After six 
months (‘T2’), one year (‘T3’) and two years (‘T4’), participants will again undergo an extensive 
neuropsychological assessment and questionnaires. At T3 and T4, motor symptoms will also 
be assessed. From T3 onwards will be a naturalistic follow-up.
Blinding. Outcome assessors will be blinded for the full length of their role as assessor, while 
non-blinded team members will not assess participants at any point in this study. Blinded 
study members will not have access to the key of the randomization. Trial participants will be 
blinded for the full length of the study. Participants will be asked not to share any details of 
their intervention with the outcome assessor at any point in the study. When the participants’ 
condition is revealed to an outcome assessor, he or she will be replaced by another assessor 
for this participant.
Drop-outs. Participants that drop out of the study after being allocated to an intervention con-
dition will not be replaced. We expect a low drop-out rate on the basis of our pilot study (one 
drop-out in 21 participants) and the low burden and short duration of both training conditions. 
In our sample size calculation, we conservatively account for 10% drop-out. In case a partici-
pant withdraws from the study after four weeks of training (or more), we will aim to schedule 
an exit-measurement to measure the intervention effect.
Medication adjustments. Participants and their neurologist will be requested to retain a stable 
medication regime during the study period, specifically during the intervention. Patients and 
their neurologist will be requested to inform the study team if medication changes are clinical-
ly necessary. 
Interventions. The intervention in this study aims to train cognitive abilities, with a focus on 
executive functions, working memory, attention, and processing speed. A modified version of 
the BrainGymmer online CT platform (www.braingymmer.com, a product by Dezzel Media B.V.) 
is used to provide the training at the patients’ home. We selected this method of cognitive 
training as it has been evaluated positively in our earlier pilot study in PD patients (see below), 
it is accessible for patients at home, and previous versions have been used in prior studies.60, 
61 A proof-of-concept in twenty PD patients showed that the experimental condition was eval-
uated as feasible and enjoyable. Moreover, the CT compared with an active control showed a 
medium interaction effect size on an executive functioning composite (i.e. Stroop Color Word 
Test, Trail Making Test and Controlled Oral Word Association Test), with a significantly positive 
change of executive functioning in the CT group but not in the active controls. Specifically, a 
large positive interaction effect size of CT on the Stroop color word test was found compared 
with controls (see Supplementary material for a visual representation).
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Table 2 Tabular overview of the study time schedule including assessments and visits.
Time-point T-2 T-1 T0 T1 T2 T3 T4
Pre-screening 
Informed consent for pre-screening X
SAGE X
PD-CFRS X X X X X
MRI safety screening X
Alcohol abuse screening (CAGE-AID) X
Eligibility screening
Montreal Cognitive Assessment X X X X X
ICD diagnostic criteria X X
SAPS-PD† X
Beck depression inventory X X X X X
Hoehn & Yahr stage X X X






1. Tower of London X X X X X
Montreal Cognitive Assessment† X X X X
Pentagon copy X X X X X
1/2. Stroop Color Word Test X X X X X
1. COWAT (‘letter fluency’)† X X X X X
2. WAIS-III digit span X X X X X
3. Rey Auditory Verbal Learning Test‡ X X X X X
3. Location Learning Test# X X X X X
4. Boston naming test X X X X X
4. Category fluency X X X X X
5. Rey Complex Figure Test X X X X X
5. Visual Form Discrimination Test X X X X X
*in a subsample of N = 80. Parallel forms of the same test are used at consecutive visits if available: †Three 
parallel forms; ‡Two parallel forms; #One parallel form. 
Cognitive domains: 1Executive functioning, 2Attention and working memory, 3Memory, 4Language, 5Visuo-
spatial. Abbreviations: CFQ = Cognitive Failures Questionnaire; COWAT = Controlled Oral Word Association 
Test; DTI = diffusion tensor imaging; MP RAGE= magnetization-prepared 180 degrees radio-frequency puls-
es and rapid gradient-echo; (f)MRI = (functional) magnetic resonance imaging; NZPAQ-SF = New Zealand 
Physical Activity Questionnaire – Short Form; PD-CFRS = Parkinson’s Disease – Cognitive Functional Rating 
Scale; PSIR = phase-sensitive inversion recovery; QPE = Questionnaire for Psychotic Experiences; QUIP-RS 
= Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease – Rating Scale; SAPS-PD: Scale 
for Assessment of Positive Symptoms for Parkinson’s disease; UPDRS = Unified Parkinson’s Disease Rating 
Scale; WAIS = Wechsler Adult Intelligence Scale. 
An overview of cognitive assessments and questionnaires, including references is provided in the Supple-
mentary material.
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Time-point T-2 T-1 T0 T1 T2 T3 T4
Questionnaires and interviews
CFQ X X X X X
Apathy scale X X X X X
Parkinson anxiety scale X X X X X
QUIP-RS X X X X X
NZPAQ-SF X X X X X
Credibility/expectancy questionnaire X
Motor symptom assessments
UPDRS-III - motor score X X X
Medication use
Levodopa equivalent daily dosage X X X X X
Neuroimaging*
MP-RAGE X X
3D PSIR X X
fMRI - resting state X X
DTI X X
*in a subsample of N = 80. Parallel forms of the same test are used at consecutive visits if available: †Three 
parallel forms; ‡Two parallel forms; #One parallel form. 
Cognitive domains: 1Executive functioning, 2Attention and working memory, 3Memory, 4Language, 5Visuo-
spatial. Abbreviations: CFQ = Cognitive Failures Questionnaire; COWAT = Controlled Oral Word Association 
Test; DTI = diffusion tensor imaging; MP RAGE= magnetization-prepared 180 degrees radio-frequency puls-
es and rapid gradient-echo; (f)MRI = (functional) magnetic resonance imaging; NZPAQ-SF = New Zealand 
Physical Activity Questionnaire – Short Form; PD-CFRS = Parkinson’s Disease – Cognitive Functional Rating 
Scale; PSIR = phase-sensitive inversion recovery; QPE = Questionnaire for Psychotic Experiences; QUIP-RS 
= Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease – Rating Scale; SAPS-PD: Scale 
for Assessment of Positive Symptoms for Parkinson’s disease; UPDRS = Unified Parkinson’s Disease Rating 
Scale; WAIS = Wechsler Adult Intelligence Scale. 
An overview of cognitive assessments and questionnaires, including references is provided in the Supple-
mentary material.
Intervention characteristics. In both conditions, 24 training sessions are performed: three 
times a week for a length of eight weeks. The training sessions last approximately 45 min-
utes, marginally dependent on the participants’ performance. Compliance and training perfor-
mance data are automatically tracked when a participant performs a training session. Partic-
ipants can independently schedule the three training sessions per week to ensure flexibility 
and a low training threshold. The training sessions can be paused at the participants’ discre-
tion but they are advised to try and complete the entire training within one hour. 
Cognitive training. In the experimental condition, 13 CT games are sequentially performed. 
The cognitive processes that the training games call upon are similar to processes that are 
tested during the neuropsychological assessments, but the games are substantially different 
from the neuropsychological tasks. The training games are equipped with a ‘dynamic difficulty 
adjustment’: the difficulty of training components is adaptive to the participants’ performance, 
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and will increase or decrease depending on individual performance. This way, participants will 
be challenged to continuously perform at their maximal ability. Training games, their duration 
and the hypothesized cognitive loading are shown in Table 3. 
Active control group. An active control condition is used to correct for the nonspecific cogni-
tive activity that participants in the CT group go through. In the control condition, participants 
undergo cognitive engagement using three games (i.e. solitaire, trivia questions and hang-
man) with a total duration of 45 minutes that will sequentially be performed and are hypothe-
sized not to train specific cognitive functions. 
Outcomes. Primary outcome. The primary outcome is the efficacy of CT on executive func-
tions, measured by the percentage correct change score on a previously used computerized 
self-paced version of the Tower of London (ToL) task.29 The ToL measures several aspects 
of executive functions, including planning, inhibition, and working memory.62 This neuropsy-
chological task consists of a model of three pins with different lengths, and three differently 
colored beads. In this task, the goal is to get from a starting position to a target position in as 
minimal steps as possible. There are five planning conditions that range in difficulty, with pos-
sible solutions ranging from one to five steps (i.e. task-load S1-S5). After nine exercise items 
Table 3 Description of training games in the CT condition with their duration and the cognitive loading.
Description Duration Cognitive loading
Repeat a drum rhythm that increases in length 3 mistakes Working memory, attention
Flanker task 80 s Cognitive flexibility
Put a sequence in the correct prompted order 180 s Visuospatial function, focused attention
An ‘N-back’ task using bottles of various shapes 
and colors 180 s Working memory
Evaluate if a ‘totem pole’ comprising blocks of dif-
ferent forms and diameters matches a top view 2 mistakes Visuospatial function, mental rotation
Follow one or more moving targets (i.e. a bunny 
with a carrot) between several distractors 4 mistakes Focused and divided attention
Accept or decline stimuli based on switching rules 
with increasing speed 90 s Cognitive flexibility, processing speed
Remember an increasing number of colored 
squares 120 s Working memory, attention
Click an increasing number of stimuli (i.e. food on 
a barbeque) at the right time (i.e. when they are 
well-done)
180 s Divided attention, psychomotor and processing speed
Search birds with a certain color and form between 
an increasing number of distractors 300 s Visuospatial function, processing speed
Stack blocks of numbers that differ by one on top 
of another to reduce the number of blocks 180 s Planning
Remember the color and accessories of a penguin 
and at the same time the location of a fish 180 s Working memory, processing speed
Finish a puzzle within a limited time 240 s Visuospatial function, processing speed
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with feedback, 100 pseudo-randomized test trials will be presented with a maximum response 
duration of 45 seconds per trial and no feedback on accuracy. 
Secondary outcomes. The secondary outcome measures include (i) subjective cognitive com-
plaints, (ii) cognitive function (other than the ToL) and (iii) structural and functional connectivity 
and brain network characteristics. All outcomes described below are changes after interven-
tion relative to baseline.
 + Subjective cognitive dysfunction change after the intervention will be measured by the 
Parkinson’s Disease Cognitive Functional Rating Scale (PD-CFRS)63 score and the Cog-
nitive Failures Questionnaire (CFQ) score at the end of the intervention (T1), and at fol-
low-up (T2, T3, and T4). We use the PD-CFRS questionnaire as a Parkinson-specific and 
sensitive measurement of subjective cognitive function. This questionnaire will be filled 
out by the participant and if possible by a caregiver. We will additionally use the CFQ as 
this measure has been used more frequently and it is more sensitive to small cognitive 
errors in daily living such as memory problems, absent-mindedness and slips of action;64
 + Cognitive function change after the intervention will be measured by
i. change on latent underlying cognitive factors in the neuropsychological assessment 
at T1 and at follow-up (T2, T3, and T4). Participants will undergo an extensive assess-
ment battery of frequently-used and validated neuropsychological tests (see Table 
2). See Lezak et al.65 for standard outcome measures of the neuropsychological 
tests. We will extract latent cognitive traits at baseline and measure training-induced 
changes on these factors at follow-up (see Analyses for a detailed description);
ii. reduction of the risk of developing PD-MCI or PD-D at follow-up at one-year and 
two-year follow-up. We will classify participants at the follow-up visits into level II PD-
MCI66 and probable PD-D67 according to the most recent diagnostic criteria;
 + Training-induced neural alterations will be measured with magnetic resonance imaging 
(MRI). Morphometric brain characteristics will be measured with standard measures (i.e. 
subcortical volume, cortical thickness, fractional anisotropy). We will measure function-
al connectivity by extracting independent components of simultaneously fluctuating 
blood-oxygen level dependent signals that represent resting-state brain networks. Brain 
network characteristics will be measured by standard topological measures (i.e. mod-




Exploratory outcomes and covariates. For exploratory purposes, the following outcomes will 
be collected. 
 + Training-induced cognitive changes on individual neuropsychological tasks (see Table 2) 
will be assessed to increase comparability with other CT studies, and to increase replica-
bility of the results in future research;
 + Improvement on the individual CT games will be measured in order to compare potential 
component-specific transfer effects. Performance on the CT components are collected 
automatically by the BrainGymmer online training module;
 + Alterations on psychiatric symptoms of anxiety, depression, apathy, and impulse control 
disorders, using the Parkinson anxiety scale, Beck depression inventory, Apathy scale, 
and Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease – Rating 
Scale, respectively.
Additionally we will collect data on the following potential confounding factors:
 + Data on physical activity at each visit will be measured by the New Zealand Physical Ac-
tivity Questionnaire – Short Form, a structured interview on mild, moderate and vigorous 
physical activity, as physical activity is known to positively influence cognitive function 
and potentially provide a neuroprotective effect;70, 71
 + We will rate motor symptom severity by the Unified Parkinson’s Disease – Rating Scale 
part III and assess disease stage by the modified Hoehn & Yahr stage;72
 + Medication usage data are collected and transformed into a ‘levodopa equivalent daily 
dosage’.33 Dopamine replacement therapy may influence cognitive functions;73, 74
 + Intervention compliance will automatically be monitored by the training module. We will 
calculate total compliance as the proportion of completed training games out of 24 total 
sessions: [Ncompleted / Ntotal] x 100%, in which Ntotal is 13 games x 24 sessions in the CT con-
dition, and 3 games x 24 sessions in the AC condition. We define non-compliance as a 
completion rate lower than 75%, in accordance with Petrelli and colleagues.75
Data-analyses. Data-analyses will be performed on the Modified-Intention-To-Treat popula-
tion, which comprises the compliant participants that underwent at least 75% of the interven-
tion and at least one post-training assessment. We will compare the baseline characteristics 
of this sample to the Intention-to-Treat population (all randomized subjects). Secondary Per 
Protocol-analyses will be performed comprising the population that underwent the complete 
study protocol. Analyses will be performed with IBM SPSS version 22 (Armonk, NY, USA) and 
in R.76 We will employ a statistical threshold of α = .05. 
The primary outcome will be analyzed using a multivariate mixed-model analysis using the 
accuracy on the five separate task-loadings (S1-S5) of the ToL at post-training visit (T1) as de-
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pendent measures, the training condition (CT vs. AC) as independent measure and baseline 
score of the outcome measures as covariates. We will construct a separate adjusted model 
with age, sex and years of education as additional covariates of no-interest. No imputation of 
missing values will be performed as this is not needed in linear mixed models.
The secondary outcome measures will also be analyzed with linear mixed-models with base-
line score of the outcome measures as covariates. Subjective cognitive dysfunction will be 
modeled with the total score of the PD-CFRS (both self-report and caregiver) and the CFQ 
a) at post-training (T1) and b) at all follow-up assessments (T2, T3 and T4) as dependent vari-
ables. We will perform a factor analysis on all neuropsychological assessment outcomes (see 
Table 2) at baseline using a factor analysis with regularized maximum likelihood estimation to 
produce latent cognitive traits. We will compute baseline trait scores (i.e. factor scores), and 
compute trait scores at follow-up measurements based on the baseline factor analysis. The 
effect of CT on cognitive functions will be assessed with a multivariate mixed-model compara-
ble to the above, using the trait scores as dependent variables. The effect of CT relative to AC 
on neuropsychiatric symptoms will be analyzed using similar multivariate mixed-models with 
as dependent variables the Beck Depression Inventory, the Parkinson Anxiety Scale, the Ap-
athy Scale and the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
– Rating Scale. Covariates will be added to the regression model based on a change-in-es-
timate method if there is a change of ≥ 10% of the regression coefficient for the intervention 
variable.
In order to analyze between-group differences in conversion to PD-MCI or PD-D, we will first 
classify patients at baseline, T3 and T4 as having normal cognition, PD-MCI or PD-D. We 
define conversion ‘down’ as conversion to a milder cognitive dysfunction classification, no 
conversion as classification in the same category at a later assessment visit and conversion 
‘up’ as conversion to a worse cognitive function classification. We will assess the association 
between the intervention and conversion rate with a Fisher’s exact test. Odds ratios and con-
fidence intervals of the conversion ‘down’ and no conversion groups versus the conversion 
‘up’ group will be computed as a measure of effect size.
We will perform Fisher’s exact tests to verify if the demographic and clinical characteristics 
of the MRI subsample are similar to those of the full study sample. Functional MRI and dif-
fusion tensor imaging data will be (pre)processed and analyzed with Statistical Parametric 
Mapping (SPM) software, FMRIB Software Library (FSL) and in-house Matlab (The MathWorks, 
Inc, Natick, MA, USA), scripts in combination with open-source toolboxes for (dynamic) net-
work analysis68, 69 to study the effects of cognitive training on the functional and structural 
brain network, respectively. We will also employ typical independent component analysis in 
combination with dual regression for resting-state functional connectivity and morphometric 
(e.g. cortical thickness) analysis on T1-weighted structural MRI to study within and between 
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group-effects of our intervention. Moreover, to establish treatment response at the individual 
level, Multivariate Pattern classification (‘machine learning’) analyses will be performed to 
identify predictive markers (clinical, neuropsychological and neuroimaging) to be able to pre-
dict (in future patients) who is most likely to benefit from cognitive training.
Sample size. The sample size calculation is performed on the basis of a previous meta-analy-
sis on the effects of CT on cognitive function.22 This study showed an effect size of Hedges g 
= .23 (i.e. f = .12), based on the effect of CT on improving global cognitive function. The sample 
size needed to detect this effect is 112, based on a repeated-measures analysis of variance, 
corrected for a moderate correlation between pre- and post-treatment measures (i.e. r ≈ .6). 
This sample size estimation also provides a good indicator for the power of our multivariate 
mixed-model regression analysis with adjustment for baseline measures. To ensure adequate 
power for the secondary study parameters, i.e. the development of PD-MCI and PD-D at one 
and two years follow-up, with an α = .05 and β = .8, and based on a small drop-out (~10%) 
given the home-based, easily-accessible training, we will include 140 participants.
Discussion 
The aim of the “COGnitive Training In Parkinson Study” (COGTIPS) is to assess the efficacy 
of an eight-week, online cognitive training program on alleviating cognitive dysfunction and 
subjective cognitive complaints, on delaying long-term cognitive deterioration and on increas-
ing brain network connectivity and efficiency. COGTIPS is the first study in PD in a large group 
of PD patients –in accordance with recommendations from an earlier meta-analysis and re-
view22, 24– that combines extensive clinical assessments with neuroimaging. We focus on PD 
patients in the ‘window of opportunity’, i.e., non-demented PD patients with mild subjective 
cognitive complaints that are expected to have the opportunity to employ significant neural 
plasticity in response to cognitive training. With the use of up to two-year follow-up assess-
ments, this study can shed more light on the long-term effects of CT and its value in delaying 
conversion to PD-MCI and PD-D. The large subsample that will undergo MRI may show insight 
in the working mechanism of CT and baseline neuroimaging may additionally provide net-
work organization characteristics that can predict individual training response.
The target population of COGTIPS consist of Dutch PD patients in the mild to moderate dis-
ease stage who experience significant subjective cognitive complaints but are not suspected 
of having PD-D. In this population that is often still active in work or social life, disease pro-
gression and cognitive decline provoke substantial worrying and are therefore an important 
subject of research.77 The target population is large as about 50.000 Dutch individuals have 
PD, roughly 50% of whom have cognitive impairments,3 which does not include the even 
more prevalent subjective cognitive complaints that do not formally meet ‘impairment’ crite-
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ria.78 However, the population is potentially heterogeneous given the large variety in age and 
degree of cognitive dysfunction. We may also expect ceiling scores on some of the neuropsy-
chological assessment tasks in this non-demented PD population. We are, however, able to 
adhere to the level II criteria for PD-MCI and the criteria for probable PD-D using an extensive 
neuropsychological assessment battery.66, 67
We will compare the CT adapted from the BrainGymmer environment to an active control 
condition based on ‘crystallized intelligence’ tasks. We thus correct for the cognitive engage-
ment that participants are subjected to, to allow for any placebo effect mainly on subjective 
cognitive improvement and training effect on repeated cognitive assessment. Any CT-specific 
results will therefore be due to the training components. In the CT condition we will use an 
individually-based difficulty adaptation to adjust the training to the patients’ abilities. This en-
sures that participants are continuously stimulated at their own cognitive level and do not get 
frustrated or anxious by a training that is too difficult or bored by one that is too easy. Consid-
ering that we apply a home-based intervention and subjects can schedule their own training 
days, we expect a low attrition rate.
An important issue to overcome will be the medication use of participants, as the full study 
period will be more than two years. It is not realistic to expect stable medication over such a 
long period of time, although we will try to minimize medication changes as much possible 
in the first year by checking medication stability before subject participation and asking both 
the subject and neurologist to try and keep the medication regime stable. We will additionally 
correct for medication changes in our analyses and use a levodopa-equivalent daily dosage 
to aggregate the different types of PD medication.
There are substantial indications that cognitive training may provide an effective, non-phar-
macological intervention to improve cognitive function in PD and delay cognitive decline, but 
evidence from large-scale RCTs is lacking. The aim of COGTIPS is to provide evidence for the 
efficacy of an easily-accessible, home-based online cognitive training, to validate the potential 
long-term effects and to shed more light on the underlying neural mechanism that mediate 
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Overview of cognitive assessments and questionnaires,  
including references
Cognitive screening 
Montreal Cognitive Assessment1 
Self-administered Gerocognitive Examination2
Neuropsychological tests 
Boston naming test3 
Category fluency4 
Computerized adaptation of the Tower of London5 
Controlled Oral Word Association Test (‘letter fluency’)6 
Location Learning Test7  
Pentagon copy from the Mini-Mental State Examination8 
Rey Auditory Verbal Learning Test9 
Rey Complex Figure Test10 
Stroop Color Word Test11 
Visual Form Discrimination Test12 
Wechsler Adult Intelligence Scale-III digit span13
Questionnaires 
Apathy scale14 
Beck depression inventory 
Alcohol and drug abuse screening (CAGE-AID15, 16) 
Cognitive Failures Questionnaire17 
Credibility/expectancy questionnaire18 
New Zealand Physical Activity Questionnaire – Short Form19 
Parkinson anxiety scale20 
Parkinson’s Disease – Cognitive Functional Rating Scale21 
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease – Rating Scale22
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MRI parameters
All scans were acquired on a Discovery* MR750 3.0T MRI scanner (General Electric, Milwau-
kee) with a 32-channel head coil at the Amsterdam UMC, VU University (Amsterdam, the 
Netherlands).
Resting-state fMRI. 272 volumes (~10 minutes) of T2*-weighted echo-planar images (EPI’s) 
with the following parameters: TR = 2200 ms, TE = 28 ms, flip angle = 80°, 42 axial slices (3.3 
x 3.3 x 3.3 mm, matrix size 64 x 64). Sequential ascending acquisition according the hypoph-
ysis – fastigium (HYFA) line. High-order shimming (HOS) was performed to compensate for 
inhomogeneity in the magnetic field. Two reference scans in opposite phase-encode direc-
tions are acquired prior to the resting-state acquisition to correct for susceptibility induced 
distortions during post-processing: TR = 8000 ms, TE = 60 ms. The field-of-view, position, 
orientation and matrix dimensions are identical to the resting-state scan. 
Diffusion-weighted MRI. Single Spin Echo multi-shell DWI with 73 diffusion weighted images 
(25 x b = 1000 s/mm2, 24 x b = 2000 s/mm2, 24 x b = 3000 s/mm2) and seven non-diffusion 
weighted (b = 0 s/mm2). TR = shortest (6000-7000 ms), TE = shortest (80-90 ms), 56 axial 
slices (2.5 x 2.5 x 2.5 mm, matrix size 128 x 128). Interleaved ascending acquisition according 
the hypophysis – fastigium (HYFA) line. High-order shimming (HOS) was performed to com-
pensate for inhomogeneity in the magnetic field. Two reference scans in opposite phase-en-
code directions are acquired prior to the diffusion-weighted image to correct for susceptibility 
induced distortions during post-processing: TR = 8000 ms, TE = 60 ms. The field-of-view, 
position, orientation and matrix dimensions are identical to the diffusion-weighted image
Structural MRI. 3D sagittal MP-RAGE T1-weighted sequence according to ADNI-3 protocol with 
the following parameters: TI = 900 ms, TE = min full echo, flip angle = 80°, 168 slices (1 x 1 x 1 
mm, matrix size 256 x 256). 3D Cube sagittal Phase sensitive inversion recovery (PSIR) with 
the following parameters: TI = 650 ms , TR = 3000 ms, TE = minimum, 168 slices (1 x 1 x 1 mm, 
matrix size 256 x 256).
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Additional figure
Effect of cognitive training compared with an active control condition in a proof-of-concept.
Supplementary material references
1. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screen-
ing tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695-699.
2. Scharre DW, Chang SI, Murden RA, et al. Self-administered Gerocognitive Examination (SAGE): a brief 
cognitive assessment Instrument for mild cognitive impairment (MCI) and early dementia. Alzheimer Dis 
Assoc Disord 2010; 24(1): 64-71.
3. Kaplan E, Goodglass H, Weintraub S. Boston naming test: Pro-ed, 2001.
4. Luteijn F, Barelds D. Herziening van de GIT. Handleiding bij de GIT-2. Harcourt Publishers, Amsterdam; 
2005.
5. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 1982; 298(1089): 199-
209.
6. Schmand B, Groenink S, Van den Dungen M. Letterfluency: psychometrische eigenschappen en Ned-
erlandse normen. Tijdschr Gerontol Geriatr 2008; 39(2): 64-74.
7. Kessels RP, Nys GM, Brands AM, van Zandvoort MJ. [The Location Learning Test as a measure of spatial 
memory: applicability of a modified administration procedure and normative data]. Tijdschr Gerontol Geri-
atr 2004; 35(4): 147-152.
8. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive 
state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189-198.
9. Saan RJ, Deelman BG. De 15-woordentest A en B (een voorlopige handleiding). Groningen: Afdeling 
Neuropsychologie, AZG, 1986.
10. Meyers JE, Meyers KR. Rey Complex Figure Test and recognition trial professional manual: Psychologi-
cal Assessment Resources, 1995.
Figure S1 Change on median neuropsychological performance on left: an executive function composite 
score (consisting of standardized scores of the Stroop color word test card III corrected for card II, the Trail 
making test part B corrected for part A and the Controlled Oral Word Association Test) and right: the Stroop 
color word test card III corrected for card II. Significant differences are shown with the corresponding P 
value. Abbreviations: AC = active control condition; CT = cognitive training.
EXECUTIVE FUNCTION COMPOSITE STROOP COLOR-WORD TEST



























COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of homebased, 
online cognitive training on cognition and brain networks in Parkinson’s disease
11. Hammes JGW. De Stroop Kleur-Woord Test. Handleiding. Amsterdam: Pearson Assessment and Infor-
mation B.V., 1971.
12. Benton AL, Sivan AB, deS Hamsher K, Varney NR. Contributions to neuropsychological assessment: A 
clinical manual: Oxford University Press, USA, 1994.
13. Wechsler D. Wechsler adult intelligence scale - third edition. Dutch version. Amsterdam: Pearson As-
sessment and Information B.V., 2000.
14. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, 
and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4(2): 134-
139.
15. Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion 
validity in a primary care practice. Wis Med J 1995; 94(3): 135-140.
16. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984; 252(14): 1905-1907.
17. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its 
correlates. Br J Clin Psychol 1982; 21 (Pt 1): 1-16.
18. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav 
Ther Exp Psychiatry 2000; 31(2): 73-86.
19. McLean G, Tobias M. The New Zealand physical activity questionnaires: Report on the validation and 
use of the NZPAQ-LF and NZPAQ-SF self-report physical activity survey instruments. . New Zealand: 
SPARC, 2004.
20. Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson 
Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 2014; 29(8): 1035-
1043.
21. Kulisevsky J, Fernandez de Bobadilla R, Pagonabarraga J, et al. Measuring functional impact of cogni-
tive impairment: validation of the Parkinson’s disease cognitive functional rating scale. Parkinsonism Relat 
Disord 2013; 19(9): 812-817.
22. Weintraub D, Mamikonyan E, Papay K, Shea Ja, Xie SX, Siderowf A. Questionnaire for impulsive-com-




Effect of eight-week  
online cognitive  
training in Parkinson’s 
disease: a randomized 
controlled trial
Tim D. van Balkom, Henk W. Berendse, Ysbrand D. van der Werf,  
Jos W.R. Twisk, Carel F.W. Peeters, Rob H. Hagen, Tanja Berk,  
Odile A. van den Heuvel,1 & Chris Vriend1
1Shared last author
Preprint at: medRxiv 2021.03.04.21252499
Under review at: Neurology
130
Abstract
Background. Cognitive training (CT) has been proposed as a non-pharmacological treatment 
option for the frequent cognitive impairments occurring in PD.
Objective. Assess the efficacy of CT on cognitive function in PD.
Methods. In this double-blind, randomized controlled trial we enrolled 140 PD patients with 
significant subjective cognitive complaints. In eight weeks, participants underwent 24 ses-
sions of computerized multi-domain CT or an active control condition for 45 minutes each 
(n=70 vs. n=70). The primary outcome was the accuracy on a computerized Tower of London 
task; secondary outcomes included effects on other neuropsychological outcomes and sub-
jective cognitive complaints. Outcomes were assessed before and after training and at six-
months follow-up, and were analyzed with multivariate mixed-model analyses.
Results. The intention-to-treat population consisted of 136 participants. Multivariate 
mixed-model analyses showed no group difference on the Tower of London accuracy cor-
rected for baseline performance: B: -0.06, 95% CI: -0.27 to 0.15, p=0.562. Participants in the 
CT group were on average 0.30 SD (i.e., 1.5 seconds) faster on the Tower of London, difficulty 
load 4 (secondary outcome): 95% CI: -0.55 to -0.06, p=0.015. CT had similar positive effects 
on other processing speed-related executive function tasks, although these did not reach 
statistical significance. At follow-up, no group differences were present.
Conclusions. The results show tentative but consistent positive effects of CT on processing 
speed during executive functioning. Future studies should investigate booster sessions to 
increase durability, optimize training duration, and study different sub-groups of PD patients 
along the continuum of cognitive decline towards PD dementia. 
Clinical trial registration. This study was preregistered at ClinicalTrials.gov, identifier 
NCT02920632.
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Background
Cognitive impairment is highly prevalent in Parkinson’s disease (PD). At diagnosis already 
25% of PD patients experience cognitive deficits in one or more domains1 and the point prev-
alence of dementia in PD patients is 25-30%.2 Estimates of the cumulative prevalence of PD 
dementia (PD-D) range from 46% after ten years of follow-up3 to as high as 83% after twenty 
years.4
The available pharmacological treatments for cognitive impairment in PD have limited effica-
cy, focus on relieving symptoms but not on delaying decline, and can have negative side-ef-
fects.2, 5 Cognitive training (CT) has been proposed as a promising alternative. CT may allevi-
ate cognitive impairment and slow down cognitive decline by boosting neuroplasticity6 and 
improving the efficiency of global and regional brain networks.7
Meta-analyses of previous CT studies in PD showed that CT has a small positive effect on 
global cognitive function.8, 9 Larger effect sizes were reported for ‘frontal’ cognitive domains, 
including a moderate effect on executive function and small to moderate effects on working 
memory and mental processing speed (mean Hedges’ g ranging from 0·30-0·74). Two studies 
additionally showed long-term positive effects of CT, lasting up to 18 months after training,10, 11 
suggesting its potential in delaying cognitive decline. Nevertheless, the available evidence is 
based on small studies with methodological limitations; consequently, double-blind random-
ized controlled trials (RCT) using valid objective and subjective cognitive outcome measures 
are needed to provide more reliable evidence.8, 12
132
Chapter 6
In this report we present the primary results of the COGnitive Training In Parkinson Study 
(COGTIPS).13 We hypothesized, based on earlier research, that CT would predominantly im-
prove executive function (primary outcome), but also other cognitive functions, i.e. working 
memory and processing speed. We also hypothesized that CT would decrease subjective 
cognitive complaints and would have long-term effects (i.e. at six-months follow-up). 
Methods
Trial design. COGTIPS is a large mono-center phase-3 double-blind RCT to assess superiority 
of eight-week computerized CT over an active control condition (AC). Participants were en-
rolled at the Amsterdam University Medical Centers (Amsterdam UMC), location VU University 
Medical Center. A detailed study protocol article was published before the end of the recruit-
ment period and de-blinding, also including the results of a pilot feasibility study.13 This trial 
was prospectively registered at ClinicalTrials.gov, identifier NCT02920632 (September 30, 
2016) and the CONSORT checklist is provided as Supplementary material.
Participants. We enrolled 140 PD patients that were eligible for participation, with a) mild to 
moderately advanced idiopathic PD, diagnosed by a neurologist (Hoehn and Yahr stage < 4),14 
b) significant subjective cognitive complaints (Parkinson’s Disease Cognitive Functional Rating 
Scale (PD-CFRS) score > 3),15 and c) home access to a computer or tablet with internet. Exclu-
sion criteria were a) Montreal Cognitive Assessment (MoCA) score < 22,16, 17 b) indications of 
current drug- or alcohol abuse (CAGE AID-interview score > 1),18, 19 c) moderate or severe de-
pressive symptoms (Beck Depression Inventory (BDI) score > 18),20 d) impulse control disorder 
(positive screening by diagnostic criteria), e) psychotic symptoms (positive screening by the 
Schedule for Assessment of Positive Symptoms – PD),21 except for benign hallucinations, or f) 
history of traumatic brain injury with loss of consciousness for > 15 min and/or posttraumatic 
amnesia > 1 h. All participants gave written informed consent and the study was approved by 
the Medical Ethical Committee of the VU University Medical Center.
Randomization and blinding. Detailed information is provided in our design article.13 Briefly, 
participants were randomized over an experimental CT condition and an AC in an 1:1 fashion. 
Randomization lists were generated using a random number sequence, stratified on educa-
tion level. Blinding of participants was ensured by not providing any details to participants 
about the two conditions. Participants remained blind to their condition throughout the entire 
study and outcome assessors were blinded during all assessments. The training interventions 
were explained after participants completed the baseline assessment. Blinded study mem-
bers (TB and trained research assistants) enrolled and assessed participants. Only non-blind-
ed study members (CV and trained research assistants) had access to the allocation and 
randomization files.
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Procedures. In both conditions, participants followed an online home-based intervention 
on computer or tablet, that had a duration of eight weeks, three times a week for approx-
imately 45 minutes (total duration: 1080 min). The CT consisted of 13 training games, that 
had an adaptive difficulty based on the individual participants’ performance, based on the 
‘Braingymmer’ online CT platform (www.braingymmer.com, a product by Dezzel Media). The 
training aimed to improve ‘frontal’ cognitive functions. The games were not part of the pre- 
and post-intervention assessments. We corrected for non-specific cognitive engagement by 
using an AC that consisted of three games without difficulty adjustments (i.e., hangman, trivia 
questions and solitaire). 
At baseline (T0), after training (T1, at approximately nine weeks) and at follow-up (T2, approx-
imately six-months after training) patients underwent an extensive assessment that included 
neuropsychological tests, questionnaires and interviews (see below and the protocol article13 
for details). 
Outcomes. The primary outcome measure was the efficacy of CT, relative to the AC, mea-
sured with the percentage correct responses (i.e. accuracy) on a computerized self-paced 
version of the Tower of London (ToL) task.22, 23 The ToL covers various executive functions 
including planning, inhibition, attention, and working memory and consists of 100 pseudo-ran-
domized trials with varying difficulty, ranging from one-step to five-step solutions (task-load 
S1-S5). Participants were excluded from ToL data analysis if they showed poor understanding 
of the task, operationalized as a score < 75% on the basic one-step (S1) trials. We used reac-
tion time on the ToL as secondary outcome. A detailed list of all assessment instruments is 
provided in Supplementary material 1.
Additional secondary outcomes were CT effects at T1 and T2 on subjective cognitive com-
plaints and cognitive performance on latent cognitive factors (see Statistical methods). Sub-
jective cognitive complaints were measured with the self-report and informant version of the 
PD-CFRS and the Cognitive Failures Questionnaire.24 Latent cognitive factors were defined on 
the basis of an extensive neuropsychological test battery that mapped global cognitive func-
tion and performance on five cognitive domains, i.e., executive function, attention/speed of 
processing/working memory, episodic memory, language, and visuospatial/visuoconstructive 
function. Based on neuropsychological function compared with healthy norm groups (see Ta-
ble S1 of the Supplementary material) we classified cognitive function of patients as cognitive-
ly normal, cognitive deficits associated with level II Movement Disorder Society (MDS) criteria 
for PD-MCI25 or cognitive features of probable PD-D.26 
Exploratory outcomes included group differences in individual neuropsychological test 
scores, performance on the CT and AC games, and effects on psychiatric symptoms, in-
cluding depression (BDI), anxiety (Parkinson Anxiety Scale),27 apathy (Apathy Scale)28 and 
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impulse control disorders (Questionnaire for impulsive-compulsive disorders in Parkinson’s 
Disease-Rating Scale; QUIP-RS).29 
No serious adverse events were expected from the interventions and assessments. We there-
fore only assessed adverse events related to impulse control disorders (including Internet 
addiction) for which PD patients are at increased risk.
Statistical methods. The sample size calculation was based on a repeated-measures ANOVA 
corrected for a moderate correlation between pre- and post-intervention outcomes (r=0.6) 
and an effect size f=0.12 of CT on global cognitive function as reported in an earlier meta-anal-
ysis in PD patients.8 The sample size needed to detect this effect at an α=0.05 and β=0.80 
was n=112. To ensure adequate power – also at follow-up – and given a small expected drop-
out, the desired sample size was set at n=140. We subsequently  adopted a better analysis 
technique (i.e., multivariate mixed-model analysis) that could handle missing values and mod-
el multivariate effects to study group differences.
Analyses were performed on the intention-to-treat population (i.e., all correctly enrolled and 
randomized participants). We used the mean or median with standard deviations or range to 
present demographic and clinical variables. We used a multivariate linear mixed-model anal-
ysis to assess differences between groups on the primary outcome measure (ToL accuracy) 
with z-transformed mean accuracy scores on task-load S1-S5 (modelled together) at T1 as mul-
tivariate outcome. We modelled standardized mean accuracy scores of these measures at T0 
as covariates, condition as independent variable and a random intercept at participant level 
to correct for correlation of the multiple variables within participants. In the intention-to-treat 
analysis, data of ten participants were missing due to failed assessment (n=4), no follow-up 
(n=2) or poor understanding (n=4) for the primary outcome measure. As this proportion was 
very small (< 5%), we performed the planned analysis without using multiple imputation. All 
analyses were repeated with adjustment for age, sex and years of education. 
We performed similar multivariate mixed-models to assess differences between groups on 
secondary outcomes, i.e., differences on the ToL reaction time on S1-S5, subjective cognitive 
complaints, and latent cognitive factors, using standardized measures. To determine the la-
tent cognitive factors, we performed a regularized maximum likelihood factor analysis (for a 
detailed description see Supplementary material 2) to compute individual scores on latent 
cognitive factors.30 The effects of CT at six months follow-up were analyzed similarly to the 
above, but with time as an additional covariate in the mixed-model. Post-hoc, we modelled 
global cognitive function classification – i.e., cognitively normal (PD-NC), PD-MCI, or PD-D – as 
an additional covariate in tests that showed CT-induced change, to assess differential training 
effects between these subgroups.
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We performed exploratory analyses of the CT effect on individual neuropsychological tests 
with univariate linear mixed-models using the performance at T1 as outcome, the performance 
at T0 as covariate and condition as independent variable. We analyzed the change in perfor-
mance on the CT and AC games using multivariate mixed-model analyses and additionally 
assessed ceiling effects on the intervention by comparing six phases of training (session 1-4 
compared with session 5-8, etc.; for a detailed description see Supplementary material 2). 
The effect of CT relative to the AC on psychiatric symptoms was analyzed using multivariate 
mixed-model analyses with standardized scores on the psychiatric symptom questionnaires at 
T1 as multivariate outcomes, the standardized T0 measurements as covariates and condition 
as independent variable. 
We ran statistical analyses in SPSS version 26.0 (Armonk, NY, USA) and performed factor 
analysis using the FMradio package in R (version 3.5.3, Boston, MA, USA), using two-sided 
tests with statistical threshold of α < 0.05. We did not correct for multiple comparisons in our 
primary and secondary analyses as these involved four multivariate models for separate re-
search questions. Exploratory analyses were separately corrected for multiple comparisons 
using a false discovery rate (q<0.05). During the trial the Clinical Research Bureau of Amster-
dam UMC performed two data monitoring visits. 
Role of the funding organization. Two members of the Dutch Parkinson’s Disease Patient 
Association made a contribution to the design of the study. The funding bodies had no role 
in the collection, analysis, and interpretation of data, writing the manuscript, or the decision 
to submit the manuscript for publication. Dezzel Media B.V. did not sponsor this study, nor 
contributed to the design of the study, the analysis and interpretation of data, writing the man-
uscript or the decision to submit the manuscript for publication.
Results
Participants. We enrolled 140 PD patients between September 15th 2017 and May 23rd 2019 
with six-month follow-up assessments until January 29th 2020. A flowchart is provided in Fig-
ure 1. Four participants were wrongfully enrolled and therefore excluded from the analyses. 
One-hundred-and-thirty-six (136) participants remained with mean age 62.9 years (SD=7.6) 
and 54 participants (39.7%) were female. Four participants (2.8%, two in either condition) 
dropped out during the intervention including one that underwent an exit measurement. One 
participant was lost to follow-up after the intervention (0.7%).
Demographic and clinical characteristics are provided in Table 1. There were small differences 
in sex distribution, education and baseline cognitive complaints between groups. The groups 
were similar on other demographic and clinical characteristics. Compared with healthy norm 
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93 not meeting inclusion criteria
19 declined to participate
3 other reasons
140 randomised
70 assigned active control
2 retrospectively not meeting 
inclusion criteria
68 included in intention-to-treat 
analysis at follow-up
64 included in per-protocol 
analysis at follow-up
2 discontinued intervention
2 intervention too burdensome
1 deviated from study protocol
1 Beck Depression Inventory > 18
68 included in intention-to-treat 
analysis
65 included in per-protocol 
analysis
68 included in intention-to-treat 
analysis
63 included in per-protocol 
analysis
68 included in intention-to-treat 
analysis at follow-up
60 included in per-protocol 
analysis at follow-up
2 discontinued intervention
1 intervention not challenging
1 health issues/difficulties performing 
the intervention
3 deviated from study protocol
2 compliance < 75%
1 Beck Depression Inventory > 18
70 assigned cognitive training




3 deviated from study protocol
1 lost to follow-up
2 missed assessment due to health issues
1 deviated from study protocol
1 missed assessment due to health issues
Figure 1 Flowchart of the enrollment procedure. 
groups, the participants’ average cognitive performance was below average on attention and 
processing speed tasks, but normal for other cognitive domains (see Table S1 and Figure S1 in 
the Supplementary material). 
Primary outcome – Tower of London accuracy. Below we only report the results of the inten-
tion-to-treat analysis. The analyses in the per-protocol sample showed similar results and are 
reported in Table S2 and S3 in the Supplementary material. In the intention-to-treat sample, 
there was no difference between groups on ToL accuracy after training across all task-loads 
S1-S5 adjusted for baseline performance: B[SE]: -0.06 [0.10], 95% CI: -0.27 to 0.15, p=0.562 
(crude model), or adjusted for baseline performance, age, sex and education level: B[SE]: 
-0.07 [0.10], 95% CI: -0.28 to 0.14, p=0.229 (adjusted model; see Figure 2a). The groups also 
showed no significant differences on the individual ToL accuracy task-loads (see Table 2). 
Secondary outcomes. Group differences and statistics on the secondary outcomes are 
depicted in Table 2. Multivariate analysis of the ToL reaction times across task loads S1-S5 
(n=126) showed that the CT group was on average 0.12 standard deviation faster after training 
compared with the AC group. This improvement was not significant: B[SE]: -0.12 [0.10], 95% 
CI: -0.31 to 0.08, p=0.232 (crude model); B[SE]: -0.12 [0.10], 95% CI: -0.31 to 0.08, p=0.232 (ad-
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  Male 47 (69%) 35 (51%)
  Female 21 (31%) 33 (49%)
Age (years) 62.9 (7.0) 62.9 (8.1)
Education (years) 16.7 (4.4) 15.5 (3.3)
Education classification (N (%))a
  3 1 (1.5%) 1 (1.5%)
  4 4 (5.9%) 4 (5.9%)
  5 16 (23.5%) 17 (25.0%)
  6 26 (38.2%) 29 (42.6%)
  7 21 (30.9%) 17 (25.0%)
Disease duration (years, median [range]) 5 [1-26] 5 [0-22]
UPDRS-III 21.0 (9.5) 20.2 (8.3)
Hoehn & Yahr stage (N (%))
  1 5 (7.4%) 4 (5.9%)
  1.5 2 (2.9%) 7 (10.3%)
  2 34 (50.0%) 28 (41.2%)
  2.5 18 (26.5%) 18 (26.5%)
  3 9 (13.2%) 11 (16.2%)
LEDD (median [range]) 650 [0-2100] 737 [0-1665]
Medication change during study (N (%)) 15 11
LEDD T1 (median [range], N=132) 710 [0-1981] 762 [0-1530]
MoCA 25.9 (2.3) 26.3 (2.0)
Global cognitive function classification (N (%))
  Normal cognition 13 (19.1%) 15 (22.1%)
  Single-domain MCI 7 (10.3%) 9 (13.2%)
  Multi-domain MCI 35 (51.5%) 34 (50.0%)
  PD dementia 13 (19.1%) 10 (14.7%)
BDI 7.87 (4.1) 8.21 (4.0)
QUIP-RS (N=125) 19.2 (12.7) 15.8 (12.8)
PAS (N=135) 10.5 (6.8) 10.3 (6.6)
AS (N=135) 13.4 (4.5) 13.2 (4.5)
Credibility-Expectancy (N=135) 32.7 (7.6) 33.9 (6.0)
Data are mean (SD) unless otherwise specified. aAccording to Verhage education classification.29 Abbre-
viations: AS = Apathy Scale; BDI = Beck Depression Inventory; PAS = Parkinson Anxiety Scale; PD-CFRS = 
Parkinson’s Disease – Cognitive Functional Rating Scale; LEDD = Levodopa equivalent daily dosage; MCI 
= mild cognitive impairment; MoCA = Montreal Cognitive Assessment; QUIP-RS = Questionnaire for Impul-




justed model). The CT group showed a statistically significant improvement of 0.28 standard 
deviation (i.e., 1.5 seconds) on task-load S4 relative to the AC group: B[SE]: -0.30 [0.12], 95% 
CI: -0.55 to -0.06, p=0.015 (crude model); B[SE]: -0.25 [0.12], 95% CI: -0.50 to 0.01, p=0.042 
(adjusted model; see Figure 2b). Estimates of the other ToL task-loads indicated numerically 
similar positive effects of CT compared with the AC, although these effects were not signifi-
cant. Subjective cognitive complaints (n=133) showed no between-group differences. 
Factor analysis on all cognitive outcomes resulted in five latent factors, that represented ep-
isodic memory (F1), executive and visuospatial function (F2), planning ability (F3), processing 
speed (F4), and attention and working memory (F5). After the intervention, there were no 
between-group differences on any of the factors (Table 2). Further details are reported in 
Supplementary material 6. We report exploratory univariate analyses of the individual neuro-
psychological test outcomes in Table S5 in the Supplementary material, showing estimates 
that suggest improvement in the CT group on the Stroop Color-Word Test card II and III and 
improvement in the AC group on the Rey Complex Figure Test, that, however, did not survive 
correction for multiple comparisons. At six-months follow-up, no between-group differences 
were observed on the ToL accuracy or on any of the secondary cognitive or exploratory psy-
chiatric outcomes (see Table S12-14 in the Supplementary material). 
Exploratory and post-hoc analyses. Exploratory analyses of improvement on the intervention 
games are provided in Table S6 in the Supplementary material. Participants improved signifi-
cantly on the training in both conditions and on all separate training games. Comparison of six 
sequential phases of the training showed that the CT group no longer improved after phase 
IV, while the AC group no longer improved after phase I (see Figure 3). There was a significant 
association between improvement on the CT games and pre-to-post training change on the 
Stroop Color-Word Test card II and card III (see Table S7 in the Supplementary material). Anal-






PD-CFRS (median [range]) 9.0 [3.3-22] 7.0 [3.3-19]
Compliance (%, median [range]) 100 [25-100] 100 [39-100]
T0-to-T1 interval (days) 64.3 (6.5) 63.6 (4.8)
T0-to-T2 interval (days) 253 (14) 250 (10)
Data are mean (SD) unless otherwise specified. aAccording to Verhage education classification.29 Abbre-
viations: AS = Apathy Scale; BDI = Beck Depression Inventory; PAS = Parkinson Anxiety Scale; PD-CFRS = 
Parkinson’s Disease – Cognitive Functional Rating Scale; LEDD = Levodopa equivalent daily dosage; MCI 
= mild cognitive impairment; MoCA = Montreal Cognitive Assessment; QUIP-RS = Questionnaire for Impul-
sive-Compulsive Disorders in Parkinson’s Disease – Rating Scale; UPDRS = Unified Parkinson’s Disease 
Rating Scale.
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Figure 2 Intervention effect in the cognitive training (CT) and active control (AC) group. The upper panels 
show effects on the Tower of London (TOL) mean accuracy of S1-S5 (A) and reaction time (B). *Indicates 
significant difference after training adjusted for baseline performance in the crude model. The lower panel 
shows results of the post-hoc analyses – the difference between intervention effects on the Tower of 
London (TOL) mean accuracy (C) and reaction time (D), separated for participants with normal cognition 
























































































Lastly, we performed post-hoc analyses of the differential effects of CT in separate cognitive 
diagnostic groups (PD-NC (n=28), PD-MCI (n=85) and PD-D (n=23)). The differential effects 
are illustrated in Figure 2 (ToL accuracy and reaction time) and Figure S3 (Stroop Color Word 
Test), and statistics are reported in Table S16 and Table S17 in the Supplementary material. 
After training, CT effects were largest in the PD-D group. Interaction effects comparing the 
effect of CT between cognitive diagnostic groups showed significantly larger effects of CT for 
the PD-D group compared with the PD-NC and PD-MCI group for the ToL accuracy and Stroop 
Color-Word Test at T1. At T2, CT had a significantly larger positive effect on the ToL accuracy 
in the PD-D group compared with the other two diagnostic groups. Estimates of the interven-
tion effect at T1 were all in favor of the CT for all diagnostic groups, except for ToL accuracy. 
The ToL accuracy showed positive estimates of the CT effect for the PD-D group but not for 
the PD-NC and PD-MCI group. At T2, there were no main or interaction effects for the ToL 
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In the COGTIPS double-blind RCT we assessed the efficacy of online home-based cognitive 
training (CT) in the largest sample of PD patients to date. Our results provide level I evidence 
that eight-week CT with BrainGymmer does not improve accuracy on a planning task (i.e., the 
primary outcome) in PD patients. On the secondary outcomes, CT showed consistent, but ten-
tative, positive effects on measures of processing speed during executive functioning, that, 
however, only reached statistical significance for the ToL. The average improvement of speed 
was up to ten percent of the baseline performance. No effects were found in other cognitive 
domains or on subjective cognitive complaints. The observed positive effects of CT were no 
longer present at six-months follow-up. 
Our study is in line with earlier aggregated findings from meta-analyses regarding the positive 
effects of CT on executive function and processing speed.8, 9 Our multi-domain CT did not 
improve ToL accuracy, in contrast with an earlier, smaller study on CT in PD,31 but the CT-relat-
ed improvement on ToL reaction time presumably reflects both improved processing speed 
and planning function as this effect was driven by ToL items of higher difficulty.32 The positive 
effects on the Stroop Color-Word Test are in line with earlier research10 and our pilot feasibility 
study.13 Stroop Color-Word Test improvement was related to improvement on the experimental 
intervention, likely due to the focus of the CT tasks on processing speed and executive func-
tions. Surprisingly, the active control group performed better than the CT group after training 
on a visuoconstructive task, but these effects were very small (<1 point difference) and might 
























































p < 0.001 p = 0.002 p = 0.642p = 0.310p < 0.001
Phase I Phase II Phase III Phase IV Phase V Phase VI
p = 0.138 p = 0.092 p = 0.920p = 0.661p = 0.759
Phase I Phase II Phase III Phase IV Phase V Phase VI
Figure 3 Improvement on cognitive training (CT; A) and active control (AC; B) training games. Mean game 
scores are shown per session with 95% CI, showing significant improvement with a ceiling effect. The 
lighter lines represent scores for individual games. The intervention period is divided in six phases of four 
sessions (marked with the vertical dotted lines). The P values provided in the figure are FDR-corrected and 
represent the difference between the two respective bins. Note that the Z-scores on the CT cannot be 
compared to the Z-scores on the active control as the CT games but not AC games were equipped with 
automatic difficulty adjustment, and the games of the two conditions were different.
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Patients in both conditions reported minor subjective improvement after finishing the inter-
vention, but without group differences. Interestingly, the positive effects of CT on processing 
speed measures did not positively affect scores on PD-specific questionnaires for subjective 
cognitive complaints, while mental slowness is a frequent early subjective complaint of PD 
patients.33 Few studies that assessed the effects of CT on subjective complaints in PD found 
small improvements10, 34 or null results.31, 35, 36 Nevertheless, the sensitivity of the PD-CFRS in 
measuring treatment effects – as opposed to its sensitivity to measuring clinically relevant 
cognitive decline15, 37 – has not yet been studied and our PD sample showed little variation 
in the total score at baseline. Limited transfer to ‘real-world’ cognitive function has previ-
ously been reported to be a shortcoming of CT and remains an important topic for future 
research.38 
At six-months follow-up the group differences on the ToL reaction time and Stroop Col-
or-Word Test that were present after training had levelled out. As yet, this does not support 
two earlier studies that assessed long-term CT effects.10, 11 The 12- and 24-months follow-up 
assessments in our sample will provide more information. Our sample was largely comparable 
to PD samples in earlier CT studies, but participants had a relatively high mean years of edu-
cation (16.1 years). Earlier studies reported a negative association between educational level 
and benefit from CT.39, 40 A higher educational level generally reflects higher cognitive reserve 
and individuals with higher cognitive reserve reportedly retain intact cognitive function longer 
through compensatory neural mechanisms, but show cognitive decline at a faster rate.41 If CT 
indeed positively impacts the underlying cognitive reserve, our one- and two-year follow-up 
assessments may show a delay in the onset or progression of cognitive decline in the CT 
group. 
In both intervention groups, participants improved significantly on the intervention games (i.e., 
near transfer). Notably, the CT group improved despite increasing training difficulty. This sup-
ports the prerequisite that individuals with PD are trainable. Improvement on the CT reached 
a ceiling effect after approximately 20 sessions. There is limited literature on training dose 
effects; one study in PD patients suggested a “more-is-better” approach42 while a meta-anal-
ysis in healthy adults showed that longer duration of training did not have larger effect sizes 
compared with shorter duration (i.e., longer/shorter than 20 hours).43 The ceiling effect in our 
study may confirm the latter, but our data do not allow conclusions about the clinical rele-
vance of training at the ceiling level. The null results at six-months follow-up indicate ‘booster’ 
training sessions may be necessary to prolong or strengthen the positive effects.
Our post-hoc tests suggested larger CT effects in PD-D patients compared with PD-NC and 
PD-MCI patients. Earlier studies did not differentiate CT effects between PD-NC, PD-MCI or 
PD-D patients. Our results were contrary to our expectation that an intervention in early-stage 
PD – when compensatory neural mechanisms may still be able to counteract progressive PD 
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pathology – would be more efficacious.13 The potential larger efficacy of CT in PD-D patients 
awaits replication in a larger sample as our PD-D sub-group was small. An explanation for 
the observed sub-group differences could be that cognitively normal PD participants in our 
sample performed at a ceiling level on cognitive tasks so that these tasks could not quantify 
improvement. Future analyses of the MRI scans in a subset of participants may be more sensi-
tive and can show how compensatory neural mechanisms that are presumably present in the 
PD-NC and PD-MCI patients are affected by CT.
Limitations and strengths. Limitations of our study were the lack of a measure for the level of 
cognitive activity and an additional waiting-list control group. Despite our eligibility criterion to 
exclude PD patients with severe cognitive impairments by using previously reported optimal 
diagnostic screening criteria for PD-D on the basis of the MoCA,17 still a significant proportion 
of patients showed cognitive deficits associated with PD-D. Lastly, at baseline there were 
small, non-significant group differences in education level, sex distribution and subjective 
cognitive complaints, despite randomization and stratification. Although we adjusted for edu-
cation and sex, this does not fully eliminate potential effects of inter-individual differences.
A major strength of our study was the sample size with an excellent intervention compliance 
and study protocol adherence. We used a prospectively registered, double-blind study, de-
signed based on recommendations of earlier reviews.8, 9 Participants underwent short- and 
long-term extensive neuropsychological assessments that adhered to the MDS Task Force 
guidelines,25, 26 with additional motor and non-motor symptom assessment. 
Conclusions. This randomized, double-blind controlled trial in a large sample of PD patients 
showed that multi-domain CT did not improve accuracy on an executive function measure 
(primary outcome), but showed small but consistent effects on processing speed during 
executive functioning. The intervention was suitable for PD patients considering the high 
compliance, and participants showed large improvement on the training tasks. Ceiling effects 
after 16-20 sessions, combined with null results at six-months follow-up, may imply that for the 
clinical use of CT in PD patients shorter periods (i.e., ±20 sessions) of intensive CT combined 
with repetitive booster sessions should be studied. 
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Supplementary material 1 - List of assessments instruments
Neuropsychological assessment
Global cognition Montreal Cognitive Assessment1 
Pentagon copy from the Mini-Mental State Examination2, 3
Executive function Computerized adaptation of the Tower of London4
Controlled Oral Word Association Test (‘letter fluency’)5 
Stroop Color Word Test6 – interference condition
Attention/speed of processing/working 
memory
Stroop Color Word Test6 – word-naming and color-naming 
condition
Wechsler Adult Intelligence Scale-III digit span7
Episodic memory Rey Auditory Verbal Learning Test8
Location Learning Test9 
Language Boston naming test10
Category fluency11 
Visuospatial/visuoconstructive function Rey Complex Figure Test12
Visual Form Discrimination Test13
Questionnaires
Anxiety symptoms Parkinson anxiety scale14
Apathy symptoms Apathy scale15
Depressive symptoms Beck depression inventory16
Impulse control disorder symptoms Questionnaire for Impulsive-Compulsive Disorders in Parkin-son’s Disease – Rating Scale17
Subjective cognitive function Parkinson’s Disease – Cognitive Functional Rating Scale18
Cognitive Failures Questionnaire19
Intervention expectation Credibility/expectancy questionnaire20
Demographic and other clinical characteristics
Age
Sex
Education level Years of education
Education level according to Verhage21
Disease onset Age at disease onset 
Motor symptom severity Unified Parkinson’s Disease Rating Scale – part III
22 
Disease stage Hoehn and Yahr stage
23 
Medication use Levodopa equivalent daily dose (LEDD) 
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Supplementary material 2 - Supplementary methods
Regularized redundancy-filtered factor analysis 
We performed a regularized maximum likelihood factor analysis on all cognitive outcomes at 
baseline.24 We performed redundancy filtering at an (absolute value) threshold t=0.95 to ac-
count for item redundancy in the raw correlation matrix. Subsequently, a penalized maximum 
likelihood estimate of the filtered correlation matrix was obtained. The optimal value of the 
penalty parameter was determined by 5-fold cross-validation. We then assessed factorizability 
of the regularized correlation matrix and its individual variables using the Kaiser-Meyer-Olkin 
(KMO) measure and removed variables that modelled poorly, i.e. KMO < 0.9. We subsequently 
performed maximum likelihood factor analytic data compression on the resulting penalized 
correlation matrix and calculated the optimal factor solution using Guttman bounds. In the re-
sulting factor model we assessed the proportion of explained variance. Lastly, we calculated 
squared multiple correlations between the observed variables and the latent common factors 
(which indicate indeterminacy of factor scores if < 0.9) and defined individual factor scores at 
T0, T1 and T2 using standardized Z-scores. 
Analysis of improvement on the intervention
To analyze the improvement in performance on the CT and active control games, we first 
standardized training scores of the individual training games to Z-scores. We performed a 
multivariate mixed-model analysis per group (CT or active control) with the thirteen or three 
training games, respectively, as multivariate outcome, and session (ranging from 1-24) as in-
dependent variable. To assess potential ceiling effects, we divided the intervention period in 
six bins of four training sessions and added these bins as covariates to the model to assess 
the difference between the intervention stages (session 1-4 compared with session 5-8 and 
so on). We performed a post-hoc analysis to assess the association between improvement 
on training games and improvement on cognitive performance. We first calculated the linear 
slope coefficient of improvement during 24 training sessions on the 13 (CT condition) or three 
(active control condition) intervention games. We then added this coefficient as a covariate to 
mixed-model analyses of neuropsychological tests that showed change in the CT group. 
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Supplementary material 3 - Neuropsychological characteristics  
of the intention-to-treat sample
Table S1 Neuropsychological function based on healthy norms (intention-to-treat sample). 
Baseline Total Active control Cognitive training P value
†
SCWT card I (N=136) 35.25 (10.25) 34.76 (11.49) 35.74 (8.91) 0.583
SCWT card II (N=136) 39.49 (10.33) 39.32 (10.14) 39.66 (10.59) 0.849
SCWT card III (N=136) 44.73 (10.13) 45.62 (10.22) 43.84 (10.04) 0.308
SCWT interference score (N=136) 53.00 (8.64) 54.19 (8.66) 51.81 (8.51) 0.108
Letter fluency (N=136) 48.03 (11.26) 48.43 (11.95) 47.63 (10.59) 0.116
Category fluency (N=135) 47.47 (9.77) 48.78 (9.82) 46.13 (9.61) 0.116
RCFT (N=136) 46.27 (15.79) 44.86 (15.70) 47.68 (15.87) 0.300
RAVLT direct recall (N=136) 43.60 (12.02) 43.96 (12.70) 43.25 (11.38) 0.733
RAVLT delayed recall (N=136) 44.74 (12.07) 44.94 (12.07) 44.54 (12.16) 0.849
RAVLT delayed recall corrected for 
direct recall score (N=136) 48.55 (11.76) 48.38 (12.12) 48.72 (11.48) 0.868
Digit span forward score (N=136) 34.28 (6.91) 34.37 (7.24) 34.19 (6.62) 0.882
Digit span backward score (N=136) 41.71 (7.21) 42.40 (7.42) 41.01 (6.98) 0.265
LLT learning curve (N=135)25 46.13 (9.88) 45.16 (9.71) 47.10 (10.04) 0.255
LLT direct recall (N=135)25 48.27 (8.42) 47.84 (7.12) 48.72 (9.59) 0.546
LLT delayed recall (N=134)25 53.91 (8.08) 53.89 (8.73) 53.93 (7.46) 0.982
BNT (N=136)26 52.61 (9.14) 52.66 (8.56) 52.56 (9.76) 0.948
BVFDT (N=136)27 49.00 (9.79) 48.34 (11.29) 49.66 (8.04) 0.432
*T-test. Norm scores are “T-scores” (M: 50, SD: 10) based on norms provided in Schmand and colleagues, 
unless otherwise specified.28
Abbreviations: BNT – Boston Naming Test; BVFDT – Benton Visual Form Discrimination Test; LLT – Loca-
tion Learning Test; RAVLT – Rey Auditory Verbal Learning Test; RCFT – Rey Complex Figure Test; SCWT 
– Stroop Color Word Test.
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Figure S1a Raincloud plots of neuropsychological test scores corrected for age, sex and/or education, 
using the appropriate norms. Test scores are provided as “T-scores” (M: 50, SD: 10). T-scores < 30 (i.e. > 
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Figure S1b Raincloud plots of neuropsychological test scores corrected for age, sex and/or education, 
using the appropriate norms. Test scores are provided as “T-scores” (M: 50, SD: 10). T-scores < 30 (i.e. > 2 
SD below average) indicate impaired performance (marked grey). Abbreviations: LLT – Location Learning 
Test; RAVLT – Rey Auditory Verbal Learning Test.
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Supplementary material 4 - Per-protocol sample description






 Male 43 (68%) 34 (52%)
 Female 20 (32%) 31 (48%)
Age (years) 63.0 (6.9) 62.9 (8.1)
Education (years) 16.9 (4.4) 15.4 (3.2)
Education classification (N (%))†
 3 1 (1.6%) 1 (1.5%)
 4 2 (3.2%) 4 (6.2%)
 5 15 (23.8%) 17 (26.2%)
 6 25 (39.7%) 27 (41.5%)
 7 20 (31.7%) 16 (24.6%)
Disease length (years, median [range]) 5 [1-26] 5 [0-22]
UPDRS-III 21.3 (9.0) 20.6 (8.2)
Hoehn & Yahr stage (N (%))
 1 3 (4.8%) 3 (4.6%)
 1.5 2 (3.2%) 7 (10.8%)
 2 33 (52.4%) 27 (41.5%)
 2.5 17 (27.0%) 17 (26.2%)
 3 8 (12.7%) 11 (16.9%)
LEDD (median [range]) 600 [0-2081] 749 [0-1665]
Medication change (N (%)) 15 (24%) 11 (17%)
LEDD T1 (median [range]) 700 [0-1981] 750 [0-1530]
MoCA 26.1 (2.3) 26.4 (1.9)
Global cognitive function classification (N (%)
 Normal cognition 13 (20.6%) 15 (23.1%)
 Single-domain MCI 7 (11.1%) 9 (13.8%)
 Multi-domain MCI 31 (49.2%) 32 (49.2%)
 PD dementia 12 (19.0%) 9 (13.8%)
BDI 7.9 (3.8) 8.1 (3.9)
Data are mean (SD) unless otherwise specified. †According to Verhage education clas-
sification.21 Abbreviations: AS = Apathy Scale; BDI = Beck Depression Inventory; PAS = 
Parkinson Anxiety Scale; PD-CFRS = Parkinson’s Disease – Cognitive Functional Rating 
Scale; LEDD = Levodopa equivalent daily dosage; MCI = mild cognitive impairment; MoCA 
= Montreal Cognitive Assessment; QUIP-RS = Questionnaire for Impulsive-Compulsive 
Disorders in Parkinson’s Disease – Rating Scale; UPDRS = Unified Parkinson’s Disease 
Rating Scale.
154





QUIP-RS (N = 118) 18.8 (12.9) 16.1 (12.9)
PAS (N = 127) 10.5 (6.8) 10.3 (6.8)
AS (N = 127) 13.6 (4.4) 13.3 (4.5)
Credibility-Expectancy (N = 127) 32.7 (7.3) 33.9 (6.1)
PD-CFRS (median [range]) 9.0 [3.3-22] 7.2 [4-19]
Compliance (%, median [range]) 100 [80-100] 100 [76-100]
T0-to-T1 interval (days) 64.5 (6.6) 63.7 (4.8)
T0-to-T2 interval (days) 252 (14) 250 (10)
Data are mean (SD) unless otherwise specified. †According to Verhage education clas-
sification.21 Abbreviations: AS = Apathy Scale; BDI = Beck Depression Inventory; PAS = 
Parkinson Anxiety Scale; PD-CFRS = Parkinson’s Disease – Cognitive Functional Rating 
Scale; LEDD = Levodopa equivalent daily dosage; MCI = mild cognitive impairment; MoCA 
= Montreal Cognitive Assessment; QUIP-RS = Questionnaire for Impulsive-Compulsive 
Disorders in Parkinson’s Disease – Rating Scale; UPDRS = Unified Parkinson’s Disease 
Rating Scale.
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Supplementary material 5 - Analyses of the primary and secondary 
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Supplementary material 6 - Results from the regularized  
redundancy-filtered factor analysis
No outcomes were eliminated from the analysis due to redundant information. One outcome 
(i.e. Pentagon copy) was removed from analysis due to extremely low variance (96% scored 
2/2, 3% scored 1/2) and the final Kaiser-Meyer-Olkin index was 0.960 which is indicative of 
great factorability.29 Estimated image dimensions using Gutmann bounds showed an optimal 
factor solution of five factors with a cumulative explained variance of 80%. This factor solution 
is illustrated in Figure S1 and individual factor statistics are shown in Table S1. Squared multi-
ple correlations between the observed features and five latent factors were all larger than 0.9, 
indicative of good determinacy of factor scores.
Figure S2 Bar graph of the five-factor solution. Length of the bars indicate the load strength on the specific 
factor. Color of the bars indicate a negative (i.e. blue) or positive (i.e. red) load. 
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Sum of squares 5.78 5.75 5.24 4.28 3.70
Proportion explained variance 0.19 0.19 0.17 0.14 0.12
Squared multiple correlations 0.95 0.90 0.92 0.93 0.96
Neuropsychological test outcome
LLT delayed recall -0.876 -0.148 -0.275 -0.113 -0.237
LLT direct recall -0.874 -0.206 -0.207 -0.186 -0.203
LLT learning curve 0.789 0.319 0.273 0.179 0.246
RAVLT recognition 0.651 0.464 0.052 0.294 0.230
RAVLT delayed recall 0.641 0.534 0.120 0.387 0.110
MOCA total score 0.560 0.538 0.206 0.299 0.256
RAVLT direct recall 0.560 0.562 0.146 0.414 0.250
BNT total score 0.406 0.391 0.346 0.196 0.166
ToL reaction time trial 2 -0.351 -0.670 -0.490 -0.314 -0.181
ToL reaction time trial 1 -0.404 -0.640 -0.465 -0.299 -0.236
ToL reaction time trial 4 -0.347 -0.636 -0.496 -0.313 -0.259
ToL reaction time trial 5 -0.245 -0.634 -0.475 -0.304 -0.241
ToL reaction time trial 3 -0.332 -0.617 -0.555 -0.322 -0.200
RCFT total score 0.302 0.604 0.218 0.241 0.144
ToL % correct trial 5 0.410 0.573 0.494 0.262 0.266
BVFDT total score 0.492 0.514 0.285 0.250 0.231
SCWT interference control -0.170 -0.504 -0.334 -0.165 -0.308
ToL % correct trial 3 0.131 0.249 0.847 0.217 -0.001
ToL % correct trial 2 0.183 0.108 0.829 0.175 0.037
ToL % correct trial 1 0.130 0.196 0.816 0.139 -0.013
ToL % correct trial 4 0.205 0.438 0.754 0.215 0.220
SCWT card II time -0.163 -0.272 -0.275 -0.848 -0.169
SCWT card I time -0.205 -0.193 -0.302 -0.809 -0.229
Letter fluency 0.361 0.403 0.230 0.656 0.184
Category fluency 0.379 0.405 0.318 0.632 0.183
SCWT card III time -0.194 -0.465 -0.362 -0.527 -0.302
Digit span forward span length 0.273 0.090 -0.010 0.169 0.902
Digit span forward score 0.306 0.124 0.017 0.183 0.901
Digit span backward score 0.363 0.196 0.123 0.382 0.630
Digit span backward span length 0.313 0.151 0.106 0.368 0.595
RAVLT learning curve 0.040 -0.174 -0.070 0.024 -0.396
Variable loads associated with a specific common factor are grouped. Factor loads > 0.4 are in bold. 
Abbreviations: BNT – Boston Naming Test; BVFDT – Benton Visual Form Discrimination Test; MOCA – Montreal Cognitive 
Assessment; RAVLT – Rey Auditory Verbal Learning Test; RCFT – Rey Complex Figure Test; SCWT – Stroop Color Word 
Test; ToL – Tower of London
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Supplementary material 7 - Exploratory univariate linear 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Effect of eight-week online cognitive training in Parkinson’s disease: 
a randomized controlled trial
Supplementary material 8 - Improvement on the experimental  
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Supplementary material 9 - Association between CT and active  
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Supplementary material 10 - Analysis of the effect of CT  
on exploratory psychiatric outcomes
Multivariate analysis of the overall psychiatric symptoms (N=130) are shown in Table S9. 
The CT group experienced on average 0.17 standard deviation less psychiatric symptoms 
averaged across questionnaires after training compared with the AC group. This difference 
was not significant: B[SE]: -0.17 [0.09], 95% CI: -0.34 to 0.00, p=0.051 (raw model); B[SE]: -0.15 
[0.09], 95% CI: -0.32 to 0.03, p=0.093 (adjusted model). The CT group experienced statisti-
cally significant lower impulse control disorder symptoms after training compared with the 
AC group, which was not significant after correcting for age, sex and years of education. This 
effect seemed driven by a post-training increase in impulsive behavior in the AC group. Post-
hoc QUIP-RS sub-score analysis (see Table S10) showed that this effect was mainly driven by 
a larger increase on the hyper-sexuality and compulsive buying sub-scale in the AC group 
and a larger decrease in the hobbyism/punding sub-score in the CT group. Mean scores re-
mained under the respective cut-off scores for clinically relevant symptoms. At follow-up, no 
group differences were present anymore (see Table S11 and Table S12).
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Supplementary material 11 - Analyses of the neuropsychological  
and clinical measures at six-months follow-up  
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Supplementary material 12 - Analyses of the neuropsychological 
and clinical measures at six-months follow-up  











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Effect of eight-week online cognitive training in Parkinson’s disease: 
a randomized controlled trial
Supplementary material 13 - Exploratory univariate linear 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Effect of eight-week online cognitive training in Parkinson’s disease: 
a randomized controlled trial
Supplementary material 14 - Post-hoc analyses of differential CT  
effects in PD patients with normal cognition,  
mild cognitive impairment, or dementia
The differential effects of CT relative to AC in PD patients with normal cognition (PD-NC), mild 
cognitive impairment (PD-MCI) or dementia (PD-D) are illustrated in Figure S3 and statistics 
are reported in Table S16 and Table S17. 
Figure S3 Difference between the CT and AC group on the Stroop color word test card II (A) and III (B), 
separated for participants with normal cognition (PD-NC), PD-mild cognitive impairment (PD-MCI) and PD 
dementia (PD-D). Data shown are observed means ± standard error.
PD-NC PD-MCI PD-D
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Abstract
There is meta-analytic evidence for the efficacy of cognitive training (CT) and in an earlier ran-
domized controlled trial we found small positive effects on executive function and processing 
speed. In this randomized controlled trial, we assessed the effects of  CT on brain network 
connectivity and topology. We randomized 140 individuals with PD into an online multi-domain 
CT and an active control condition; 86 participated in the MRI study (n=43 per condition). 
Participants performed 24 sessions of either intervention in eight weeks. Resting-state fMRI 
scans were acquired in addition to extensive clinical and neuropsychological assessments 
pre- and post-intervention. In line with our preregistered analysis plan (osf.io/3st82), we com-
puted connectivity between ‘cognitive’ resting-state networks and computed topological 
outcomes at the whole-brain and sub-network level. We assessed group differences after the 
intervention with mixed-model analyses adjusting for baseline performance and analyzed the 
association between network and cognitive performance changes with repeated measures 
correlation analyses. After intervention there were no group differences on between-network 
connectivity and network topological outcomes. No associations between neural network 
and neuropsychological performance change were found. CT increased segregated network 
topology in a small sub-sample of cognitively intact participants. Post-hoc nodal analyses 
showed post-intervention enhanced connectivity of both the dorsal anterior cingulate cortex 
and dorsolateral prefrontal cortex in the CT group. The results suggest no large-scale brain 
network effects of eight-week computerized CT, but rather localized connectivity changes of 
key regions in cognitive function, that potentially reflect the specific effects of the interven-
tion.
Clinical trial registration. This study was preregistered at ClinicalTrials.gov, identifier 
NCT02920632.
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Introduction
Cognitive impairment is a common and debilitating non-motor symptom of Parkinson’s dis-
ease.1, 2 Cognitive impairment is already present at diagnosis in a quarter of PD patients and 
can ultimately lead to PD dementia in the large majority of patients.1, 3 In late stages of PD, 
rivastigmine is effective as symptomatic treatment of PD dementia.4, 5 To date, there is little 
evidence for efficacy of treatment of cognitive impairment pre-dementia, although cognitive 
training (CT) has shown promising results.6 CT is a relatively cost-efficient and easy-to-admin-
ister therapy option without the side-effects that are often caused by adjuvant medication.5 In 
an earlier report, we showed that online, multi-domain CT had small positive effects on execu-
tive function and processing speed in a large sample of PD patients.7
While cognitive impairment in PD is associated with widespread cortical atrophy,8, 9 altered 
structural and functional connectivity,10-14 and disrupted brain networks,15-18 to date little is 
known about the impact of CT on these neural alterations. In a review on the neural cor-
relates of CT we describe how CT counteracts dysfunctional brain network changes that are 
associated with aging and neurodegenerative processes by enhancing compensatory mech-
anisms (such as increased neural activity during task performance) and normalizing functional 
connectivity.19 Nevertheless, only one study in PD patients was included in this review.20 Two 
earlier, exploratory studies on CT in PD that were not included in this review because of the 
small sample sizes showed decreased regional brain activity during executive function21 and 
increased intrinsic functional activity (i.e., during resting-state) in regions of attention-related 
and frontoparietal resting-state networks.22
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Rather than focusing on morphometry or connectivity of a single brain area, contemporary 
neuroimaging methods are used to study the brain as a complex network: a ‘graph’. Complex 
networks have distinctive properties, such as small-world organization (i.e., an integrated but 
simultaneously clustered network), a modular structure, and a power-law degree distribution 
(i.e., only a small proportion of network nodes has many connections).23-25 Inter-individual 
differences in the topology of the human neural network are associated with differences in 
cognitive and emotional function.26 Individuals with PD show abnormalities in functional and 
structural network topology such as a progressive decline in local and global efficiency,27-29 
decreased clustering,27, 29, 30 and reorganization of highly connected regions (‘hubs’),28, 31 but 
also increased modularity and local efficiency which is presumed to be compensatory.31 How 
CT may normalize the topology of the neural network is largely unknown and not studied in 
PD. In healthy young subjects, working memory training increased modularity,32 small-world 
organization,33 and modular efficiency and node strength,34 while cognitive strategy training 
decreased modularity in individuals with traumatic brain injury.35 Modularity may withal be of 
particular interest as it has repeatedly been recognized as a predictor of therapeutic effica-
cy.36-38
In this study, we elaborated on the clinical findings that we published earlier,7 showing small 
positive effects of CT on speed of processing during executive function tasks. We assessed 
the effect of eight-week online multi-domain CT relative to an active control condition on neu-
ral network connectivity and topology in a large sample of individuals with PD. We investigat-
ed the effect of CT on whole-brain network properties using graph indices and also assessed 
the effect on resting-state functional networks that have been proposed to play a large role 
in cognitive function, i.e. the frontoparietal network (FPN), salience network (SN) and default 
mode network (DMN).39-41 We hypothesized that, on a global level, CT increases neural ef-
ficiency, modularity and participation coefficient (i.e., ratio between connections within and 
between modules). For the intrinsic functional networks, we hypothesized that 1) CT increases 
segregation of neurocognitive networks, i.e. a higher anti-correlation between the DMN, and 
the FPN and SN, and 2) CT increases efficiency, centrality and clustering of the FPN, SN and 
DMN. Lastly, we hypothesized that CT-related neural network changes are related to changes 
in cognitive performance.
Methods
Participants. This study was part of the randomized controlled clinical trial ‘COGTIPS’ (COGni-
tive Training In Parkinson Study; ClinicalTrials.gov registration NCT02920632). For a detailed 
overview of the methodology we refer to the protocol article42 and results on the primary 
clinical outcomes are reported here.7 The analysis plan of the current fMRI study was prereg-
istered at the Open Science Framework (registration: osf.io/3st82). 
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From the full sample of COGTIPS, a sub-sample underwent an MRI scan. General inclusion 
criteria for participation were 1) mildly to moderately advanced idiopathic PD (Hoehn & Yahr 
stage < 4)43 diagnosed by a neurologist, 2) significant subjective cognitive complaints (PD 
Cognitive Functional Rating Scale score > 3)44, and 3) home access to and proficiency in using 
a computer or tablet with internet. General exclusion criteria were 1) a Montreal Cognitive As-
sessment score < 22,45, 46 2) indications of current drug- or alcohol abuse (CAGE AID-interview 
score > 1),47, 48 3) moderate to severe depressive symptoms (Beck Depression Inventory score 
> 18),49 4) an impulse control disorder (positive screening by diagnostic criteria), 5) psychotic 
symptoms except for benign hallucinations (positive screening by the Schedule for Assess-
ment of Positive Symptoms – PD),50 or 6) a history of traumatic brain injury. Exclusion criteria 
for participation in the MRI study were 1) presence of metal in the body (e.g., a neurostimula-
tor), 2) pregnancy, or 3) difficulty with or shortness of breath during 60 minutes of lying still, 
and 4) after baseline scan a space occupying lesion and/or significant vascular abnormalities 
(Fazekas > 1). 
All procedures were performed according to the declaration of Helsinki and all participants 
gave written informed consent to participate. The study was approved by the VU University 
Medical Center medical ethical committee.
Procedure and randomization. After eligibility screening, participants underwent an exten-
sive baseline assessment that entailed neuropsychological testing, questionnaires and MR 
imaging. An overview of outcomes for this study is listed below and described previously 
in detail.42 After baseline assessment, participants were randomized, stratified according to 
education level (low/average versus high), in 1:1 fashion to the experimental cognitive training 
group (CT) or the active control group (AC) using random number sequence generated ran-
domization lists. Participants remained blind to their allocated condition throughout the entire 
study and outcome assessors were blinded for the full duration of their role as assessor. 
Participants performed their respective intervention at home, from their personal computer 
or tablet via internet. After the intervention, approximately nine weeks after baseline assess-
ment, participants performed a second assessment that entailed neuropsychological testing 
(using parallel tests if available), questionnaires and MR imaging.
Interventions. Both interventions entailed 24 online, home-based sessions with a duration of 
approximately 45 minutes. Participants were instructed to perform their respective interven-
tion three times a week; we did not specify training days to enhance feasibility. Participants 
were able to pause the intervention session if, for example, they were interrupted or in ‘wear-
ing-off’ state, limiting task execution. The CT, adapted from the ‘Braingymmer’ platform, con-
sisted of thirteen adaptive training games that aimed to improve executive function, working 
memory, processing speed and attention (www.braingymmer.com, a product by Dezzel Me-
dia). The AC consisted of three non-adaptive games without an expected training effect (i.e., 
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solitaire, hangman and trivia questions) and was used to correct for non-specific cognitive 
activity.
Measurements. We measured change in the processing speed/executive function domain 
with 1) the reaction time on a computerized version of the Tower of London (ToL) task; a plan-
ning/executive function task where the participant has to count the number of bead moves 
needed to reach a solution configuration from a start configuration, ranging from 1-5 moves 
(i.e., difficulty loads S1-S5), and 2) the Stroop Color-Word Test (SCWT); an interference control/
processing speed task that consists of word-reading (SCWT-I), color-naming (SCWT-II) and 
color-word interference (SCWT-III) components. Accuracy on the ToL (i.e., percentage correct-
ly answered trials) was additionally assessed as this was the primary outcome of the clinical 
trial. Importantly, these tasks were not part of the CT and any improvements would therefore 
not simply be due to a learning effect.
We compared cognitive function of our study population with healthy norm group data and 
classified cognitive function as either cognitively normal (PD-NC), cognitive deficits associat-
ed with PD-MCI according to level II Movement Disorder Society (MDS) criteria,51 or cognitive 
deficits associated with probable PD-D.52 We additionally assessed motor symptoms (Unified 
PD Rating Scale – III),53 disease stage (Hoehn and Yahr), and medication use (levodopa equiv-
alent daily dose).54 Subjective cognitive complaints were assessed with the PD-Cognitive 
Functional Rating Scale and Cognitive Failures Questionnaire55 and we used additional ques-
tionnaires to assess psychiatric symptoms and participants’ expectation of the intervention 
outcome. 
Image acquisition. At both time-points, we performed MRI on a GE Signa HDxT 3 T MRI scan-
ner (General Electric, Milwaukee, U.S.). We equipped the 32-channel head coil with foam pads 
to maximally immobilize the head and thereby reduce head motion. Resting-state functional 
MRI (rs-fMRI) was acquired using a 10-minute gradient echo-planar imaging (EPI) sequence 
(TR = 2200 ms; TE = 28 ms; 64 × 64 matrix; field of view = 21.1 cm; flip angle = 80°) with 40 
ascending slices per volume (3.3 × 3.3 mm in-plane resolution; slice thickness = 3.0 mm; in-
terslice gap = 0.3 mm), which provided whole-brain coverage. Participants were instructed to 
keep their eyes closed, not think about anything in particular, and not fall asleep. Anatomical 
MRI was acquired using a 3D T1-weighted structural magnetization-prepared rapid acquisition 
gradient-echo (MPRAGE) with scan parameters according to the ADNI-3 protocol (TR = 6.9 ms, 
TI = 900 ms, TE = 3.0 ms, matrix size 256 x 256, 1 mm3 isotropic voxels, 168 sections).56
Image preprocessing. We corrected for susceptibility induced distortions in the functional 
image by acquiring scans with a reversed phase-encoding direction and applying topup57 
from the FMRIB Software Library (FSL) software suite.58 Anatomical and functional images 
were subsequently preprocessed using fmriprep (v1.4.0; see Supplementary material 1 for the 
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full boilerplate).59 Briefly, an average robust template was created from the T1-weighted struc-
tural images at either time point using FreeSurfer 6.0.1.60 Using this robust template, brain 
surfaces were reconstructed and parcellated according to an atlas (see below). We visually 
inspected the brain surfaces for any defects. Rs-fMRI images from both time points were skull-
stripped, realigned and slice-time corrected, and co-registered to the robust template. Noise 
regressors were extracted per subject for further denoising of the preprocessed functional 
time-series. Noise-regressors included global signals within the ventricles (CSF) and white 
matter (WM) and automatically identified motion-related components based on their high-fre-
quency content and correlation with motion parameters using automatic removal of motion 
artifacts using independent component analysis (ICA-AROMA).61 We removed the first three 
non-steady state volumes from the fMRI and spatially smoothed the remaining images with 
a 6mm full-width half-maximum (FWHM) isotropic, Gaussian kernel. Simultaneous nuisance 
regression and temporal filtering (0.009 – 0.13 Hz) was performed using Denoiser (github.
com/arielletambini/denoiser). Following the benchmark test from Parkes and colleagues62 we 
regressed out all motion-related components identified by ICA-AROMA and eight tissue-aver-
aged physiological regressors: averaged signal in the WM and CSF, along with their temporal 
derivatives, squares and derivatives squared. No global signal regression was applied. We 
assessed framewise displacement (FD), computed with fmriprep, as a measure for motion 
and excluded patients with a liberal motion cut-off of FD > 0.5 mm. We additionally assessed 
differences in image quality metrics calculated with MRIqc (DVARS, entropy-focus criterion, 
full-width half maximum smoothness and temporal signal-to-noise ratio)63 across groups and 
time-points (see Supplementary material 2). 
Timeseries extraction. To extract brain region specific timeseries, we parcellated cortical 
brain areas into 300 regions according to the Schaefer atlas, which has specifically been de-
veloped to match a widely-used seven-network human resting-state network parcellation.64 
The cortical brain areas were derived from registering the Schaefer atlas to FreeSurfer space 
and we added 14 subcortical areas segmented using FreeSurfer65 leading to a total of 314 
brain areas. This parcellation was registered to the preprocessed and denoised functional 
images in T1-weighted space using AFNI’s 3Dresample. Quality of the registration was visually 
inspected. Because EPI distortions around air-tissue boundaries can lead to signal drop-out, 
we applied a mask to the functional image66 and excluded brain regions with <4 active voxels 
in any participant, prior to timeseries extraction.67 Fourteen brain areas were excluded leading 
to a total of 300 brain regions common across subjects and time points (Supplementary ma-
terial 3).
Resting-state fMRI outcome measures. Between-network connectivity measures. To as-
sess connectivity between the FPN, DMN, and SN, we computed the average Fisher r-to-z 
transformed Pearson correlation of the resting-state fMRI time-series between the nodes that 
belonged to these resting-state networks, based on the network parcellation by Yeo and col-
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leagues.68 We designated the ventral attention network from the Yeo et al parcellation as SN. 
We used Pearson correlations to replicate earlier functional connectivity studies (as opposed 
to wavelet coherence, see below). We did not use the absolute value of the correlations, to 
maintain valuable information about potential between-network anti-correlations. As indicated 
in the preregistration, we assessed connectivity between other resting-state networks, i.e., 
the dorsal attention, limbic, motor and visual networks as exploratory outcomes but do not 
present these findings here due to space limitations.
Graph measures. Weighted, fully connected (i.e., non-thresholded) connectivity matrices for 
the calculation of graph indices were computed using a wavelet coherence method in the 
frequency range f = [0.009, 0.08].69 This method and frequency range are less contaminated 
by head motion compared to Pearson correlation connectivity matrices, while the test-retest 
reliability is better compared with partial correlation coefficient connectivity matrices.70
We assessed global network integration, segregation and connectivity between modules 
using the following respective measures: a) global efficiency (GE): the inverse of the mean 
shortest (characteristic) path length in the network,25 b) modularity (Q): the degree to which 
a network can be divided in sub-communities (i.e., modules), using modularity maximization 
with a generalized Louvain method for community detection,71 c) average participation coef-
ficient (PC): the degree to which a node is connected with other communities than its own. 
For the FPN, DMN and SN, we additionally computed a) efficiency (E, as described above), b) 
clustering coefficient (CC): the fraction of a node’s neighbors that are also neighbors of each 
other, and c) normalized betweenness centrality (BC): the average sub-network fraction of 
shortest paths in a network that pass through a node, normalized by the size of the network. 
We performed exploratory analyses on the absolute Fisher r-to-z transformed Pearson cor-
relation connectivity matrices using the same graph indices to assess reliability of the results 
and enhance comparability with previous research. We additionally assessed the effects of 
CT on rich club72 and diverse club coefficients,73 see Supplementary material 4 for method-
ological details.
Analyses. The sample size was based on the estimated effect of CT on global cognitive func-
tion: effect size f = .12, sample needed to detect effect: 112.6, 42 Based on earlier studies that 
showed changes in functional activity and connectivity preceding cognitive decline in PD,74-76 
neuroimaging indices seem more sensitive to change compared with (global) cognitive tests 
– and effect sizes are likely larger. Therefore, we enrolled 86 participants for the MRI sub-
study.
We performed analyses on the intention-to-treat population (all correctly enrolled and ran-
domized participants). Group differences in demographic and clinical variables were analyzed 
with the appropriate tests, i.e., Student’s t-tests, Mann-Whitney U tests or Fisher’s exact tests. 
191
Eight-week multi-domain cognitive training does not impact large-scale functional brain 
networks in Parkinson’s disease
For analysis of the abovementioned neuroimaging indices, we used univariate mixed-model 
analyses to assess the effect of CT relative to AC. We used the after training outcome (T1) as 
dependent variable, the group (CT vs. AC) as independent variable and the baseline outcome 
(T0) as covariate. We additionally performed these analyses correcting for age, years of edu-
cation and sex. 
For analysis of global graph measures, we considered a significance level of α = .05 signif-
icant. To correct for multiple comparisons in sub-network analyses we used a D/AP-Sidak 
adjustment that takes into account the mutual correlation between outcome measures 
(computed using (https://www.quantitativeskills.com/sisa/calculations/bonhlp.htm).77 For be-
tween-network connectivity analyses, we computed an α corrected for three comparisons, 
adjusted for the correlation r = .544 between the three indices after training (αBN = .031). For 
sub-network graph analyses, we computed a separate α for each graph measure adjusted 
for the correlation between the respective sub-network measures at baseline (rFPN = .387, αFPN 
= .026; rDMN = .408, αDMN = .026; rSN = .413, αSN = .027). We additionally performed sub-group 
analyses based on the cognitive status of participants, i.e., PD-NC, PD-MCI or PD-D, by adding 
an additional covariate with relevant contrasts to the analyses described above. Lastly, we 
performed post-hoc analyses to assess functional connectivity and graph properties of key 
nodes – on the basis of previous literature – of the studied sub-networks and additionally 
examined connectivity of these nodes with subcortical areas, specifically the caudate nucleus, 
thalamus and hippocampus, as impaired cortico-subcortical connections are implicated in PD 
and these subcortical areas are particularly implicated in cognitive -function (see Supplemen-
tary material 10).78-80
Multivariate (ToL) and univariate (SCWT) linear mixed-model analyses were used to assess 
differences between groups on the neuropsychological outcomes, as discussed in detail else-
where.42 Participants were excluded from ToL data analysis if they showed poor understand-
ing of the task, operationalized as load 1 score < 75%.
The association between change in resting-state functional connectivity and change in cog-
nitive function was analyzed with repeated-measures correlation analyses using the R pack-
age ‘rmcorr’.81 We assessed the repeated-measures correlation between the neuroimaging 
outcomes (15 in total) and cognitive outcomes. We analyzed the average ToL reaction time 
over S1-S5 and the SCWT card I-III separately. Associations with ToL accuracy change were 
analyzed in an exploratory fashion as this was the primary outcome of the trial. We used an α 
corrected for multiple comparisons per cognitive test, adjusted for the baseline association 




Participants. In COGTIPS, we enrolled and randomized 86 participants in the fMRI study 
(out of the full sample of 140 participants). The fMRI sub-sample was representative for the 
full sample concerning demographic characteristics but had a shorter disease duration; for a 
comparison see Supplementary material 5. The participants were evenly distributed across 
both conditions. A total of thirteen participants (AC n = 8, CT n = 5) were excluded from the 
analyses due to discontinuation of the intervention, excessive in-scanner motion or fMRI scan 
failure (see Figure 1). Of the remaining participants, the groups were evenly matched across 
demographic and clinical characteristics except for baseline subjective cognitive complaints 
(see Table 1). The CT group also contained more female participants compared with the AC 
group, although this difference was not statistically significant. Inspection of fMRI data quality 
showed no group differences in motion, but did show, independent of time, a higher tempo-
ral derivative of root mean square variance over voxels (DVARS) and entropy-focus criterion 
(EFC), indicating better average image quality, in the CT group (Supplementary Material 2).
Behavioral training effects in the fMRI sample differed compared with the effects in the full 
study sample. Positive training effects on the ToL reaction time and SCWT in the full study 
sample were attenuated in the smaller fMRI sample, while in this sample there were more pro-
nounced differences on the ToL accuracy in favor of the AC (see Supplementary material 6). 
Figure 1 Flowchart of participants.
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Sex (N (%)) p = .227‡
  Male 23 (68%) 19 (51%)
  Female 11 (32%) 18 (49%)
Age (years) 63.8 (6.1) 63.2 (8.3) t = .345, p =.731
Education (years) 16.7 (4.3) 15.5 (3.6) t = 1.257, p = .213
Education classification (N (%))† U = 575, p = .514
  3 0 (0%) 1 (2.7%)
  4 2 (5.9%) 3 (8.1%)
  5 7 (20.6%) 10 (27.0%)
  6 15 (44.1%) 12 (32.4%)
  7 10 (29.4%) 11 (29.7%)
Disease duration (years, median [range]) 4 [1-16] 4 [0-13] U = 597, p = .710
UPDRS-III 19.4 (9.2) 20.6 (9.2) t = -.555, p =.581
Hoehn & Yahr stage (N (%)) U = 581, p = .557
  1 2 (5.9%) 3 (8.1%)
  1.5 1 (2.9%) 4 (10.8%)
  2 17 (50.0%) 15 (40.5%)
  2.5 9 (26.5%) 11 (29.7%)
  3 5 (14.7%) 4 (10.8%)
LEDD (median [range]) 795 [0-1790] 630 [80-1665] U = 538.5, p = .297
Medication change during study (N (%)) 8 (7.2%) 7 (7.8%) p = .773‡
LEDD T1 (median [range]) 787 [0-1790] 630 [80-1530] U = 537, p = .289
MoCA 26.2 (2.5) 26.6 (1.7) t = -.777, p =.440
Global cognitive function classification (N 
(%)) p = .379
‡
  Normal cognition 8 (23.5%) 11 (29.7%)
  Single-domain MCI 5 (14.7%) 6 (16.2%)
  Multi-domain MCI 13 (38.2%) 17 (45.9%)
  PD dementia 8 (23.5%) 3 (8.1%)
BDI 8.4 (3.8) 8.0 (4.3) t = .395, p =.694
QUIP-RS (N=70) 20.5 (12.7) 16.1 (13.1) t = 1.411, p = .163
PAS 11.6 (7.4) 9.2 (6.2) t = 1.471, p =.146
AS 14.2 (4.3) 12.9 (4.3) t = 1.250, p = .216
Data are mean (SD) unless otherwise specified. †According to Verhage education classification. ‡Fisher’s 
exact test. 
Abbreviations: AS = Apathy Scale; BDI = Beck Depression Inventory; PAS = Parkinson Anxiety Scale; PD-
CFRS = Parkinson’s Disease – Cognitive Functional Rating Scale; LEDD = Levodopa equivalent daily dos-
age; MCI = mild cognitive impairment; MoCA = Montreal Cognitive Assessment; QUIP-RS = Questionnaire 









Credibility-Expectancy (N=70) 31.3 (6.4) 33.1 (6.7) t = -1.168, p =.247
PD-CFRS (median [range]) 10 [4-22] 7 [3-18] U = 422, p = .017
Compliance (%, median [range]) 100 [71-100] 100 [92-100] U = 642.5, p = .864
T0-to-T1 interval (days) 64.7 (7.3) 63.8 (5.0) t = .608, p = .545
Data are mean (SD) unless otherwise specified. †According to Verhage education classification. ‡Fisher’s 
exact test. 
Abbreviations: AS = Apathy Scale; BDI = Beck Depression Inventory; PAS = Parkinson Anxiety Scale; PD-
CFRS = Parkinson’s Disease – Cognitive Functional Rating Scale; LEDD = Levodopa equivalent daily dos-
age; MCI = mild cognitive impairment; MoCA = Montreal Cognitive Assessment; QUIP-RS = Questionnaire 
for Impulsive-Compulsive Disorders in Parkinson’s Disease – Rating Scale; UPDRS = Unified Parkinson’s 
Disease Rating Scale.
Preregistered analyses. Main outcomes: functional connectivity and network topology dif-
ferences. Univariate mixed-model analyses of connectivity between the SN, FPN and DMN 
did not reveal significant group differences after training (Figure 2a-c). Analysis of global effi-
ciency, modularity and participation coefficient at the global network level showed no group 
differences after training (Figure 2d-f). Efficiency, clustering coefficient and betweenness cen-
trality at sub-network level did also not differ between groups after training. All statistics are 
reported in Table 2. For replicability we performed the same analyses using graph outcomes 
calculated with Pearson correlation-based connectivity matrices; these analyses resulted in 





































































































Figure 2 No between-group differences on between-network connectivity (panels A-C) and global network 
topology (panels D-F).
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Table 2 Group differences, corrected for baseline value, on primary neuroimaging outcomes.
Crude models Adjusted models†




SN – FPN 0.017 [0.014] -0.011 to 0.046 0.227 0.019 [0.014] -0.010 to 0.048 0.197
SN – DMN 0.004 [0.015] -0.025 to 0.0330.791 0.006 [0.014] -0.023 to 0.0340.695
FPN – DMN 0.004 [0.014] -0.024 to 0.0320.771 0.000 [0.014] -0.028 to 0.029 0.981
Graph outcomes
Global
GE 0.002 [0.003] -0.005 to 0.008 0.624 0.002 [0.003]
-0.005 to 
0.008 0.622
Q 0.001 [0.002] -0.003 to 0.006 0.568 0.000 [0.002] -0.004 to 0.0040.911
PC -0.010 [0.009] -0.028 to 0.0070.249 -0.007 [0.009] -0.025 to 0.011 0.435
FPN
GE -0.003 [0.007] -0.017 to 0.012 0.710 -0.003 [0.007] -0.018 to 0.012 0.682
CC‡ 0.124 [3.364] -6.584 to 6.8320.971 0.973 [3.396] -5.798 to 7.744 0.775
BC‡ 0.050 [0.078] -0.106 to 0.205 0.526 0.062 [0.078] -0.094 to 0.217 0.430
DMN
GE -0.002 [0.007] -0.016 to 0.012 0.759 -0.003 [0.007] -0.017 to 0.010 0.638
CC‡ 0.444 [3.342] -6.221 to 7.108 0.895 0.651 [3.404] -6.137 to 7.439 0.849
BC‡ 0.005 [0.059] -0.112 to 0.123 0.931 -0.016 [0.056] -0.128 to 0.097 0.778
SN
GE -0.006 [0.011] -0.027 to 0.016 0.606 -0.010 [0.011] -0.031 to 0.012 0.381
CC‡ -1.593 [3.535] -8.640 to 5.4550.654 -1.969 [3.571] -9.090 to 5.152 0.583
BC‡ -0.001 [0.095] -0.190 to 0.188 0.994 -0.036 [0.095] -0.226 to 0.154 0.707
†Corrected for age, sex, education in years and, for between-network connectivity analyses, framewise dis-
placement. ‡Statistics multiplied by 103 because of small values. Abbreviations: BC – Betweenness central-
ity; CC – Clustering coefficient; DMN – Default mode network; FPN – Frontoparietal network; GE – Global 
efficiency; PC – Participation coefficient; Q – Modularity; SN – Salience network.
Exploratory outcomes. To assess the association between functional connectivity or network 
topology change and change on the ToL or SCWT, we performed group-wise repeated-mea-
sures correlation analyses. In both groups, no significant associations were present between 
change on ToL accuracy or reaction time, or SCWT performance, and functional connectivity 
or network topology when correcting for multiple comparisons (α = .007; see Supplementary 
material 8). 
We performed sub-group training effect analyses, distinguishing effects between patients 
with PD-NC, PD-MCI or PD-D. Only in the PD-NC sub-sample (n = 19) there was a post-inter-
vention difference between groups, showing higher modularity (B[SE]: .008 [.004], p=.033) 
and lower participation coefficient (B[SE]: -.042 [.015], p=.007) in the CT group, suggesting a 
more segregated network topology. These effects were, however, not associated with change 
in neuropsychological test performance. At sub-network level, an isolated between-group 
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difference in the PD-D sub-sample was found showing higher post-training betweenness cen-
trality in the CT versus the AC group, that did not survive correction for multiple comparisons. 
No between-network functional connectivity differences were present (see Supplementary 
Material 9). 
There were no group differences in the normalized clubness coefficients after intervention, 
adjusted for baseline values – rich club coefficient: B[SE]: -.006 [.019], p=.767, diverse club 
coefficient: B[SE]: -.030 [.031], p=.336. 
Post-hoc analyses (not preregistered). Post-hoc, we performed nodal analyses on the func-
tional connectivity and topology of key sub-network key regions (see Supplementary material 
10), as averaging across network nodes could potentially obscure more localized effects. To 
limit the number of comparisons, we analyzed key region functional connectivity or topo-
logical outcomes that showed significant correlations with neuropsychological outcomes at 
baseline (across groups). We found group differences indicative of increased connectivity in 
the CT group between the right dorsal anterior cingulate cortex (dACC) and the FPN, and of 
the left dorsolateral prefrontal cortex (dlPFC) within the FPN, that did, however, not survive 
correction for multiple comparisons (Figure 3a-b). Because the dACC and dlPFC are implicat-
ed in associative cortico-striato-thalamo-cortical circuits we further inspected connectivity of 
these nodes with subcortical areas. Results suggested group connectivity differences of both 
nodes predominantly with the right caudate nucleus, indicative of stable/increased connec-
tivity in the CT group versus decreased/stable connectivity in the AC group (see Figure 3c-d). 
Analysis of key region nodal participation coefficient, clustering coefficient and betweenness 
centrality showed no group differences after training. 
Discussion
There is an increasing need for treatment options for cognitive impairment in PD as a large 
majority of individuals with PD ultimately develops dementia. CT has been proposed as 
non-pharmacological treatment option and earlier meta-analyses have suggested positive 
effects on frontal cognitive functions, but the neural correlates remain largely unknown. In this 
study, we assessed the effect of eight-week online multi-domain CT on the functional brain 
network by studying large-scale brain networks in the largest sample of PD patients to date. 
Our results do not support the hypothesis that CT enhances the functional neural system on a 
global level. Post-hoc analyses, however, suggested that CT may improve specific functional 
connections, notably in cortico-cortical and cortico-subcortical circuits that are prominently 
implicated in PD. 
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In this study, we used functional connectivity and graph theoretical measures to map function-
al brain network alterations after CT. While earlier studies in multiple sclerosis and Alzheimer’s 
disease that applied a multi-domain CT of similar length (4-12 weeks) showed that functional 
connectivity within networks increased,82-84 our intervention did not affect global and sub-net-
work brain topology. Two of these studies also used active comparators, albeit potentially less 
engaging control conditions (i.e., news-paper reading and social interaction) compared with 
ours. One study in individuals with amnestic mild cognitive impairment that studied a 26-week 
multi-domain CT relative to a documentary-watching control condition showed enhanced 
segregation between task-positive and task-negative networks.85 In contrast to these studies, 
we used an empirically-based, widely-used network parcellation,68 instead of independent 
component analysis to overcome potential replicability limitations of data-driven methods. 
To our knowledge, this is the first study on the effect of CT on brain network topology in 
PD patients. Although there is ample evidence for the existence of network topological 
alterations already early in PD, therapeutic effects on these alterations are still relatively un-
explored in PD – as it is in CT literature. Earlier studies – although mainly in healthy young 
subjects – have confirmed that CT is able to alter network topology,32-35 and modularity may 
be an important predictor of therapeutic success.36-38 When we added contrasts to assess CT 
Figure 3 Group differences in connectivity between the dorsal anterior cingulate cortex (dACC) and fronto-
parietal network (FPN, panel A) and right caudate nucleus (panel C) and the dorsolateral prefrontal cortex 
(dlPFC) and the FPN (panel B) and right caudate nucleus (panel D). P values mark difference at post-training 
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effects per cognitive status, cognitive training did seem to decrease participation coefficient 
while modularity increased in cognitively normal individuals – although the latter result did 
not survive correction for multiple comparisons. These effects, indicating a more segregated 
network, are associated with more healthy brain topology.86 The sub-group was very small, 
however, and therefore these effects need to be replicated in a larger sample of exclusively 
cognitively intact PD patients.
To ensure that potential effects were not levelled out by our method of averaging connectivity 
strength across network nodes, we analyzed connectivity of specific network nodes that pre-
viously have been reported to play a key role in the respective networks. The results of these 
analyses did replicate the findings from earlier studies and revealed localized changes in 
cortico-cortical and cortico-subcortical connections of the dorsal ACC and dlPFC, key regions 
of the SN and FPN, respectively. First, it should be noted that these analyses were performed 
post-hoc and replication of these findings is needed. Our results support multiple earlier find-
ings in neurodegenerative diseases and healthy aging that showed CT-induced connectivity 
alterations of the ACC85, 87, 88 and dlPFC20, 88, 89 using seed-based analysis methods. These 
structures are critically involved in cognition, especially executive function and this pattern 
of results thus fits the focus of our experimental intervention on executive functions, mental 
speed and attention.
In the dACC and dlPFC, CT induced increased average connectivity with FPN nodes. These 
connectivity changes may indicate that executive function and cognitive control networks 
alter on a more localized level: first, the dACC is a large structure with monitoring, controlling 
and evaluating functions and its connections to frontal and parietal areas are important for 
cognition and – specifically – executive control.90, 91 Second, increased connectivity of the left 
dlPFC with FPN nodes may exhibit enhanced intrinsic connectivity of this control network that 
is primarily associated with cognitive control and working memory and exerts top-down con-
trol of attention.91, 92 After CT, functional connectivity of the right dlPFC and dorsal ACC with 
the ipsilateral caudate nucleus was additionally higher compared with the AC group. These 
cortico-subcortical connections belong to the highly dopamine-dependent cortico-striato-thal-
amo-cortical (CSTC) circuits involved in executive function80, 93 and cognitive control.94 Our 
data showed that functional connectivity with the caudate nucleus was higher post-training 
in the CT group, with stable or increased connectivity in the CT group relative to a decrease 
in the AC group connectivity. Taken together, the key region connectivity findings cautiously 
suggest that CT may improve more localized, functional coupling that is generally impaired in 
PD. 
Despite the fact that the cortico-cortical and cortico-subcortical connectivity changes and the 
network topological changes in de PD-NC group fit the existing literature, these results need 
to be taken with caution as these were post-hoc analyses with no significant association with 
199
Eight-week multi-domain cognitive training does not impact large-scale functional brain 
networks in Parkinson’s disease
training-induced change in cognitive performance. The clinical relevance of these changes 
may therefore be limited. Still, neuroimaging may be better able to catch subtle changes in 
cognitive function that precede measurable change on neuropsychological tasks – e.g., in 
our previous studies we observed functional activity and connectivity changes in de novo PD 
patients while neuropsychological test performance was still normal.75, 76 Additionally, although 
our earlier systematic review of neural correlates of CT showed that it induced diffuse func-
tional connectivity alterations across the cortex rather than targeted at specific brain areas,19 
the small behavioral effects in our sample retrospectively make the existence of such large-
scale effects on brain topology and connectivity inconceivable. It is conceivable, however, 
that these effects may generalize to large-scale network connectivity and topology if CT is 
more efficacious and its durability enhanced, e.g., with extended training duration, addition of 
booster sessions or adjuvant neurostimulation such as repetitive transcranial magnetic stimu-
lation.
This is the largest study yet on the neuroimaging effects of CT in PD. The comprehensive 
set of clinical, neuropsychological and imaging data provide a complete picture of the po-
tential changes induced by CT. Additionally, in our study we used – as far as available – best 
practice methods to map neuropsychological test performance,51 preprocessing pipelines,59 
definition of the connectivity matrix,70 and resting-state network parcellation.68 While we 
aimed to exclude individuals with severe cognitive impairment by using previously reported 
optimal diagnostic screening criteria for PD-D on the basis of Montreal Cognitive Assessment 
score,46 in the end our patient sample did consist of a small proportion of individuals with 
possible PD-D on the basis of the full diagnostic criteria.52 Our fMRI sample was represen-
tative for the full study sample on the basis of clinical and demographic characteristics. The 
subtle behavioral CT effects from the full study sample did, however, not reach significance 
in this sub-sample, potentially due to the smaller size of the fMRI sub-sample. The lack of 
robust behavioral effects may explain the absence of large-scale brain network alterations 
after CT. We additionally used a wavelet coherence method to compute connectivity matrices, 
with the advantage of being less susceptible to in-scanner head movement, but most earlier 
studies applying graph theory used Pearson correlational methods which may induce (small) 
differences in results. Our proof-of-concept analyses using graph outcomes calculated with 
Pearson correlation connectivity matrices did, however, not provide different results. Lastly, 
our participants moved considerably during the fMRI scan; we excluded the participants with 
extreme movement, but for pragmatic reasons our cut-off was quite liberal.62
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In conclusion, we studied the effect of eight-week online multi-domain CT on functional con-
nectivity and brain network topology in individuals with PD. We did not find evidence for al-
terations in connectivity between large-scale networks or brain network topology. Analogous 
to effects on cognitive performance, CT effects on network function were small, at the most 
targeting regional connectivity in fronto-striatal circuits. Post-hoc results hinted at increased 
segregation of global network topology specifically in cognitively intact PD patients, but repli-
cation in larger, homogeneous samples is needed. 
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Supplementary material 1 – fMRIPrep boilerplate
Results included in this manuscript come from preprocessing performed using fMRIPrep 1.4.1 
(RRID:SCR_016216),1 which is based on Nipype 1.2.0 (RRID:SCR_002502).2
Anatomical data preprocessing. A total of 2 T1-weighted (T1w) images were found within the 
input BIDS dataset. All of them were corrected for intensity non-uniformity (INU) with N4Bi-
asFieldCorrection,3 distributed with ANTs 2.2.0 (RRID:SCR_004757).4 The T1w-reference was 
then skull-stripped with a Nipype implementation of the antsBrainExtraction.sh workflow (from 
ANTs), using OASIS30ANTs as target template. Brain tissue segmentation of cerebrospinal 
fluid (CSF), white-matter (WM) and gray-matter (GM) was performed on the brain-extracted 
T1w using fast (FSL 5.0.9, RRID:SCR_002823).5 A T1w-reference map was computed after reg-
istration of 2 T1w images (after INU-correction) using mri_robust_template (FreeSurfer 6.0.1).6 
Brain surfaces were reconstructed using recon-all (FreeSurfer 6.0.1, RRID:SCR_001847),7 and 
the brain mask estimated previously was refined with a custom variation of the method to 
reconcile ANTs-derived and FreeSurfer-derived segmentations of the cortical gray-matter of 
Mindboggle (RRID:SCR_002438).8 Volume-based spatial normalization to one standard space 
(MNI152NLin6Asym) was performed through nonlinear registration with antsRegistration 
(ANTs 2.2.0), using brain-extracted versions of both T1w reference and the T1w template. The 
following template was selected for spatial normalization: FSL’s MNI ICBM 152 non-linear 6th 
Generation Asymmetric Average Brain Stereotaxic Registration Model (RRID:SCR_002823; 
TemplateFlow ID: MNI152NLin6Asym).9
Functional data preprocessing. For each of the 2 BOLD runs found per subject (across all 
tasks and sessions), the following preprocessing was performed. First, a reference volume 
and its skull-stripped version were generated using a custom methodology of fMRIPrep. The 
BOLD reference was then co-registered to the T1w reference using bbregister (FreeSurfer) 
which implements boundary-based registration.10 Co-registration was configured with nine 
degrees of freedom to account for distortions remaining in the BOLD reference. Head-mo-
tion parameters with respect to the BOLD reference (transformation matrices, and six cor-
responding rotation and translation parameters) are estimated before any spatiotemporal 
filtering using mcflirt (FSL 5.0.9).11 BOLD runs were slice-time corrected using 3dTshift from 
AFNI 20160207 (RRID:SCR_005927).12 The BOLD time-series, were resampled to surfaces on 
the following spaces: fsnative, fsaverage5. The BOLD time-series (including slice-timing cor-
rection when applied) were resampled onto their original, native space by applying a single, 
composite transform to correct for head-motion and susceptibility distortions. These resa-
mpled BOLD time-series will be referred to as preprocessed BOLD in original space, or just 
preprocessed BOLD. The BOLD time-series were resampled into standard space, generating 
a preprocessed BOLD run in [‘MNI152NLin6Asym’] space. First, a reference volume and its 
skull-stripped version were generated using a custom methodology of fMRIPrep. Automatic 
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removal of motion artifacts using independent component analysis (ICA-AROMA)13 was per-
formed on the preprocessed BOLD on MNI space time-series after removal of non-steady 
state volumes and spatial smoothing with an isotropic, Gaussian kernel of 6mm FWHM (full-
width half-maximum). Corresponding “non-aggresively” denoised runs were produced after 
such smoothing. Additionally, the “aggressive” noise-regressors were collected and placed 
in the corresponding confounds file. Several confounding time-series were calculated based 
on the preprocessed BOLD: framewise displacement (FD), DVARS and three region-wise 
global signals. FD and DVARS are calculated for each functional run, both using their imple-
mentations in Nipype (following the definitions by Power et al.).14 The three global signals are 
extracted within the CSF, the WM, and the whole-brain masks. Additionally, a set of physiolog-
ical regressors were extracted to allow for component-based noise correction (CompCor).15 
Principal components are estimated after high-pass filtering the preprocessed BOLD time-se-
ries (using a discrete cosine filter with 128s cut-off) for the two CompCor variants: temporal 
(tCompCor) and anatomical (aCompCor). tCompCor components are then calculated from 
the top 5% variable voxels within a mask covering the subcortical regions. This subcortical 
mask is obtained by heavily eroding the brain mask, which ensures it does not include cor-
tical GM regions. For aCompCor, components are calculated within the intersection of the 
aforementioned mask and the union of CSF and WM masks calculated in T1w space, after 
their projection to the native space of each functional run (using the inverse BOLD-to-T1w 
transformation). Components are also calculated separately within the WM and CSF masks. 
For each CompCor decomposition, the k components with the largest singular values are 
retained, such that the retained components’ time series are sufficient to explain 50 percent 
of variance across the nuisance mask (CSF, WM, combined, or temporal). The remaining com-
ponents are dropped from consideration. The head-motion estimates calculated in the correc-
tion step were also placed within the corresponding confounds file. The confound time series 
derived from head motion estimates and global signals were expanded with the inclusion of 
temporal derivatives and quadratic terms for each.16 Frames that exceeded a threshold of 0.5 
mm FD or 1.5 standardised DVARS were annotated as motion outliers. All resamplings can 
be performed with a single interpolation step by composing all the pertinent transformations 
(i.e. head-motion transform matrices, susceptibility distortion correction when available, and 
co-registrations to anatomical and output spaces). Gridded (volumetric) resamplings were per-
formed using antsApplyTransforms (ANTs), configured with Lanczos interpolation to minimize 
the smoothing effects of other kernels.17 Non-gridded (surface) resamplings were performed 
using mri_vol2surf (FreeSurfer).
Many internal operations of fMRIPrep use Nilearn 0.5.2 (RRID:SCR_001362),18 mostly within 
the functional processing workflow. For more details of the pipeline, see the section corre-
sponding to workflows in fMRIPrep’s documentation.
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Supplementary material 2 – Image quality metrics per group  
and time-point
Quality of the fMRI data was extracted and compared across groups and time points with the 
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Supplementary material 3 – Brain regions used for analyses
For functional connectivity and graph analysis we used the brain regions from the Schaefer 
7-network and FreeSurfer subcortical atlases, that had adequate quality and were common 
across all participants and time-points, as listed below.
Table S1a Overview of nodes included for analyses.
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Table S1b Overview of nodes excluded for analyses.
LH_Cont_Cing_1 – 2 RH_Cont_Cing_1 – 2
LH_Default_Temp_2 RH_Default_Temp_2
LH_Limbic_OFC_1 – 3 RH_Limbic_OFC_1 – 3
Left-Accumbens-area Right-Accumbens-area
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Supplementary material 4 – Rich and diverse club coefficient  
analysis methods
Rich and diverse club coefficient calculation. Rich club and diverse club coefficient were ad-
ditionally assessed as exploratory outcome. Briefly, the brain’s rich club is a set brain regions 
that is highly and strongly connected within the neural network and is densely interconnect-
ed.19 A rich club organization is associated with cognitive performance - executive function 
in particular - in healthy elderly.20 The diverse club, on the other hand, has recently been 
proposed as a different set of highly connected brain region in the neural network that has 
diverse connectivity (i.e., high participation coefficient).21 The diverse club seems is important 
for integration within the network compared with the rich club and shows increased activity 
in complex cognitive tasks. We defined the club size by first ranking nodes on strength or 
participation coefficient and subsequently assessed clubness using a range of percentile 
cut-offs (highest 30% to highest 5%, see below). Both clubness coefficients (θrich and θdiverse) 
were calculated using the following equation for fully weighted networks, as used in previous 
studies:21, 22 θ = e ⁄ (n ∙ (n − 1) ⁄ 2), where e is the sum of edge weights between the club’s nodes 
and n is the number of nodes within the club. The normalized clubness coefficients were sub-
sequently calculated by dividing the coefficient by the mean club coefficient of 1000 random 
networks (as described earlier), indicating that a normalized θ > 1 means larger than random. 
As for all cut-offs the normalized clubness was > 1 and at cut-offs > 10% the diverse clubness 
increased disproportionally, we used the highest 10% strengths and PCs within individual 
networks (i.e., 30 nodes) as rich or diverse clubs.
Clubness definition. The size of the rich and diverse clubs were computed by first assessing 
normalized clubness coefficient in a range of cut-off values. As the graphs in our sample were 
fully weighted so that the degree of every node n is theoretically n − 1, we used a range of 
percentages to define the clubness cut-off, as shown in Figure S2. Nodes that most frequently 
belonged to either club are presented in Figure S3; cortical node names correspond to the 
Schaefer atlas.23
The rich and diverse club coefficients were calculated as follows, in line with earlier studies.21, 
22 First, each node’s strength was calculated by summing the edge strength with all other 
nodes and participation coefficient was calculated with the Brain Connectivity Toolbox func-
tion participation_coef.m, using the community structure as calculated with the generalized 
Louvain method. Nodes were sorted on strength or participation coefficient and the highest 
values were extracted using a range of cut-offs from 30% to 5% (corresponding to a range of 
90 to 15 nodes), to define rich and diverse clubs with different sizes, respectively. 
211
Eight-week multi-domain cognitive training does not impact large-scale functional brain 
networks in Parkinson’s disease
For these clubs, the clubness coefficient  was calculated by dividing total edge strength by 
total possible edge strength: θ = e ⁄ (n ∙ (n − 1) ⁄ 2), where e was the sum of edge club’s edge 
strengths and n was the number of nodes. Similarly, this process was repeated to compute 
random network clubness θrand for 1000 random networks that were computed per individual 
preserving the degree-, weight-, and strength-distributions, using the Brain Connectivity Tool-
box function null_model_und_sign. Lastly, normalized clubness coefficient (θnorm) was comput-
ed: θrand = θ ⁄ θnorm.
Figure S2 Normalized rich and diverse club coefficient for a range of club size cut-offs.
Figure S3a Network nodes that most frequently were element of the rich club.
212
Chapter 6 - Supplementary material
Figure S3b Network nodes that most frequently were element of the diverse club.
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Supplementary material 5 – Comparison between fMRI  
and non-fMRI sample
Table S2 Comparison between sample included in fMRI analyses and sample not included of the full COG-
TIPS intention-to-treat sample (n = 136).
fMRI sample (n=71) Non-fMRI sample (n=65) P value
Sex (N (%)) .861
  Male 42 (69%) 40 (51%)
  Female 29 (31%) 25 (49%)
Age (years) 63.5 (7.3) 62.2 (7.8) .337
Education (years) 16.1 (4.0) 16.1 (3.9) .919
Education classification (N (%))a .949
  3 1 (1.4%) 1 (1.5%)
  4 5 (7%) 3 (4.6%)
  5 17 (23.9%) 16 (24.6%)
  6 27 (38%) 28 (43.1%)
  7 21 (29.6%) 17 (26.2%)
Disease duration (years, median [range]) 4 [0-16] 7 [1-26] .008
UPDRS-III 20.0 (9.1) 21.1 (8.7) .482
Hoehn & Yahr stage (N (%)) .733
  1 5 (7%) 4 (6.2%)
  1.5 5 (7%) 4 (6.2%)
  2 32 (45.1%) 30 (46.2%)
  2.5 20 (28.2%) 16 (24.6%)
  3 9 (12.7%) 11 (16.9%)
LEDD (median [range]) 640 [0-1790] 720 [0-2100] .754
MoCA 26.4 (2.1) 25.8 (2.2) .136
Global cognitive function classification 
(N (%)) .079
  Normal cognition 19 (26.8%) 9 (13.8%)
  Single-domain MCI 11 (15.5%) 5 (7.7%)
  Multi-domain MCI 30 (42.3%) 39 (60.0%)
  PD dementia 11 (15.5%) 12 (18.5%)
BDI 8.2 (4.0) 7.9 (4.1) .663
PD-CFRS (median [range]) 7.2 [3.3-22] 8.7 [3.3-19] .944
Data are mean (SD) unless otherwise specified. aAccording to Verhage education classification.29 
Abbreviations: BDI = Beck Depression Inventory; PD-CFRS = Parkinson’s Disease – Cognitive Functional 
Rating Scale; LEDD = Levodopa equivalent daily dosage; MCI = mild cognitive impairment; MoCA = Montre-
al Cognitive Assessment; UPDRS = Unified Parkinson’s Disease Rating Scale.
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Supplementary material 6 – Summary of behavioral results  
in the fMRI and full study sample
The CT vs. AC group differences after training in the fMRI sample are shown in Table S3. The 
full study sample group differences are shown in Table S4. The estimates show that effects 
on the ToL accuracy are larger in the fMRI sample in favor of the AC group, while the effects 
on the ToL reaction time and SCWT present in the full study sample are attenuated in the fMRI 
sample. 
Regarding the full study sample, there was no group difference on ToL accuracy after training 
across all task-loads S1-S5 or on any individual task-load. Multivariate analysis of the ToL reac-
tion times across task loads S1-S5 (N=130) showed, however, group differences after training 
with a significant effect on ToL reaction time load S4. Estimates of the other ToL task-loads 
indicated numerically similar, but non-significant, positive effects of CT compared with the AC. 
Univariate analyses of individual neuropsychological test outcomes additionally showed esti-
mates suggesting improvement in the CT group on the Stroop Color-Word Test card II and III 
that, however, did not survive correction for multiple comparisons. 
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Supplementary material 7 – Analysis of graph outcomes calculated 
with Pearson correlation-based connectivity matrices  
(instead of wavelet coherence-based)
Graph outcomes calculated with Pearson correlation-based connectivity matrices showed 
high correspondence with the wavelet-coherence based graph outcomes, as shown below 
(Table S5).
Table S5 Correlation of global and subnetwork graph measures calculated by the wavelet coherence 
method with those calculated by the Pearson correlation method.
Variable r Variable r
Global efficiency .768 FPN – Global efficiency .876
Participation coefficient .548 FPN – Betweenness centrality .553
Modularity .455 FPN – Clustering coefficient .549
SN – Global efficiency .937 DMN – Global efficiency .747
SN – Betweenness centrality .672 DMN – Betweenness centrality .559
SN – Clustering coefficient .712 DMN – Clustering coefficient .403
Table S6 Group differences, corrected for baseline value, on primary neuroimaging outcomes calculated 
on the basis of Pearson correlation connectivity matrices.
Graph outcomes
Crude models Adjusted modelsa
B [SE] 95% CI P value B [SE] 95% CI P value
Global
GE 0.004 [0.004] -0.004 to 0.013 0.301 0.003 [0.004] -0.005 to 0.011 0.484
Q -0.006 [0.004] -0.014 to 0.003 0.178 -0.008 [0.004] -0.016 to 0.000 0.060
PC -0.002 [0.010] -0.022 to 0.018 0.821 0.002 [0.010] -0.018 to 0.022 0.816
FPN
GE 0.002 [0.008] -0.015 to 0.018 0.824 0.000 [0.008] -0.017 to 0.016 0.964
CCb 5.113 [3.235] -1.338 to 11.564 0.118 4.503 [3.270] -2.018 to 11.024 0.173
BCb 0.001 [0.193] -0.384 to 0.386 0.995 0.058 [0.193] -0.328 to 0.443 0.766
DMN
GE 0.003 [0.008] -0.013 to 0.018 0.738 0.000 [0.008] -0.016 to 0.015 0.959
CCb 5.207 [3.557] -1.885 to 12.300 0.148 4.159 [3.518] -2.856 to 11.174 0.241
BCb -0.106 [0.130] -0.365 to 0.154 0.421 -0.119 [0.129] -0.376 to 0.138 0.359
SN
GE 0.003 [0.011] -0.020 to 0.025 0.819 -0.003 [0.011] -0.025 to 0.020 0.808
CCb 3.972 [4.260] -4.522 to 12.465 0.354 2.474 [4.242] -5.984 to 10.931 0.562
BCb -0.036 [0.184] -0.404 to 0.331 0.844 -0.042 [0.187] -0.416 to 0.331 0.822
aCorrected for age, sex, education in years and, for between-network connectivity analyses, framewise dis-
placement. bStatistics multiplied by 103 because of small values. Abbreviations: BC – Betweenness central-
ity; CC – Clustering coefficient; DMN – Default mode network; FPN – Frontoparietal network; GE – Global 
efficiency; PC – Participation coefficient; Q – Modularity; SN – Salience network.
218
Chapter 6 - Supplementary material
Table S7 Univariate mixed-model analysis of group differences on global graph outcomes per sub-group 
based on cognitive status calculated on the basis of Pearson correlation connectivity matrices.
PD-NC PD-MCI PD-D
B [SE] 95% CI Pvalue B [SE] 95% CI
P




































Based on 3 comparisons per sub-group, with mean r = .443 between the graph outcomes, corrected α = 
.027. 
Abbreviations: GE – Global efficiency; Q – Modularity; PC – Participation coefficient; PD-NC – Normal 
cognition; PD-MCI – Mild cognitive impairment; PD-D – Dementia.
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Supplementary material 8 – Repeated-measures  
correlation analyses
Table S8a Repeated measures correction analyses per group of the association between change on 
neuropsychological test performance (left-most column) and change in between-network connectivity and 
network topological measures.
Active control Cognitive training
r (df) 95% CI P value r (df) 95% CI P value
ToL 
Accuracy
SN - DMN 0.201 (31) 0.332 to 0.678 0.262 0.048 (35) -0.129 to 0.202 0.778
SN - FPN -0.055 (31) 0.318 to 0.608 0.760 0.237 (35) -0.137 to 0.162 0.158
FPN - DMN -0.158 (31) 0.119 to 0.573 0.380 -0.029 (35) -0.178 to 0.217 0.863
GE 0.042 (31) 0.147 to 0.550 0.816 -0.202 (35) -0.218 to 0.202 0.230
PC 0.055 (31) -0.092 to 0.286 0.760 0.137 (35) -0.154 to 0.243 0.418
Q 0.103 (31) -0.012 to 0.373 0.569 0.061 (35) -0.151 to 0.119 0.722
SN - Efficiency 0.208 (31) 0.091 to 0.503 0.246 0.003 (35) -0.130 to 0.171 0.984
SN - BC 0.094 (31) 0.056 to 0.477 0.603 0.048 (35) -0.285 to 0.074 0.776
SN - CC 0.186 (31) 0.203 to 0.526 0.301 -0.155 (35) -0.178 to 0.197 0.359
FPN - Efficiency 0.082 (31) 0.080 to 0.521 0.652 0.116 (35) 0.010 to 0.315 0.493
FPN - BC -0.097 (31) -0.245 to 0.362 0.591 0.225 (35) -0.218 to 0.105 0.181
FPN - CC 0.050 (31) 0.116 to 0.559 0.784 -0.118 (35) -0.145 to 0.308 0.487
DMN - Efficiency 0.105 (31) -0.264 to 0.347 0.562 -0.103 (35) -0.368 to 0.130 0.543
DMN - BC 0.051 (31) -0.307 to 0.178 0.777 0.298 (35) -0.092 to 0.338 0.073




SN - DMN -0.070 (31) -0.497 to -0.079 0.699 0.292 (34) -0.358 to -0.010 0.084
SN - FPN -0.093 (31) -0.353 to 0.019 0.608 0.086 (34) -0.301 to 0.123 0.619
FPN - DMN 0.031 (31) -0.534 to -0.168 0.865 0.077 (34) -0.383 to 0.006 0.653
GE -0.005 (31) -0.237 to 0.307 0.976 -0.219 (34) -0.529 to -0.176 0.199
PC 0.287 (31) 0.074 to 0.337 0.105 0.205 (34) -0.082 to 0.457 0.229
Q -0.367 (31) -0.472 to -0.134 0.036 -0.002 (34) -0.297 to 0.062 0.990
SN - Efficiency -0.147 (31) -0.247 to 0.114 0.413 -0.015 (34) -0.408 to 0.095 0.929
SN - BC -0.172 (31) -0.445 to 0.032 0.337 0.261 (34) 0.033 to 0.399 0.124
SN - CC -0.042 (31) -0.224 to 0.267 0.815 -0.155 (34) -0.391 to -0.058 0.368
FPN - Efficiency 0.245 (31) -0.306 to 0.076 0.170 -0.056 (34) -0.572 to -0.066 0.747
FPN - BC 0.155 (31) -0.486 to -0.081 0.388 0.020 (34) -0.254 to 0.212 0.909
FPN - CC 0.210 (31) -0.202 to 0.303 0.241 -0.312 (34) -0.553 to -0.149 0.064
DMN - Efficiency -0.283 (31) -0.443 to 0.104 0.111 -0.247 (34) -0.236 to 0.201 0.146
DMN - BC -0.329 (31) -0.440 to -0.066 0.062 0.181 (34) -0.122 to 0.207 0.292
DMN - CC -0.013 (31) -0.200 to 0.315 0.945 -0.346 (34) -0.497 to -0.079 0.039
Based on 15 comparisons per neuropsychological test, with mean r = .264, corrected α = .007. 
Abbreviations: BC – Betweenness centrality; CC – Clustering coefficient; DMN – Default mode network; FPN – Fron-
toparietal network; GE – Global efficiency; PC – Participation coefficient; Q – Modularity; SN – Salience network; ToL 
– Tower of London task
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Table S8b Repeated measures correction analyses per group of the association between change on 
neuropsychological test performance (left-most column) and change in between-network connectivity and 
network topological measures.
Active control Cognitive training
r (df) 95% CI P value r (df) 95% CI P value
SCWT 1
SN - DMN 0.049 (33) -0.215 to 0.185 0.779 0.271 (36) -0.369 to -0.043 0.100
SN - FPN 0.347 (33) -0.124 to 0.218 0.041 0.107 (36) -0.218 to 0.157 0.523
FPN - DMN 0.002 (33) -0.247 to 0.109 0.992 0.092 (36) -0.239 to 0.096 0.584
GE 0.351 (33) -0.010 to 0.417 0.039 0.025 (36) -0.238 to 0.083 0.881
PC 0.043 (33) -0.190 to 0.260 0.804 -0.003 (36) -0.051 to 0.292 0.986
Q -0.211 (33) -0.076 to 0.265 0.224 0.012 (36) -0.356 to -0.073 0.942
SN - Efficiency 0.219 (33) 0.059 to 0.552 0.206 0.089 (36) -0.341 to -0.022 0.593
SN - BC -0.063 (33) -0.133 to 0.256 0.718 0.105 (36) -0.303 to 0.238 0.529
SN - CC 0.400 (33) 0.088 to 0.572 0.017 0.045 (36) -0.171 to 0.063 0.789
FPN - Efficiency 0.118 (33) -0.367 to 0.024 0.500 -0.025 (36) -0.112 to 0.241 0.880
FPN - BC -0.138 (33) -0.568 to -0.279 0.428 -0.183 (36) -0.053 to 0.370 0.272
FPN - CC 0.399 (33) -0.135 to 0.361 0.018 -0.063 (36) -0.082 to 0.293 0.708
DMN - Efficiency 0.013 (33) -0.561 to -0.109 0.942 -0.101 (36) -0.183 to 0.204 0.547
DMN - BC -0.367 (33) -0.617 to -0.268 0.030 0.130 (36) -0.231 to 0.214 0.438
DMN - CC 0.353 (33) -0.244 to 0.173 0.037 -0.128 (36) -0.217 to 0.229 0.443
SCWT 2
SN - DMN -0.029 (33) -0.349 to -0.006 0.870 0.224 (36) -0.541 to -0.065 0.176
SN - FPN -0.287 (33) -0.522 to -0.080 0.095 0.205 (36) -0.249 to 0.223 0.216
FPN - DMN -0.200 (33) -0.361 to -0.028 0.249 0.139 (36) -0.295 to 0.185 0.405
GE -0.315 (33) -0.404 to 0.433 0.065 0.079 (36) -0.292 to 0.185 0.636
PC 0.323 (33) -0.123 to 0.240 0.058 0.018 (36) -0.209 to 0.147 0.916
Q 0.005 (33) -0.224 to 0.301 0.976 -0.009 (36) -0.277 to 0.077 0.959
SN - Efficiency -0.205 (33) -0.153 to 0.331 0.238 0.019 (36) -0.356 to 0.065 0.909
SN - BC 0.366 (33) -0.157 to 0.421 0.031 0.202 (36) -0.231 to 0.257 0.224
SN - CC -0.317 (33) -0.332 to 0.426 0.063 0.013 (36) -0.248 to 0.148 0.938
FPN - Efficiency -0.174 (33) -0.542 to 0.022 0.318 0.063 (36) -0.121 to 0.384 0.707
FPN - BC -0.185 (33) -0.473 to -0.204 0.288 0.133 (36) -0.012 to 0.379 0.426
FPN - CC -0.330 (33) -0.533 to 0.327 0.053 0.000 (36) -0.117 to 0.334 0.999
DMN - Efficiency -0.171 (33) -0.555 to -0.190 0.325 -0.078 (36) -0.255 to 0.162 0.641
DMN - BC 0.121 (33) -0.539 to 0.101 0.488 0.306 (36) -0.309 to 0.039 0.062
DMN - CC -0.308 (33) -0.613 to 0.111 0.072 -0.060 (36) -0.212 to 0.246 0.721
Based on 15 comparisons per neuropsychological test, with mean r = .264, corrected α = .007. 
Abbreviations: BC – Betweenness centrality; CC – Clustering coefficient; DMN – Default mode network; FPN – Frontoparietal 
network; GE – Global efficiency; PC – Participation coefficient; Q – Modularity; SCWT – Stroop Color Word Task; SN – Salience 
network.
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Active control Cognitive training
r (df) 95% CI P value r (df) 95% CI P value
SCWT 3
SN - DMN -0.137 (33) -0.226 to 0.208 0.433 0.124 (36) -0.375 to -0.046 0.458
SN - FPN -0.106 (33) -0.417 to 0.007 0.546 0.259 (36) -0.222 to 0.484 0.116
FPN - DMN 0.094 (33) -0.233 to 0.274 0.593 0.081 (36) -0.317 to 0.120 0.629
GE 0.021 (33) -0.369 to 0.428 0.905 -0.011 (36) -0.191 to 0.190 0.948
PC -0.230 (33) -0.512 to -0.088 0.183 -0.084 (36) -0.342 to 0.139 0.618
Q 0.260 (33) -0.010 to 0.353 0.131 0.238 (36) -0.185 to 0.262 0.150
SN - Efficiency 0.207 (33) -0.130 to 0.359 0.233 0.079 (36) -0.197 to 0.253 0.638
SN - BC 0.129 (33) -0.158 to 0.373 0.460 0.112 (36) -0.068 to 0.356 0.505
SN - CC 0.059 (33) -0.202 to 0.406 0.737 0.013 (36) -0.187 to 0.187 0.938
FPN - Efficiency -0.042 (33) -0.420 to 0.086 0.812 0.129 (36) -0.036 to 0.392 0.439
FPN - BC 0.015 (33) -0.439 to 0.066 0.930 -0.062 (36) -0.097 to 0.337 0.710
FPN - CC -0.038 (33) -0.347 to 0.262 0.828 -0.009 (36) -0.126 to 0.238 0.956
DMN - Efficiency 0.233 (33) -0.437 to 0.209 0.179 0.053 (36) -0.190 to 0.321 0.754
DMN - BC 0.162 (33) -0.377 to 0.131 0.354 -0.093 (36) -0.328 to 0.118 0.579
DMN - CC 0.013 (33) -0.381 to 0.182 0.941 -0.037 (36) -0.225 to 0.273 0.826
Based on 15 comparisons per neuropsychological test, with mean r = .264, corrected α = .007. 
Abbreviations: BC – Betweenness centrality; CC – Clustering coefficient; DMN – Default mode network; FPN – Frontoparietal 
network; GE – Global efficiency; PC – Participation coefficient; Q – Modularity; SCWT – Stroop Color Word Task; SN – Salience 
network.
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Supplementary material 9 - Effects of CT grouped by cognitive  
status
Table S9a Univariate mixed-model analysis of group differences on between-network connectivity per 
sub-group based on cognitive status.
PD-NC PD-MCI PD-D
B [SE] 95% CI Pvalue B [SE] 95% CI
P




































Based on 3 comparisons per sub-group, with mean r = .544 between the connectivity outcomes, correct-
ed α = .031. Abbreviations: DMN – Default mode network; FPN – Frontoparietal network; PD-NC – Nor-
mal cognition; PD-MCI – Mild cognitive impairment; PD-D – Dementia; SN – Salience network.
Table S9b Univariate mixed-model analysis of group differences on global graph outcomes per sub-group 
based on cognitive status.
PD-NC PD-MCI PD-D
B [SE] 95% CI Pvalue B [SE] 95% CI
P




































Based on 3 comparisons per sub-group, with mean r = .443 between the graph outcomes, corrected α = 
.027. Abbreviations: GE – Global efficiency; Q – Modularity; PC – Participation coefficient; PD-NC – Nor-
mal cognition; PD-MCI – Mild cognitive impairment; PD-D – Dementia.
Table S9c Univariate mixed-model analysis of group differences on sub-network graph outcomes per 
sub-group based on cognitive status.
PD-NC PD-MCI PD-D
B [SE] 95% CI Pvalue B [SE] 95% CI
P





































Based on 9 comparisons per sub-group, with mean r = .361 between the graph outcomes, corrected α = 
. 0.013. 
Abbreviations: DMN – Default mode network; FPN – Frontoparietal network; GE – Global efficiency; Q 
– Modularity; PC – Participation coefficient; PD-NC – Normal cognition; PD-MCI – Mild cognitive impair-
ment; PD-D – Dementia; SN – Salience network;.
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PD-NC PD-MCI PD-D
B [SE] 95% CI Pvalue B [SE] 95% CI
P





































































Based on 9 comparisons per sub-group, with mean r = .361 between the graph outcomes, corrected α = 
. 0.013. 
Abbreviations: DMN – Default mode network; FPN – Frontoparietal network; GE – Global efficiency; Q 
– Modularity; PC – Participation coefficient; PD-NC – Normal cognition; PD-MCI – Mild cognitive impair-
ment; PD-D – Dementia; SN – Salience network;.
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Supplementary material 10 - Nodal connectivity and topology  
of sub-network key regions 
Table S10 Selected sub-network key region node coordinates.
Schaefer node Network region MNI Coordinates
7NetworksLH_SalVentAttn_FrOperIns_3 Dorsal anterior insula L -33 19 8
7Networks_LH_SalVentAttn_Med_1 Caudodorsal ACC L -6 9 41
7Networks_LH_Cont_Par_1 Inferior posterior parietal cortex L -54 -50 45
7Networks_LH_Cont_PFCl_3 Dorsolateral PFC L -41 41 14
7Networks_LH_Default_PFC_11 Medial PFC L -4 50 31
7Networks_LH_Default_pCunPCC_4 PCC/Precuneus L -5 -56 28
7Networks_RH_SalVentAttn_FrOperIns_3 Dorsal anterior insula R 38 21 4
7Networks_RH_SalVentAttn_Med_1 Caudodorsal ACC R 7 9 41
7Networks_RH_Cont_Par_2 Inferior posterior parietal cortex R 53 -42 48
7Networks_RH_Cont_PFCl_5 Dorsolateral PFC R 44 44 11
7Networks_RH_Default_PFCdPFCm_8 Medial PFC R 5 40 43
7Networks_RH_Default_pCunPCC_3 PCC/Precuneus R 5 -54 24
Abbreviations: ACC – anterior cingulate cortex; L – left; PFC – prefrontal cortex; PCC – posterior cingulate 
cortex; R – right.
Table S11 Group differences on post-hoc outcomes of sub-network key region functional connectivity with 
cognitive networks.
Connectivity of sub-network key regions within or between networks
Crude model Adjusted model*
 B [SE] 95% CI Pvalue B [SE] 95% CI
P
value
dACC R - FPN 0.037 [0.019] -0.001 to 0.075 0.054 0.041 [0.019] 0.003 to 0.079 0.034
dACC L - DMN 0.020 [0.021] -0.022 to 0.062 0.349 0.016 [0.021] -0.026 to 0.058 0.446
AI R - DMN -0.011 [0.020] -0.052 to 0.030 0.604 -0.011 [0.019] -0.049 to 0.028 0.588
dACC R - DMN 0.020 [0.021] -0.022 to 0.062 0.352 0.017 [0.021] -0.025 to 0.058 0.423
medial PFC L - DMN 0.038 [0.029] -0.020 to 0.097 0.196 0.034 [0.029] -0.023 to 0.091 0.238
medial PFC R - DMN -0.009 [0.028] -0.065 to 0.047 0.749 -0.020 [0.027] -0.074 to 0.034 0.462
medial PFC L - SN -0.002 [0.029] -0.060 to 0.056 0.937 -0.007 [0.029] -0.064 to 0.051 0.817
dlPFC L - FPN 0.054 [0.022] 0.009 to 0.099 0.018 0.054 [0.022] 0.010 to 0.098 0.017
dlPFC R - FPN 0.022 [0.027] -0.033 to 0.076 0.432 0.020 [0.028] -0.035 to 0.076 0.467
Based on 9 comparisons, with mean r = .249 between the outcomes, corrected α = .010. *Corrected for age, 
sex, education in years and framewise displacement. Abbreviations: AI – anterior insula; dACC – dorsal anteri-
or cingulate cortex; DMN – Default mode network; dlPFC – dorsolateral prefrontal cortex; FPN – Frontoparietal 
network; PFC – prefrontal cortex; SN – Salience network. 
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Table S12 Group differences on post-hoc outcomes of sub-network key region functional connectivity with 
subcortical structures.
Cortico-subcortical connectivity of sub-network key regions
Crude model Adjusted model*
B [SE] 95% CI P value B [SE] 95% CI P value
dACC L
Thalamus L 0.036 [0.030] -0.023 to 0.096 0.225 0.022 [0.029] -0.036 to 0.081 0.450
Thalamus R 0.072 [0.033] 0.006 to 0.138 0.032 0.054 [0.032] -0.009 to 0.118 0.092
Caudate L 0.076 [0.034] 0.008 to 0.145 0.028 0.070 [0.034] 0.002 to 0.137 0.045
Caudate R 0.060 [0.029] 0.001 to 0.118 0.046 0.052 [0.029] -0.005 to 0.110 0.075
Hippocampus L 0.037 [0.035] -0.033 to 0.107 0.299 0.037 [0.036] -0.035 to 0.110 0.304
Hippocampus R 0.032 [0.035] -0.038 to 0.102 0.370 0.027 [0.035] -0.043 to 0.098 0.441
dACC R
Thalamus L 0.056 [0.034] -0.012 to 0.123 0.104 0.046 [0.034] -0.022 to 0.113 0.182
Thalamus R 0.094 [0.037] 0.021 to 0.167 0.013 0.085 [0.037] 0.012 to 0.158 0.024
Caudate L 0.083 [0.035] 0.013 to 0.154 0.021 0.074 [0.035] 0.005 to 0.143 0.036
Caudate R 0.094 [0.030] 0.034 to 0.154 0.003 0.088 [0.029] 0.030 to 0.145 0.004
Hippocampus L -0.003 [0.038] -0.080 to 0.073 0.928 0.004 [0.039] -0.074 to 0.082 0.915
Hippocampus R 0.029 [0.035] -0.041 to 0.099 0.408 0.029 [0.035] -0.041 to 0.099 0.414
dlPFC L
Thalamus L 0.016 [0.035] -0.055 to 0.086 0.662 0.006 [0.035] -0.064 to 0.076 0.871
Thalamus R 0.041 [0.043] -0.046 to 0.127 0.351 0.031 [0.043] -0.056 to 0.117 0.481
Caudate L 0.060 [0.032] -0.005 to 0.124 0.071 0.045 [0.031] -0.018 to 0.107 0.159
Caudate R 0.034 [0.038] -0.043 to 0.110 0.383 0.026 [0.039] -0.052 to 0.103 0.513
Hippocampus L -0.036 [0.036] -0.108 to 0.037 0.328 -0.039 [0.035] -0.109 to 0.030 0.264
Hippocampus R 0.013 [0.040] -0.066 to 0.093 0.735 0.013 [0.040] -0.066 to 0.093 0.736
dlPFC R
Thalamus L 0.026 [0.038] -0.050 to 0.103 0.490 0.015 [0.038] -0.060 to 0.091 0.686
Thalamus R 0.076 [0.044] -0.013 to 0.165 0.091 0.068 [0.045] -0.022 to 0.157 0.135
Caudate L 0.060 [0.033] -0.006 to 0.125 0.072 0.050 [0.033] -0.015 to 0.115 0.133
Caudate R 0.089 [0.031] 0.026 to 0.152 0.006 0.090 [0.032] 0.027 to 0.153 0.006
Hippocampus L 0.016 [0.039] -0.062 to 0.094 0.685 0.040 [0.038] -0.036 to 0.115 0.295
Hippocampus R 0.028 [0.041] -0.053 to 0.109 0.487 0.047 [0.040] -0.032 to 0.126 0.241
Based on 24 comparisons, with mean r = .227. between the outcomes, corrected α = .004. *Corrected for age, sex, edu-
cation in years and framewise displacement. Abbreviations: dACC – dorsal anterior cingulate cortex; dlPFC – dorsolateral 
prefrontal cortex.
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Table S13 Nodal graph outcomes of sub-network key regions.
Graph outcomes of selected network key regions
Crude model Adjusted modela
B [SE] 95% CI P value B [SE] 95% CI P value
Participation 
coefficient















Medial prefrontal cortex L -0.015 [0.011] -0.038 to 0.008 0.189 -0.012 [0.011]
-0.034 to 
0.011 0.299
Posterior cingulate cortex L -0.015 [0.010]-0.035 to 0.005 0.147 -0.011 [0.010]
-0.032 to 
0.009 0.272






















Dorsal anterior cingulate 
cortex L 0.366 [0.345]
-0.322 to 
1.054 0.292 0.263 [0.339]
-0.414 to 
0.939 0.441
Medial prefrontal cortex L 0.158 [0.237] -0.315 to 0.632 0.507 0.084 [0.233]
-0.381 to 
0.548 0.721
Inferior parietal lobe R -0.031 [0.298]
-0.625 to 





































Posterior cingulate cortex L 0.001 [0.004]-0.008 to 0.010 0.755 0.001 [0.005]
-0.008 to 
0.010 0.860
Dorsal anterior insula R 0.000 [0.005]
-0.009 to 
0.010 0.924 0.001 [0.005]
-0.009 to 
0.010 0.867


































Correlation with behavioral outcomes at baseline informed selection of region for analysis.  aCorrected for age, sex and 
education in years; bStatistics multiplied by 103 because of small values.
227
Eight-week multi-domain cognitive training does not impact large-scale functional brain 
networks in Parkinson’s disease
Supplementary material references
1. Esteban O, Markiewicz CJ, Blair RW, et al. fMRIPrep: a robust preprocessing pipeline for functional MRI. 
Nat Methods 2019; 16(1): 111-116.
2. Gorgolewski K, Burns CD, Madison C, et al. Nipype: a flexible, lightweight and extensible neuroimaging 
data processing framework in python. Front Neuroinform 2011; 5: 13.
3. Tustison NJ, Avants BB, Cook PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 
2010; 29(6): 1310-1320.
4. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with 
cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 
2008; 12(1): 26-41.
5. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field 
model and the expectation-maximization algorithm. IEEE Trans Med Imaging 2001; 20(1): 45-57.
6. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neu-
roimage 2010; 53(4): 1181-1196.
7. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruc-
tion. Neuroimage 1999; 9(2): 179-194.
8. Klein A, Ghosh SS, Bao FS, et al. Mindboggling morphometry of human brains. PLoS Comput Biol 2017; 
13(2): e1005350.
9. Evans AC, Janke AL, Collins DL, Baillet S. Brain templates and atlases. Neuroimage 2012; 62(2): 911-
922.
10. Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration. 
Neuroimage 2009; 48(1): 63-72.
11. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear 
registration and motion correction of brain images. Neuroimage 2002; 17(2): 825-841.
12. Cox RW, Hyde JS. Software tools for analysis and visualization of fMRI data. NMR Biomed 1997; 10(4-5): 
171-178.
13. Pruim RHR, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-AROMA: A robust ICA-
based strategy for removing motion artifacts from fMRI data. Neuroimage 2015; 112: 267-277.
14. Power JD, Mitra A, Laumann TO, Snyder AZ, Schlaggar BL, Petersen SE. Methods to detect, character-
ize, and remove motion artifact in resting state fMRI. Neuroimage 2014; 84: 320-341.
15. Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD 
and perfusion based fMRI. Neuroimage 2007; 37(1): 90-101.
16. Satterthwaite TD, Elliott MA, Gerraty RT, et al. An improved framework for confound regression and 
filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data. 
Neuroimage 2013; 64: 240-256.
17. Lanczos C. Evaluation of noisy data. Journal of the Society for Industrial and Applied Mathematics, 
Series B: Numerical Analysis 1964; 1(1): 76-85.
18. Abraham A, Pedregosa F, Eickenberg M, et al. Machine learning for neuroimaging with scikit-learn. 
Front Neuroinform 2014; 8: 14.
19. van den Heuvel MP, Sporns O. Rich-club organization of the human connectome. J Neurosci 2011; 
31(44): 15775-15786.
20. Baggio HC, Segura B, Junque C, de Reus MA, Sala-Llonch R, Van den Heuvel MP. Rich Club Organiza-
tion and Cognitive Performance in Healthy Older Participants. J Cogn Neurosci 2015; 27(9): 1801-1810.
21. Bertolero MA, Yeo BTT, D’Esposito M. The diverse club. Nat Commun 2017; 8(1): 1277.
22. Alstott J, Panzarasa P, Rubinov M, Bullmore ET, Vertes PE. A unifying framework for measuring weight-
ed rich clubs. Sci Rep 2014; 4: 7258.
23. Schaefer A, Kong R, Gordon EM, et al. Local-Global Parcellation of the Human Cerebral Cortex from 








The overall aim of this thesis was to gain a better understanding of the clinical and neurobio-
logical characteristics of cognitive impairment in Parkinson’s disease (PD) and the efficacy of 
cognitive training for its treatment. We used neuropsychological and neuroimaging data from 
a large outpatient cohort of PD patients to study cognitive heterogeneity and the underlying 
dopaminergic and serotonergic deficiencies. We further systematically reviewed the literature 
on the neural correlates of cognitive training (CT) and performed a randomized controlled 
trial in 140 PD patients on the neuropsychological and brain network effects of an eight-week 
online cognitive training program.
In this general discussion, I will first summarize the main findings of my thesis and discuss 
the scientific and clinical implications. Thereafter, I will integrate our findings with the existing 
scientific data on the topic and propose recommendations for future research.
Summary of the findings
In Chapter 2 we reported the findings of a hierarchical cluster analysis in a large sample of 
226 mostly early-stage PD patients who underwent assessment of motor symptoms, neu-
ropsychological function, neuropsychiatric symptoms and other non-motor functions. The 
objective of the study was to assess the heterogeneity in the clinical symptom profile of PD, 
with a focus on cognitive heterogeneity. In this cluster analysis we included multiple neuro-
psychological tests combined with measures for the severity of anxiety and motor symptoms. 
We distinguished four symptom profiles. Two antipodal clusters consisting of one cluster with 
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relatively young, unimpaired patients and a second cluster with relatively old and severely 
impaired patients. Additionally, we identified two symptom profiles with similar mean age and 
disease stage, but significant differences in their clinical symptom profile: one cluster showed 
executive function and working memory impairments while the other cluster showed more 
severe motor symptoms and mnemonic deficits but with relatively intact executive function. 
Whereas the model did have limitations as it contained only one neuropsychiatric measure 
due to multicollinearity between neuropsychiatric outcomes, the results suggest the existence 
of parallel disease pathways that may have predictive value for the rate of cognitive decline, 
for the profile and course of neuropsychiatric symptoms and for treatment efficacy.
To evaluate the dopaminergic and serotonergic deficiencies associated with cognitive impair-
ment in PD, we performed a dopamine transporter SPECT study in the same patient cohort 
(reported in chapter 3). We studied the association of striatal and extra-striatal 123I-FP-CIT 
binding with neuropsychological task performance in 129 PD patients. Binding of 123I-FP-CIT 
in the caudate head and anterior putamen was associated with processing speed tasks, 
while extra-striatal binding did not show any significant associations with cognitive function. 
Contrary to our hypotheses and earlier studies on 123I-FP-CIT binding, we found no relation of 
striatal dopamine transporter binding with executive function. This study showed that deteri-
oration of the striatal dopamine system may be involved in impairment of mental processing 
speed – an impairment that is frequently reported as an early subjective complaint in individ-
uals with PD. 
To date, the therapeutic options for cognitive impairment, in particular before onset of demen-
tia, are limited. We performed a randomized controlled trial, the COGnitive Training In Par-
kinson Study (COGTIPS), to study the effects of home-based, multi-domain CT in PD patients 
with subjective cognitive complaints. In chapter 5, we described the study protocol and the 
planned statistical analyses. Briefly, 140 PD patients were randomized into an experimental 
adaptive and challenging cognitive training or an active control condition. The primary out-
come was the accuracy on a planning task – the Tower of London – and secondary outcomes 
included the reaction time on this task, performance on other cognitive tasks, subjective cog-
nitive complaints and cognitive function at six-months follow-up. We additionally performed 
an exploratory analysis of neuropsychiatric outcomes. In chapter 6, we provide the results of 
the primary and secondary clinical outcomes of COGTIPS. The eight-week CT did not improve 
planning accuracy, the primary outcome measure of the study, relative to the active control 
condition. Nevertheless, the intervention did produce small significant differences between 
the groups on the Tower of London reaction time. Effects on the Stroop Color Word Test were 
similar, indicating that CT induced an improvement of processing speed during executive 
function tasks. Improvement on the experimental training games correlated with the improve-
ment on the Tower of London and Stroop Color Word Test. Interestingly, post-hoc sub-group 
analyses suggested that CT was more efficacious in patients that were cognitively more im-
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paired and fulfilled the diagnostic criteria for PDD. As this sub-sample was small, this result re-
quires replication. At six-months follow-up, the initial positive effects were no longer present. 
To summarize, this study corroborates positive effects of CT on cognitive function – although 
the effects were small and did not transfer to subjective complaints. I therefore postulate that 
the lack of (sustained) differences after six months suggests that a single training regime of 
just eight weeks may not suffice and prolonged training or booster sessions are necessary for 
the effects to endure. 
The purpose of chapter 4 was to improve our understanding of the neural processes underly-
ing the effects of CT on cognitive function. We performed a systematic review of studies that 
used functional MRI (fMRI) before and after CT in healthy elderly and subjects with a neurode-
generative disease. First, this literature study provided convincing evidence that CT can alter 
brain activation and connectivity. Integrative evidence from task-based fMRI studies suggest-
ed that in healthy populations, CT induced lower regional brain activity potentially as a result 
of enhanced neural efficiency. Conversely, in individuals with neurodegenerative diseases 
brain activity increased after CT, presumably showing that CT increased the neural effort that 
can be delivered to successfully fulfill task demands. Resting-state fMRI studies showed that 
CT increased connectivity and enhanced segregation between task-positive and task-neg-
ative resting-state networks. Despite reasonable overlap between findings of the studies, 
there were considerable limitations that hampered (meta-analytic) estimation of effects, such 
as heterogeneity in training programs, imaging methodologies and regions of interest. We 
suggested that integrative approaches, such as complex network analysis, could provide 
more information on the large-scale brain network effects of CT. We aimed to overcome the 
limitations of earlier studies in chapter 7, where we studied the effects of CT on resting-state 
network connectivity and the brain network topology in our COGTIPS sample. This study 
showed, contrary to our hypotheses based on chapter 4, that our eight-week intervention 
did not affect global brain network connectivity and topology. Post-hoc analyses at the nod-
al level, however, showed that CT enhanced connectivity of two key network regions, i.e., 
the dorsal anterior cingulate cortex and dorsolateral prefrontal cortex (dlPFC). These results 
suggest regional connectivity changes due to CT as opposed to changes in large-scale brain 
networks, which corroborated the COGTIPS diffusion tensor imaging analyses that showed 
only local effects of our CT in the anterior thalamic radiation.1 Sub-group analyses additional-
ly showed that CT enhanced network segregation in cognitively intact participants, but this 
sub-sample was very small.
The clinical applicability of profiling and implications for treatment
There is increasing attention for the clinical and cognitive heterogeneity of PD, but its clinical 
applicability and its treatment implications remain limited. Cross-sectional studies have sug-
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gested the existence of clinical subgroups that relate to different cognitive profiles, most no-
tably the postural instability and gait dysfunction subtype that is associated with more severe 
cognitive impairment. The general idea of clinical profiling is that, based on cross-sectional 
findings, one can make inferences about shared underlying neural disease processes and the 
rate of clinical symptom progression, including cognitive decline. Nevertheless, only recent 
studies have tried to investigate these assumptions. 
Individuals with specific clinical profiles of PD are thought to have a shared underlying neural 
substrate, such as similar neurotransmitter deficiencies, atrophy patterns or dysfunctional 
brain networks. The non-tremor dominant subtype of PD, which is associated with an en-
hanced risk of developing dementia, exhibits more extensive cortical Lewy body pathology 
compared with the tremor-dominant, the early disease onset and the late disease onset with 
rapid motor symptom progression subtypes.2 There is also evidence for distinct neural cor-
relates underlying two identifiable cognitive syndromes – a dysexecutive versus posterior 
cortical – as reported in studies based upon the CamPaIGN cohort. In a resting-state fMRI 
study, the dysexecutive syndrome was associated with lower somatomotor connectivity while 
the posterior cortical syndrome was associated with lower frontoparietal network connectivity 
and higher temporal/limbic network connectivity.3 More research, however, linking clinical 
profiles to neural mechanisms is needed. 
Recent studies have additionally shed light on the prognostic value of profiling. Several stud-
ies, using prospective or retrospective cohorts, found a ‘malignant onset’ of PD (more severe 
motor and non-motor symptoms at time of diagnosis) to be predictive of worse outcome at 
up to thirty years.4-7 Patients classified with the ‘malignant’ symptom profile had an increased 
risk to reach milestones such as dementia, wheelchair dependency and death.6 Interestingly, 
as the participants had consented to donate their brain for postmortem research, the authors 
were able to investigate neuropathological features of the profiles and found no differences 
between mild, intermediate and malignant groups in – amongst others – Braak staging and 
Lewy pathology. So while there are large differences in the age at onset and symptom profile 
of PD, and the disease progression seems to follow a non-linear course with milder profiles 
having relatively slow disease progression, in the end nearly all PD patients in this sample 
reached an ‘endpoint’ of wide-spread Lewy pathology and advanced Braak stages, regard-
less of clinical symptom profile. Of note, one study showed that clinical profiles characterized 
by more non-motor symptoms led to earlier dementia and death after an average of five years 
follow-up.5 This study, in contrast to our study, distinguished between a cluster with depres-
sive symptoms and a cluster with cognitive impairment (apathetic symptoms were compara-
ble between the two), suggesting specific psychiatric and cognitive profiles. 
Still, cross-sectional data-driven profiling may not be the optimal method to study disease 
heterogeneity and its course. Membership of profiles or subtypes is not ‘fixed’ as patients 
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show shifts in clinical characteristics with progression of their disease.8 Consequently, taking 
this longitudinal factor into consideration could add to the reliability and clinical applicability 
of evaluating the heterogeneity of PD. An elegant example hereof is a recent study in the 
PPMI cohort that defined profiles on the basis of multivariate longitudinal data, using a deep 
learning algorithm.9 This study distinguished three disease profiles of demographic, clinical, 
imaging and biospecimen features and their progression, in line with earlier cross-sectional 
studies. A malignant, rapid progression profile correlated not only with more severe clinical 
symptoms at baseline but also the presence of Alzheimer’s disease pathology, i.e., amyloid 
beta markers in the CSF. Another – potentially less mathematically complex – analysis meth-
od for longitudinal subtyping is latent growth curve modeling, such as latent class growth 
analysis.10 Latent class growth analysis assumes that in a heterogeneous sample of longitudi-
nal data, there are n latent classes that show a similar change on an outcome over time. The 
assessment of latent classes of change on a multivariate outcome has for example already 
been performed in symptom development in children with attention deficit/hyperactivity dis-
order.11 Applying this technique to cohort data could test hypotheses about the cognitive het-
erogeneity and its symptom progression as, for example, found in our cluster analysis (for an 
example based on hypothetical data see Figure 1). Deep learning algorithms or latent growth 
analysis could provide more knowledge about the heterogeneity of the course of PD as op-
posed to the heterogeneity at a single time-point. To get a grip on the complexity of cognitive 
symptom progression, detailed monitoring of cognitive function is necessary with follow-up 
intervals exceeding at least four years,12 as in large cohort studies such as ICICLE-PD13 or 
PROPARK (a recently initiated Dutch cohort collaboration of university medical centers).
Disappearing borders and globalization of the scientific community facilitate large, multi-cen-
ter, longitudinal cohort-based studies that focus on multi-disciplinary risk scores for disease 
progression including cognitive decline. Two recent studies have provided promising results 
in predicting future disease progression. A study in a very large sample that consisted of 
Figure 1 Illustration of the presumed longitudinal progression of cognitive, motor and neuropsychiatric 
symptoms of clinical subgroups based on hypothetical data using a multivariate latent growth analysis. 
Lines denote individuals and the colors represent clinical subgroups that show similar clinical profiles at ba-
seline, but show different progression over time. A combination of a multivariate approach with longitudinal 
symptom monitoring may provide more information on the latent profiles of disease progression, instead 
of profiling based on cross-sectional differences (that may also be dependent on demographic and clinical 
differences).














nine world-wide cohorts proposed a prediction score based on clinical and genetic data that 
robustly predicted cognitive impairment and dementia in PD with an area under the curve 
above 0.85.14 A much simpler model (albeit in a substantially smaller sample), using only age, 
axial motor symptom severity and category fluency performance at diagnosis resulted in 
similar discriminative ability.15 Together, these findings provide evidence for the development 
of individualized, prognostic markers of cognitive dysfunction. An important ethical issue re-
mains, for the time being, that (protective) treatment options for patients with poor prognoses 
are still nonexistent. But, as a future perspective, the growing knowledge of the clinical (risk) 
profiles of PD has the potential to guide personalized treatment.
For now, there is little scientific evidence to guide personalization in the treatment of cog-
nitive deficits in PD. A large prospective cohort study in the Netherlands, the Personalized 
Parkinson Project (‘Parkinson Op Maat’), has recently been initiated and specifically aims 
to distinguish new biomarkers of treatment response.16 Moreover, Titova and Chaudhuri 
proposed several specific strategies to guide personalized medicine in PD.17 Regarding cog-
nitive deficits they suggested that cholinesterase inhibitor treatment, lifestyle counselling 
and cognitive training could be considered in the presence of multimodal biomarkers, i.e., 
lower acetylcholinesterase activity, H1/H2 microtubule-associated protein tau genotype and 
impaired semantic fluency and pentagon copying. Whereas these strategies focus primarily 
on individuals at risk for dementia, they provide a starting point for tailored treatment of cog-
nitive deficits in the full spectrum of PD. The available evidence for the efficacy of dopamine 
replacement therapy (in early PD, focusing on ‘frontal’ cognitive functions) and cholinesterase 
inhibitors (in PD dementia, focusing on attention and alertness) may in the future be combined 
with tailored non-pharmacological interventions to better fit the patients’ need. The COGTIPS 
program may be more suitable for patients that experience attention, processing speed and 
executive function deficits. Patients with visuospatial and mnemonic dysfunction, which are 
associated with cholinergic dysfunction and cortical Lewy bodies,18 could hypothetically profit 
more from directed and divided attention training or mnemonic strategy training in addition 
to the use of acetylcholinesterase inhibitors. Nevertheless, the first goal should be to expand 
the benefits and diminish the limitations of CT in order to work towards tailored training pro-
grams.
Should we put our hopes on cognitive training?
There is an ongoing discussion in the scientific field about the relevance of ‘function’ or ‘drill’ 
CT – training certain cognitive functions by repeated stimulating engagement.19-21 The abil-
ity of CT to enhance certain functions that are directly trained is evident. The clinical data 
of the COGTIPS trial confirmed this, as participants showed marked improvement on their 
respective training games. Rationally, this should also not be surprising as it (in part) reflects 
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practice effects. Nevertheless, it provides evidence for the capacity of PD patients to practice 
and learn complex cognitive functions. The ability of CT to transfer the positive effects to un-
trained functions is more controversial. A recent Cochrane meta-analysis (that did not include 
the COGTIPS data) showed that there is little evidence for the efficacy of CT in specifically 
PD mild cognitive impairment and PD dementia, with all included studies having an unclear 
or high risk of bias due to methodological limitations or ambiguities.22 Our results in COGTIPS 
support the transfer of CT effects to untrained domains with the CT group showing signifi-
cant acceleration of mental processing speed during complex executive function tasks (i.e. 
‘near transfer’). On the other hand, however, the results were limited to the executive domain 
and other cognitive domains remained unaltered. The next step is the translation to other 
modalities and real-world situations – ‘far transfer’. The results from our resting-state fMRI 
study (chapter 7) showed small, yet relevant effects from post-hoc analyses, but did not show 
changes in the large-scale neural networks that we hypothesized based on reviewing the 
relevant literature (chapter 4). Generally, CT (including COGTIPS) has not convincingly proven 
to enhance activities of daily living or alleviate subjective complaints and thereby perhaps be 
able to delay (early) retirement because of cognitive difficulties. In the following paragraphs, I 
will discuss domains that deserve attention to enhance knowledge about CT and increase its 
clinical applicability. Ultimately, I summarize the findings from my thesis and the future pros-
pects from this discussion in an adapted version of our working model from chapter 4 & 5 in 
Figure 2.
Methodological issues in CT research – and how to deal with them
Towards a standardized protocol. When reviewing the many overviews that are published on 
the efficacy of CT, there are many discrepancies and disagreements, but one thing reviews 
agree upon is that there are too many methodological limitations in the current CT litera-
ture.22-24 One important issue – which also counts for our trial – is the lack of standardized 
protocols and training programs.22 For example, no two studies that were included in the 
meta-analysis by Leung and colleagues23 studied the same training program. There are some 
programs that are more frequently used than others, including RehaCom by Hasomed, the 
Useful Field of View training by Posit Science, and the Strategic Memory Advanced Reason-
ing Training (SMART) by the Texas Center for BrainHealth. These programs have, however, 
not yet been studied in PD. Moreover, these programs may not include the most relevant 
treatment elements, due to the fact that they are not specifically focused on the cognitive 
impairments associated with PD and do not account for the motor symptoms that accompany 
the disease. I argue that standardized protocols are needed; the protocol-based treatment of 
mental disorders25 that is widely-used in the Dutch mental health care may be a fitting model 
to work towards. These protocols could consist of a set of specific CT components that focus 
on the individuals’ cognitive profile, and that have been associated with cognitive gain and, 
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even more so, with transfer to daily function – as I discuss later in this chapter. For the train-
ing program used in COGTIPS, for example, certain games were significantly correlated with 
improvement on executive function tasks. Reporting more detailed information on the asso-
ciation between training components and cognitive improvement may inform new studies 
on their intervention and may in the end lead to an evidence-based set of cognitive training 
interventions. In the end, consensus on CT interventions is a requirement for its clinical appli-
cation.
Robust trial design. Early trials studying CT in PD have been small, but recently, larger and 
robustly designed trials have been initiated. These trials, including COGTIPS, but also the 
Parkin’Play study26 and a prospective memory training study (ClinicalTrials NCT03582670) are 
necessary to decide on the clinical applicability of CT for individuals with PD. Such trials have, 
however, the downside of being ‘sluggish’: the rigorous design leads to robust evidence but 
has the downside of inflexible, slow development of knowledge. ‘Tweaking’ of trial param-
eters is not possible during ongoing randomized clinical trials – and rightly so because of 
ethical reasons. Other trial types with more flexible designs, however, may accelerate the sci-
entific process, for example trials using n=1 or Bayesian methods. In a recent opinion article, 
the scientific “mantra of large n” was disputed and a case was made for more single-subject 
studies, as it were ‘trial-and-error’ studies.27 An often discussed reason for not studying single 
subjects is the lack of generalizability, but for the same reason results from a large trial includ-
ing many patients with inherent heterogeneous characteristics may also not be translatable to 
every individual. Single-subject studies can be more detailed as a highly frequent, thorough 
examination of demographic and clinical characteristics of one individual is very feasible. 
Studies using alternating within-subject experimental and control interventions can elegantly 
add a controlled design.28 
Bayesian trial designs have the advantage of being more flexible than traditional RCT de-
signs.29, 30 The limitations of using the P value are overcome as this method assesses the 
probability of an experimental method to be clinically relevant based on previously found 
treatment effects (the ‘prior’) in combination with parameters based on its trial data (‘likeli-
hood’). These parameters are updated as data are collected and trial parameters may adap-
tively be altered when results show for example evidence for treatment efficacy or its futility. 
Likewise, in the context of CT Bayesian methods may facilitate dose-response studies: the 
intensity of CT, the duration of the training and the need for booster sessions. 
The complementary evidence of traditional RCTs combined with more flexible trial designs – 
that have the added advantage of lower costs and participant burden – to ‘tweak’ CT to its 
optimal state is needed to work towards a better view on the clinical relevance of CT.
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Towards far transfer of CT effects. A limitation of CT that is frequently discussed is the trans-
ferability of the training effects.31, 32 Practice can improve certain cognitive operations dramat-
ically as illustrated by one case that trained its working memory capacity to 82 digits.33 This 
specific capacity is, however, of little use in everyday life. The discussion of transfer dates 
back to the beginning of the twentieth century, when Thorndike described how improving 
ones “mental function” could potentially influence other processes.34 In a bottom-up view 
of transfer, cognitive function is seen as a collaboration of specific skills and training such 
skills, for example a fundamental ability such as mental processing speed, could improve 
related (more complex) functions.35 This is in line with our findings that cognitive training may 
enhance neural networks that underlie a variety of cognitive functions. In a top-down view, 
transfer of skills seems determined by characteristics of the content that is transferred, and 
the context from and to which it is transferred.36 Studies on the generalization of knowledge 
have found that this process is facilitated by providing varied contexts or broad experiences 
in the training sessions.37 Likewise, adaptive training, as opposed to non-adaptive training, 
seems critical to induce far transfer as it remains challenging.38, 39 Lastly, somewhat trivially, 
transfer is dependent upon the understanding and correct execution of the skill in the first 
place. Knowledge of enhancing transfer may direct future CT studies.
Bottom-up: boosting cognitive training. The neuropsychological effects of CT, including 
COGTIPS, are small, do not yet generalize to other domains and subjective experience and 
consequently, methods should be sought to enhance and prolong CT effects. Knowledge of 
the dose-response characteristics of CT is limited – and presumably differs per intervention. 
A meta-analysis of CT in healthy elderly showed that more than three sessions per week did 
not have added value compared with fewer sessions and more than 20 hours of training did 
not show larger effects compared with fewer hours,40 but robust evidence is lacking. Ratio-
nally, CT should not necessarily be limited to a fixed number of sessions or weeks, especially 
in neurodegenerative diseases. Analogous to the treatment of other chronic symptoms, CT 
should perhaps rather be used as a therapeutic intervention for the maintenance of cognitive 
function, potentially incorporated in someone’s lifestyle. At the same time, the benefits of cog-
nitive gain should outweigh the costs of the burden and for now there is too little evidence for 
CT to be used continuously.
Booster sessions, i.e., an additional set of training sessions after several weeks or months, 
may be an intermediate step. One study in individuals with Alzheimer’s disease showed that 
one-month CT alternating with one-month breaks resulted in a significantly higher Mini-Mental 
State Examination score at the end of the year compared with repeated cycles of non-specific 
exercises.41 Studies in healthy elderly yielded positive added effects of booster sessions to 
CT.42, 43 While some studies found long-term effects of CT up to eighteen months after the end 
of the intervention44, 45 and we await replication of these long-term effects at one- and two-
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year follow-up in the COGTIPS sample, booster sessions may be a viable and effective option 
to prolong positive training effects.
The efficacy of cognitive training may additionally be enhanced by adjuvant neurostimulation. 
Evidence for the involvement of the dlPFC in the effect of our CT may guide the choice of the 
target for neurostimulation techniques. Stimulation of the dlPFC is already being studied in 
psychiatric disorders. In obsessive-compulsive disorder, for example, repetitive transcranial 
magnetic stimulation (rTMS) has been shown to improve emotion regulation by stimulation 
of the dlPFC.46 Its added effect to cognitive behavioral therapy is currently being studied in 
a randomized clinical trial (NCT03667807), under the assumption that rTMS may potentiate 
behavioral changes associated with treatment, thereby enhancing treatment effect.47 Combin-
ing CT with physical interventions such as aerobic or high intensity interval training may have 
added effect compared with either intervention alone,48, 49 and physical interventions have the 
added potential of improving motor function.50 A promising lifestyle intervention focusing on 
multiple domains, combining a CT intervention – that included psychoeducation, group cog-
nitive strategy training and computerized CT – with diet, exercise, and vascular risk manage-
ment interventions was assessed in the Finnish Geriatric Intervention Study to Prevent Cog-
nitive Impairment and Disability (FINGER).51 This study, in a sample of 1260 cognitively healthy 
elderly at risk for developing dementia, showed that the 2-year multi-domain intervention had 
positive effects on cognitive function, BMI, dietary habits, and physical activity. As the results 
of this Finnish study were very promising, the intervention is currently adapted across the 
world to replicate the findings and strengthen the evidence.52 Lastly, combining pharmacolog-
ical agents such as the choline-esterase inhibitor donepezil (given its positive effects pre-de-
mentia)53 with CT could enhance cognitive function and additionally enhance the efficacy of 
CT in non-demented PD patients,53 but more research on pharmacological treatment before 
the onset of PD dementia is needed. Still, there should be attention for the feasibility of these 
combined interventions and – at least partly – home-based interventions that are remotely 
supervised may be preferred.
Top-down: increasing the ecological validity of CT. From a top-down view, computerized CT 
may lack transfer to everyday life because of its narrow, focused content. CT tasks are often 
gamified versions of neuropsychological tasks, as there is evidence for the validity of the 
tasks at measuring certain cognitive functions. This is, however, to some extent a fallacy as 
neuropsychological tasks inherently lack ecological validity because of their traditional means 
of detecting neurological damage.54 A straightforward solution could be to move towards CT 
in real-world situations: cognitive rehabilitation. A best-of-both-worlds solution, combining 
(near) real-world situations with the easy-to-administer, standardized and low cost nature 
of computerized CT may be found in virtual reality (VR). VR may train cognitive functions by 
mimicking real-world situations and could relatively easily be personalized to focus on indi-
vidual difficulties. VR is already being used in psychiatric disorders55, 56 and there is tentative 
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evidence for its efficacy in physical therapy in PD.57 As technology is advancing lightning-fast 
and VR is increasingly available for the general public – and at reasonable costs – VR is a 
feasible solution to enhance the ecological validity of CT. 
In functional neuroimaging research, there is also a shift towards ecologically valid tasks. 
Functional MRI during performance of traditional tasks, e.g., n-back or Tower of London, can 
measure specific brain activation, but its constrained nature limits the ecological validity of the 
brain activation. On the other hand, resting-state fMRI is highly unconstrained and, while rest-
ing-state functional connectivity is associated with cognitive and behavioral functions, there 
is large inter-individual variability. Other task paradigms during fMRI, such as movie viewing, 
Figure 2 Updated working model of the effects of CT, adapted from chapter 4 & 5, based on the working 
model proposed by Gerrits.74 Panel A illustrates the effects of CT on cognitive function, regional brain acti-
vity and brain network connectivity resulting from the COGTIPS study (chapter 6 & 7, and Vriend et al.)1 and 
the systematic literature review (chapter 4). The effects of CT were limited to specific cognitive domains 
and regional functional connectivity. The dotted lines are hypothetical as we did not study the long-term 
effects of CT on brain network function. Panel B illustrates future research prospects and their potential po-
sitive effects on the efficacy and durability of CT. Modifications to CT (purple) and adding booster sessions 
or extending training duration (red) can possibly induce far transfer to subjective experience and expand 
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may provide an elegant balance in the constraints of a task with adequate ecological validity. 
Movie viewing during functional MRI elicits, for example, diverse and concerted brain activa-
tion and functional brain states can be reliably traced back to certain movie events.58 Combin-
ing ecologically valid virtual reality CT with functional neuroimaging may provide invaluable 
and reliable information on elicited brain states and allows for more tailored intervention guid-
ed by the individual’s dysfunctional neural patterns.59
One size does not fit all: who profits from CT? In addition to reliable prediction models of 
disease progression, as discussed earlier, prediction of treatment response in individual pa-
tients may also be feasible. To date, most CT studies have focused on predicting treatment 
outcome based on average group features. Studies have shown somewhat conflicting results 
about PD patient characteristics that predict better CT efficacy, such as worse60, 61 but also 
better baseline cognitive performance,62 a younger age,61 higher education,62 and shorter 
disease duration.62 Studies in healthy elderly have provided similar findings63-65 and also 
suggested an interaction between baseline performance and the complexity of the cognitive 
outcome task, with higher initial performers showing larger gains on more complex tasks.65 
Additionally, cognitive reserve and brain network modularity are suggested to be modulators 
of CT that may be used as predictive biomarkers at the individual level.
Cognitive reserve is a concept that states that individuals are differentially resistant to brain 
damage due to individual differences in cognitive and neural network processes.66 Individu-
als with high cognitive reserve can generally tolerate more brain damage before decline is 
measurable using standard neuropsychological testing,66 and this concept can as such ex-
plain inter-individual differences in the onset and rate of cognitive decline. Cognitive reserve 
develops during life and is associated with higher education, the level of occupation and the 
amount of social and leisure activities.67 One study reported that individuals with predomi-
nantly Alzheimer’s disease dementia with a lower cognitive reserve benefited more from CT 
compared with high reserve individuals.68 CT effects may be dependent on cognitive reserve: 
high-reserve individuals may need relatively earlier intervention before onset of measurable 
cognitive decline, compared with individuals with low cognitive reserve, to intervene before 
neuropathology has progressed too far and neural compensatory mechanisms may no longer 
be available. Quantification of cognitive reserve using questionnaires67 or by linking cognitive 
function with gray matter atrophy as measured with MRI69 could aid in deciding the right tim-
ing for intervention. 
Brain network modularity has received particular attention as a potential predictor of 
(non-pharmacological) treatment outcome at the individual level. The nodes of a brain net-
work are segregated in multiple sets of highly interconnected communities (‘modules’) that 
have sparse connections with other communities. Loss of this internally segregated organi-
zation of the network is associated with (cognitive) aging.70-72 In a narrative review, Gallen and 
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d’Esposito argued that, based on exercise and CT studies in healthy individuals and traumatic 
brain injury patients, higher modularity is a robust biomarker of brain plasticity.73 They pro-
posed that higher modularity of the brain network may be associated with a more optimal net-
work organization during rest and hence a better ability to adapt to the intervention demands. 
It would be relevant to replicate these findings in future CT studies, including the COGTIPS 
sample. 
Ultimately, adequate individual biomarkers, that recommend or discourage CT for specific 
individuals at specific time-points, could be used in longitudinal cohort studies on the rate of 
cognitive decline to define the optimal individual therapeutic starting point. 
The utopia of preventing dementia. The ultimate goal of research in the context of cognitive 
decline is to prevent dementia. There is a plethora of modifiable risk factors that may predict 
dementia at later age, including hypertension, obesity, diet, substance use and depression.75 
On the other hand, there is an equally large amount of non-modifiable factors that predict de-
mentia, such as presence of the apolipoprotein E ε4 allele, dementia in first-degree relatives 
and – of course – age. The question is, consequently, if treatment efforts aimed at modifiable 
factors outweigh the risk associated with factors that are non-modifiable.
Several studies, including the previously mentioned FINGER study, report on preventive in-
terventions. There is ample evidence for positive effects of single-domain interventions (e.g., 
CT) and interventions focusing on multiple lifestyle domains, yet the effects on the incidence 
of dementia (i.e., preventing dementia) at a later age is still unknown. In the general popu-
lation, the incidence of dementia increases dramatically with higher age, annual incidences 
reaching about 40% at age 100.76 Dementia could therefore be seen as a nearly inevitable 
consequence of aging. However, observations in individuals who aged cognitively intact up to 
100 years of age, showed that these centenarians have, on average, higher cognitive reserve, 
are of higher socio-economic classes, and are less likely to carry the apolipoprotein E ε4 al-
lele.76 Interventions focusing on cognitive reserve and socio-economic equality may thus be 
relevant to improve healthy (cognitive) aging at the population level, but as these factors have 
been identified retrospectively, additional – as yet unknown – variables might be involved. At 
the same time, the genetic profile of this healthy sample implicates that developing dementia 
might also be “bad luck”: no (current) therapeutic and lifestyle intervention can alter the ge-
netic make-up and subsequently increase the chance of aging cognitively healthy. In addition 
to trying to emphasize the malleability of cognitive function, it is therefore equally important 





In this thesis, we present the results of a series of studies aimed at increasing our understand-
ing of cognitive profiles in PD and assessing the efficacy of ‘practicing’ cognitive function. We 
found evidence for the existence of distinct cognitive profiles and, in addition, identified cog-
nitive correlates of striatal dopamine transporter deficits. In our randomized controlled trial of 
CT in PD, we found small, yet consistent positive effects of CT on processing speed during 
executive function tasks, but these effects levelled out after training ended and there were no 
transfer effects to subjective experience. This suggests that booster sessions may be needed 
to enhance and prolong CT effects. While a systematic review of the neural correlates of CT 
suggested changes in large-scale brain networks by CT, our analyses in the COGTIPS sample 
only showed small, regional changes in functional connectivity induced by CT. The field might 
benefit from standardized, personalized training protocols, and more knowledge on dose-re-
sponse characteristics and the added value of booster sessions, where more flexible study 
designs such as Bayesian trial designs may accelerate its development. To positively influ-
ence the quality of life, adaptations to current training designs need to be studied, including 
multimodal interventions and virtual reality training. Despite the progressive, neurodegener-
ative nature of PD, with increasing attention and advancing technology there is still consider-
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De ziekte van Parkinson (ZvP) is een neurologische bewegingsstoornis die bij ongeveer 1-3% 
van de mensen ouder dan 60 jaar vóórkomt. Het is een neurodegeneratieve ziekte; dat wil 
zeggen, een ziekte waarvan de ernst in de loop van de tijd toeneemt. De symptomen waarop 
de waarschijnlijkheidsdiagnose is gebaseerd zijn de zogenoemde ‘motorische symptomen’: 
traagheid van bewegen (bradykinesie), stijfheid (rigiditeit) en trillen van de ledematen in rust 
(rusttremor). Het ziekteproces van de ZvP heeft als bekendste gevolg dat cellen die de sig-
naalstof dopamine produceren in de zwarte kern of substantia nigra, een hersenstructuur 
in het midden van de hersenen, doodgaan. Er is vooralsnog geen manier om deze celdood 
met een hersenscan vast te stellen en de diagnose ZvP kan dan ook pas na de dood met 
volledige zekerheid worden bevestigd. De ZvP lijkt de hersenen echter op veel meer vlakken 
te beïnvloeden, van celdood in de zenuwcellen van de hersenen (grijze stof) tot aantasting 
van diverse stoffen die informatie overdragen tussen zenuwcellen (signaalstofsystemen of 
neurotransmittersystemen). Het is dan ook niet verassend dat de symptomen van de ZvP 
veel breder reiken dan alleen problemen in het bewegingsapparaat. Zo worden ook niet-
motorische symptomen gezien, waaronder stoornissen van het autonome zenuwstelsel, 
slaapstoornissen, psychiatrische stoornissen en stoornissen in het denkvermogen – ook wel 
cognitieve functiestoornissen genoemd. Het onderzoek beschreven in dit proefschrift had tot 




De profielen van cognitief functioneren in de ZvP 
Mensen met de ZvP kunnen al vroeg tijdens het beloop van de ziekte problemen in het  
denkvermogen gaan merken. Onderzoek heeft aangetoond dat, op het moment dat de diag-
nose wordt gesteld, tot een kwart van de mensen al één of meer cognitieve functiestoornis-
sen heeft. Over het algemeen komen deze stoornissen voornamelijk in de executieve functies 
voor. Deze parapluterm verwijst naar ‘superviserende’ functies van het denkvermogen, zoals 
het vermogen tot aandacht verdelen, gedrag remmen, flexibel schakelen, plannen en multi-
tasken. Andere cognitieve problemen die zich des te meer later gedurende het ziekteverloop 
manifesteren bij de ZvP, komen voor in het geheugen, op het vlak van de aandacht en snel-
heid van denken, en binnen de visueel-ruimtelijke functies (belangrijk voor het waarnemen en 
verwerken van ruimtelijke informatie). Uiteindelijk lijken de voortschrijdende ziekteprocessen 
ervoor te zorgen dat de ruime meerderheid van mensen met de ZvP zodanig ernstige en 
gevarieerde cognitieve problemen ontwikkelt dat er kan worden gesproken van parkinsonde-
mentie. Parkinsondementie geeft grote problemen in het alledaags functioneren en wordt in 
verband gebracht met andere psychische symptomen. Hoewel er al veel bekend is over de 
uitingsvorm en het beloop van cognitieve functiestoornissen bij de ZvP, mist er kennis over 
de grote verschillen tussen patiënten met deze problemen: het lijkt toch net wat complexer te 
liggen.
Het cognitieve ‘profiel’ van de ZvP – d.w.z. de gebieden waarop problemen worden ervaren 
– verschilt fors van persoon tot persoon. De executieve functiestoornissen staan lang niet bij 
elke persoon met de ZvP op de voorgrond en waar de ene persoon met de ZvP jaren na de 
diagnose nog weinig klachten ervaart, kan de andere persoon al na enkele jaren parkinson-
dementie ontwikkelen. Onderzoek heeft al aangetoond dat mensen met enkel executieve 
functiestoornissen een betere prognose hebben dan mensen die voornamelijk geheugen-
stoornissen en problemen in de visueel-ruimtelijke verwerking hebben. Ook lijkt het type 
motorische symptomen een voorspellende rol te hebben: mensen met balans- en loopstoor-
nissen bij de ZvP lijken een grotere kans op cognitieve achteruitgang te hebben ten opzichte 
van mensen die voornamelijk last van rusttremor hebben. Het vermoeden is dat gedeelde 
onderliggende ziekteprocessen bijdragen aan bepaalde profielen van cognitieve functie-
stoornissen, maar hier is tot op heden nog beperkt zicht op. 
In de onderzoeken die beschreven staan in hoofdstuk 2 en hoofdstuk 3 onderzochten wij 
een groep parkinsonpatiënten die op de polikliniek bewegingsstoornissen van het Amster-
dam UMC locatie VUmc waren geweest. Het doel was om meer zicht te krijgen op de variatie 
in cognitieve functiestoornissen en de bijdrage van verschillende onderliggende ziektepro-
cessen. Wij voerden in het onderzoek in hoofdstuk 2 een analyse uit die de volledige groep 
van 226 parkinsonpatiënten opsplitste op basis van de ernst en het profiel van cognitieve 
problemen: een clusteranalyse. Op basis van deze analyse vonden wij vier verschillende 
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subgroepen (Figuur 1). Groep 1 was relatief jong en gezond en groep 2 was relatief ouder met 
ernstige symptomen op verschillende vlakken. Daarnaast vonden wij twee groepen (3 en 4) 
met dezelfde leeftijd en ziektestadium, maar die verschillende profielen van cognitieve  
problemen hadden. Groep 3 had voornamelijk problemen in de executieve functies, waar 
groep 4 juist meer problemen had in het geheugendomein. Ook had groep 4 ernstigere 
motorische symptomen. Deze resultaten doen vermoeden dat de ZvP niet één ziektebeloop 
kent, maar verschillende – welke mogelijk ook informatie zouden kunnen geven over achter-
uitgang op de lange termijn. 
In hoofdstuk 3 beschrijven we een onderzoek naar de bijdrage van verschillende signaal- 
stoffen aan cognitieve problemen bij de ZvP. 129 parkinsonpatiënten hadden beeldvormend 
onderzoek van de hersenen ondergaan, genaamd een single-photon emission computed 
tomography (SPECT) scan. Zij hadden een radioactieve stof ingespoten gekregen die bindt 
aan bepaalde eiwitten in de hersenen, waaronder de dopaminetransporter en in mindere 
mate ook de serotoninetransporter. Deze transportereiwitten zijn belangrijk in het reguleren 
van de informatieoverdracht van signaalstoffen. De mate van radioactieve straling die ver-
volgens wordt opgevangen door de SPECT-scan geeft informatie over hoeveel van deze 
transportereiwitten aanwezig zijn, waarbij een lager opgevangen signaal impliceert dat dit 
signaalstofsysteem meer beschadigd is. Wij analyseerden hoe het cognitief functioneren 
samenhing met de integriteit van het dopaminerge signaalstofsysteem (in het striatum) en van 
het serotonerge signaalstofsysteem (in de thalamus en hippocampus – Figuur 2). We vonden 
dat voornamelijk de snelheid van informatieverwerking bij mensen met de ZvP samenhing 
met de aanwezigheid van dopamine in het striatum, maar dat het serotonerge signaalstof- 
systeem niet bijdroeg aan het cognitief functioneren. Deze resultaten suggereren dat het 
dopaminerge signaalstofsysteem mogelijk niet (enkel) belangrijk is voor de superviserende 













Figuur 1 De vier subgroepen met verschillende 
symptoomprofielen (hoofdstuk 1). Hoe verder van het 









Figuur 2 Schematische weergave van de gebieden 
waar in we hoofdstuk 3 onderzoek naar deden, met 




Het feit dat het serotoninesysteem beperkt invloed leek te hebben zou te maken kunnen 
hebben met de relatief zwakke bindingssterke die de radioactieve stof die wij gebruikten had 
voor de serotoninetransporter. 
Behandeling van cognitieve functiestoornissen in de ZvP 
Het tweede deel van dit proefschrift beschrijft onderzoek naar de behandeling van cognitieve 
stoornissen bij de ZvP. Er zijn zeer effectieve medicijnen voor de ZvP. Het meest bekende 
medicijn is levodopa – een middel wat ervoor zorgt dat er meer dopamine in de hersenen 
beschikbaar komt. Dit medicijn zorgt vroeg in het ziektebeloop voor minder ernstige mo-
torische symptomen en kan ook een positief effect hebben op de vroege cognitieve proble-
men. Helaas lijkt levodopa, naarmate de ziekte voortschrijdt, niet meer voldoende. Ten eerste 
zorgt de ziekteprogressie ervoor dat het doseren van levodopa ingewikkelder wordt en bij 
hoge doseringen kunnen vervelende bijwerkingen ontstaan – niet in de laatste plaats op cog-
nitief gebied. Ten tweede lijkt de ZvP de hersenen aan te tasten op veel meer vlakken dan 
alleen het dopaminerge systeem, zeker later tijdens het beloop van de ziekte.  
Recent is er voor de behandeling van cognitieve stoornissen meer aandacht voor cognitieve 
training. Cognitieve training is een revalidatiemethode waarbij door herhaalde uitdaging van 
het denkvermogen functies van het denkvermogen getraind worden. Cognitieve training gaat 
uit van veranderbaarheid van de hersenen (neuroplasticiteit). Het versterken van relevante 
hersenconnecties via neuroplasticiteit, of het compenseren van afgestorven connecties, zou 
kunnen zorgen voor verbetering van functioneren en vertraging van achteruitgang. Er is tot 
nu toe bij de ZvP slechts beperkt bewijs dat cognitieve training effectief is. Kleine studies 
hebben positieve effecten aangetoond, maar robuust, betrouwbaar bewijs mist nog. Ook 
weten we nog niet goed wat cognitieve training met de hersenen doet: worden de hersenen 
bijvoorbeeld gezonder, of lijken er compensatie-effecten plaats te vinden?
Om een antwoord te krijgen op deze openstaande vragen voerden wij een onderzoek uit om 
de effectiviteit van cognitieve training bij de ZvP te testen: de COGnitieve Training In Parkin-
son Studie (COGTIPS). In hoofdstuk 5 beschrijven we de manier waarop we het onderzoek 
uitvoerden. We verdeelden 140 mensen met de ZvP en klachten in het cognitief functioneren 
in twee gelijke groepen. De ene groep voerde de cognitieve training uit, waarbij ze elke trai- 
ningssessie dertien spellen deden die te maken hadden met de executieve functies, snelheid 
van het denken, geheugen en visuele verwerking. Deze spellen pasten zich aan het niveau 
van de deelnemer aan, zodat – wanneer mensen er beter in werden – de training uitdagend 
bleef. De tweede groep voerde de controletraining uit; zij voerden drie spellen uit die geen 
duidelijke trainingscomponent hadden – deze pasten zich niet aan het niveau van de deelne-
mer aan en richten zich niet specifiek op de cognitieve stoornissen. Beide groepen trainden 
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acht weken lang, driemaal per week op de computer. Deze training was in spelvorm, om de 
therapietrouw te stimuleren. 
Effect van cognitieve training op het denkvermogen. Vóór de training, na de training en 
zes maanden na afloop van de training brachten we het cognitief functioneren in kaart met 
testjes die het cognitief functioneren kunnen meten (een neuropsychologisch onderzoek). 
Op deze manier konden we het effect van de cognitieve training onderzoeken zoals be-
schreven in hoofdstuk 6. We zagen dat de deelnemers in beide groepen verbeterden in 
hun trainingsspellen. Dat geeft aan dat mensen met de ZvP leerbaar zijn wanneer zij nieuwe 
cognitieve activiteiten moeten verrichten. De deelnemers die de cognitieve training hadden 
uitgevoerd presteerden na acht weken beter op testjes waarbij snelheid van denken een rol 
speelt. Deze groep werd gemiddeld tot tien procent sneller na de training. Deze verbetering 
hing ook samen met verbetering op de trainingsspellen. Op andere gebieden van het  
denkvermogen, zoals geheugen of visuele verwerking, was er geen verschil tussen de groe-
pen. We zagen verder dat de deelnemers in beide groepen gemiddeld iets minder klachten 
in het denkvermogen ervaarden na hun training. Hierin verschilden beide groepen niet van 
elkaar. De analyse van langetermijneffecten liet bovendien zien dat zes maanden na afloop 
van de training de groepsverschillen niet meer aanwezig waren. De training lijkt dus kleine 
positieve effecten te hebben die echter niet blijvend zijn op de lange termijn. 
Effect van cognitieve training op de hersenen. Het effect van cognitieve training op de 
hersenen onderzochten we door gebruik te maken van hersenscanonderzoek met functio-
nele MRI-scans. Met een functionele MRI-scan wordt het zuurstofgehalte van bloed in de 
hersenen gemeten, wat op zijn beurt een schatting kan geven van de activiteit van her- 
sendelen. Middels deze scan kan de activiteit van de hersenen tijdens uitvoer van cognitieve 
tests worden onderzocht. Ook kan de functionele MRI-scan tijdens rust worden afgenomen 
om te onderzoeken welke hersengebieden spontaan synchroon actief en inactief zijn en zo-
doende lijken te communiceren. Deze communicatie is belangrijk omdat hersenen func- 
tioneren in netwerken: groepen van hersengebieden die gezamenlijk actief zijn en zo be- 
langrijke denkfuncties ondersteunen. 
We voerden we een literatuurstudie uit (hoofdstuk 4) waarbij we resultaten van eerder 
onderzoek naar het effect van cognitieve training op de hersenen combineerden. We zagen 
dat cognitieve training zorgde voor lagere hersenactiviteit bij gezonde ouderen, wat waar-
schijnlijk een teken is van efficiënter gebruik van de hersencapaciteit. Bij mensen met neu-
rodegeneratieve ziektes zorgde het voor verhoogde hersenactiviteit; waarschijnlijk duidend 
op versterking van het eerdergenoemde compensatiemechanisme. De communicatie van 
hersenengebieden verbeterde voorts na cognitieve training. 
Daarnaast onderging een subgroep van de deelnemers aan de COGnitieve Training In Parkin-
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son Studie (86 personen) een hersenscan voor en na de cognitieve training, om de effecten 
van onze cognitieve training op de hersenen te onderzoeken (hoofdstuk 7). In dit onderzoek 
zagen wij dat de cognitieve training geen effecten had op de communicatie van grote hersen-
netwerken. Wel zagen wij dat de communicatie van enkele specifieke hersengebieden die 
bij de ZvP vaak aangedaan zijn, wat beter leek te verlopen na de training. Dit waren echter 
relatief onzekere effecten en deze zullen verder onderzocht moeten worden voordat er veel 
betekenis aan gegeven kan worden. Dit resultaat komt overeen met het feit dat de effecten 
van onze training op het cognitief functioneren ook relatief klein waren.
Verbeterpunten en toekomstig onderzoek 
Aan het onderzoek beschreven in dit proefschrift zaten enkele verbeterpunten die kunnen 
worden meegenomen voor toekomstig onderzoek, zoals ook beschreven in de discussie 
(hoofdstuk 8). Hoewel we relatief grote groepen deelnemers hadden, lijken nog grotere 
groepen nodig om een goed beeld te krijgen van de verscheidenheid van cognitieve stoor-
nissen die voorkomt bij de ZvP. Idealiter zou de clusteranalyse die we hebben uitgevoerd 
worden herhaald in een onafhankelijke groep parkinsonpatiënten, om de betrouwbaar- 
heid hiermee te verhogen. Ook zou het interessant zijn de subgroepen over langere tijd te 
monitoren, zodat ook meer duidelijk wordt over verschillen in het ziektebeloop. Tot slot zou 
aanvullend hersenscanonderzoek meer informatie kunnen geven over de processen die aan 
de subgroepen ten grondslag liggen. Wat betreft het onderzoek naar de signaalstofsyste-
men die betrokken zijn bij cognitieve functiestoornissen in de ZvP is onderzoek met andere 
radioactieve stoffen nodig die beter binden aan het serotonerge systeem, maar ook andere 
signaalstofsystemen die mogelijk betrokken zijn bij de ZvP. 
Aangaande de behandeling van cognitieve functiestoornissen bij de ZvP was dit onderzoek 
het eerste grootschalige onderzoek naar cognitieve training. Er is debat over de vraag in  
hoeverre cognitieve functietraining, zoals wij onderzocht hebben, effectief is in het ver-
beteren van klachten in het dagelijks leven en ons onderzoek gaf ook geen bewijs hiervoor. 
Het feit dat de groep deelnemers die we onderzochten sterke variatie toonde in de mate 
van cognitieve problemen kan de betrouwbaarheid van de resultaten enigszins hebben ver-
stoord. In toekomstig onderzoek is het verder belangrijk om te onderzoeken of een hogere 
intensiteit of langere duur van de training een groter effect geeft. Om verder de effectiviteit 
van cognitieve training te verbeteren zou kunnen worden gedacht aan combinatie-interven-
ties, zoals cognitieve training samen met intensieve fysieke activiteit of gelijktijdige stimulatie 
van de hersenen, of aan trainingsonderdelen die meer gericht zijn op de taken die in het 





CV & List of publications
Curriculum vitae
Tim studied Psychology at Utrecht University. He graduated with his bachelor's degree Psy-
chology, with the neuropsychology specialization, in 2013 and received his master's degree 
Neuropsychology in 2015. During his master's, Tim did his clinical internship at the Neuropsy-
chology department of the Erasmus Medical Center under supervision of Lize Jiskoot and his 
scientific internship at Odile van den Heuvel and Ysbrand van der Werf's Neuropsychiatry lab 
at the Anatomy & Neuroscience department, under supervision of Chris Vriend.
In December 2014, Tim was appointed as research assistant at the Center Neuropsychiatry 
Parkinson, an outpatient clinic focused on neuropsychiatric symptoms of Parkinson's disease 
at the Amsterdam UMC (location VUmc). In March 2015, Tim started his PhD trajectory in the 
same lab, under supervision of Odile van den Heuvel, Henk Berendse, Chris Vriend and Ys-
brand van der Werf. In his PhD trajectory he focused on the profiles and practice of cognitive 
function in Parkinson's disease (see this book). In April 2016, Tim started the residency in 
Health care psychology (GZ-opleiding) at GGZ inGeest, with internships at the Amsterdam 
UMC, location VUmc outpatient clinic for psychosomatic disorders and the GGZ inGeest out-
patient clinic for Anxiety and Depression, Haarlem. He finished his residency in March 2020.
As of November 2020, Tim is working part-time as scientific researcher/post-doc on the 
COGnitive Training In Parkinson Study. Starting December 2020, Tim additionally started his 
position at Altrecht, Center for Psychodiagnostics, with a focus on neuropsychological assess-





van Balkom TD, van den Heuvel OA, Berendse HW, van der Werf YD, Vriend C. The Effects of Cognitive 
Training on Brain Network Activity and Connectivity in Aging and Neurodegenerative Diseases: a System-
atic Review. Neuropsychology Review 2020; 30: 267-286.
Vriend C, van Balkom TD, van Druningen C, Klein M, van der Werf YD, Berendse HW, van den Heuvel OA. 
Processing speed is related to striatal dopamine transporter availability in Parkinson’s disease. NeuroIm-
age: Clinical 2020; 26: 102257.
Vriend C, van Balkom TD, van den Heuvel OA. De neurale correlaten van cognitieve-functietraining bij 
ziekte en gezondheid. Neuropraxis 2020; 24(1): 2-9.
van Balkom TD, Berendse HW, van der Werf YD, Twisk JWR, Zijlstra I, Hagen RH, Berk T, Vriend C, van 
den Heuvel OA. COGTIPS: a double-blind randomized active controlled trial protocol to study the effect 
of home-based, online cognitive training on cognition and brain networks in Parkinson’s disease. BMC 
Neurology 2019; 19(1): 1-13.
van Balkom TD, Vriend C, Berendse HW, Foncke EMJ, van der Werf YD, van den Heuvel OA, Klein M. 
Profiling cognitive and neuropsychiatric heterogeneity in Parkinson’s disease. Parkinsonism & Related 
Disorders 2016; 28: 130-136.
Preprints
van Balkom TD, Berendse HW, van der Werf YD, Twisk JWR, Peeters CFW, Hagen RH, Berk T, van den 
Heuvel OA, Vriend C. Effect of Eight-Week Online Cognitive Training in Parkinson’s Disease: A Random-
ized Controlled Trial. medRxiv 2021; 2021.03.04.21252499. (under review at Neurology)
Vriend C, van Balkom TD, Berendse HW, van der Werf YD, van den Heuvel OA. Cognitive training in 
Parkinson’s disease induces local, not global, changes in white matter microstructure. medRxiv 2021; 
2021.04.23.21255914. (accepted at Neurotherapeutics)
Under review
van Balkom TD, van den Heuvel OA, Berendse HW, van der Werf YD, Vriend C. Eight-week multi-domain 






In de afgelopen ruim zes jaar die ik aan mijn promotieonderzoek heb besteed heb ik hulp, 
steun, afleiding, inspiratie en aanmoediging gehad van veel inspirerende mensen in mijn 
omgeving, zonder wie ik deze uitdaging niet had kunnen voltooien. 
Allereerst wil ik mijn dankbaarheid en respect uiten naar alle deelnemers die ik gedurende 
deze jaren ben tegengekomen. Een groot aantal mensen met de ziekte van Parkinson heeft 
deelgenomen aan de verschillende onderzoeken binnen ons team, waaronder COGTIPS. Ik 
heb onze deelnemers leren kennen als een hechte, betrokken community die onbaatzuchtig 
deelnamen aan wetenschappelijk onderzoek voor diegenen die in de toekomst dezelfde 
diagnose zullen krijgen. In de onderzoekskamers heb ik enthousiasme over lopende pro-
jecten en eigen initiatieven voorbij zien komen, maar ook verdriet bij confrontatie met eigen 
grenzen, irritatie na lange taken en angst voor hetgeen komen gaat. Ik heb ontzettend veel 
bijzondere mensen mogen ontmoeten en ben dankbaar voor deze ervaringen.
Odile, Henk, Chris en Ysbrand, ik had mij geen beter promotieteam kunnen wensen. Hoewel 
het lastig is om de waardering voor de afgelopen zes jaar in enkele zinnen te verwoorden, 
hier een poging. Odile, vanaf het begin van mijn stage binnen team Neuropsychiatrie heb 
ik betrokkenheid gevoeld bij de stappen die ik op professioneel en persoonlijk vlak heb 
gemaakt. Je hebt oog voor de belangrijke momenten, al zijn ze nog zo klein. Je hebt een 
vermogen om te motiveren, kan aanjagen en begrenzen, en denkt in mogelijkheden vanuit 
een aanstekelijk enthousiasme. Vele meetings die wij hebben gehad liep ik met eenzelfde 
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enthousiasme de (digitale) deur uit. Ik weet na al die jaren nog steeds niet hoe je alles op een 
rijtje houdt, maar veel respect voor jou als wetenschapper, clinicus en mens. 
Chris, vanaf het begin van mijn stage tot de laatste momenten van mijn promotietraject ben 
je ontzettend belangrijk geweest. Het was bijzonder leuk om op jouw eerste project als PI te 
werken en om jouw snelle ontwikkeling na je eigen promotie mee te maken. Je onbegrensde 
energie en wetenschappelijke creativiteit zijn inspirerend en ontzagwekkend, maar je per-
soonlijke betrokkenheid is minstens net zo speciaal om te vinden in een supervisor. Ondanks 
het feit dat in de loop van de tijd je takenpakket uitbreidde en je een onmisbare schakel in 
vrijwel alle trials en projecten bent geworden, had je altijd een (ruim) moment. In de coro-
naperiode heb ik dan ook onze koffietjes gemist! Wanneer je je avontuurlijk voelt en de ring 
van Amsterdam uit gaat: in 030 ben je altijd welkom. En ik denk dat jouw eigen woorden dit 
het beste zeggen: collega, broer, vriend – bedankt! 
Henk, veel dank voor je betrokken begeleiding. De MDO’s waar ik bij kon aansluiten, het 
spreekuur waar ik bij kon meelopen, de parkinsonmeetings: ik heb veel van je geleerd. Ook 
denk ik dat je een ontzettend waardevol lid van mijn promotieteam en ook COGTIPS bent 
geweest, met vaak scherpe vragen en een realistische blik. Je bracht nuance aan wanneer 
nodig, maar was altijd constructief en meedenkend. Ys, tot slot ook veel dank aan jou. Ik 
heb veel geleerd van je neurowetenschappelijke kennis, uitzonderlijke presentatieskills en 
prachtige Engelse accent, je vermogen om politiek correct je punt te maken en je onuitput-
telijke ideeën. Een professor pur sang: creatief, ontzettend intelligent, kundig en enigszins 
verstrooid. Het is inspirerend om een hoofdstuk mee te hebben gemaakt van hoe je samen 
met Odile, van een uitwisseling van ideeën in de medische faculteit, tot een enorm onder-
zoeksteam bent gekomen, waarin jullie een indrukwekkende productie combineren met een 
– mijns inziens – bijzonder fijn werkklimaat. 
Bij dezen wil ik ook mijn dank uiten aan alle leden van de leescommissie voor het lezen van 
dit proefschrift: Jan Smit, Gert Geurtsen, Rick Helmich, Bob van Hilten, Hanneke Hulst en 
Joke Spikman.
Dit proefschrift was er bij lange na niet geweest zonder team COGTIPS. Ik wil de project-
groep, met behalve mijn promotieteam ook Tanja Berk, Rob Hagen en Ursula Klumpers, 
bedanken. Tanja en Rob, en met jullie ook collega-patiëntonderzoekers, het feit dat jullie zo 
betrokken zijn vanaf de opzet van onderzoek naar de ziekte van Parkinson is uniek en voegt 
veel toe. Ook mijn dank aan Jos Twisk en Carel Peeters voor de zeer waardevolle input op 
het gebied van de statistische analyses; statistiek is in eerste instantie mijn drijfveer geweest 




Essentieel onderdeel van het team was het COGTIPS-leger: Anne, Annewies, Anouk T, Anouk 
van W, Bernardo, Brechje, Dagmar, Eline K, Eline V, Dimitri, Kavita, Liza, Fieke, Iman, Iris, 
Jasmijn, Jochem, Julia B, Julia V, Margot, Marte, Max, Meggie, Melissa, Monique, Nina, Phil, 
Rishendly, Selina en Vera, en de pilotsquad met Fabienne, Charlotte, Elizabeth, Emma en Mar-
tine. Bijna dagelijks was de zoetgevooisde stem van het COGTIPS-rolkoffertje hoorbaar wan-
neer deze van het O2-gebouw naar de Oldenaller reed voor een meting. Jullie hebben zó 
een grote rol in het onderzoek gespeeld en bijgedragen aan het bijzonder soepel verlopen 
van dit grote project; mijn dank hiervoor is groot. Jullie hebben mij veel geleerd en ik heb de 
hoop dat dit andersom ook het geval is. 
Ook dank aan de gebruikerscommissie van COGTIPS, met hierin naast de projectleden ook 
Hans Bosboom, Gert Geurtsen, Willem Oudegeest en Els van der Rhee. Daarnaast wil ik ook 
mijn dank uiten naar Ben Schmand, Jaap Murre en Jessica Buitenweg voor de adviezen in 
de opzet van dit onderzoek, aan Louis Kinsbergen en collega’s van Dezzel voor het ontwerp 
van de cognitieve training, en aan de nog niet genoemde co-auteurs van de artikelen in dit 
proefschrift, Corné van Druningen, Elisabeth Foncke en Martin Klein.
Bedankt team Neuropsychiatrie voor de prachtige jaren die ik hier heb gehad. Bedankt aan 
de oude garde, de medische faculteitgroep: Anita, Froukje, Kathleen, James, Mardien,  
Merijn, Niels G, Premika, Sarah, Sonja, Stella. De twee weggestopte hokjes waar we werkten 
ademden niet alleen wetenschap, maar ook familiegevoel en gezelligheid. Speciale dank 
aan Sonja, voor de kans een zomerstage bij jou en Chris te doen en later samen te werken 
op het beruchte lichttherapieproject. Bedankt Dilene en Hein, takk Anders en veel dank aan 
mijn huidige collega-promovendi, de Loetjesquad: Cees, Christa, Elvira, Emma, Inga, Ires, Jari, 
Max, Niels de J, Selina, Sophie, Tjardo en Veerle. Zo veel projecten, zo veel drukte, maar dat 
iedereen desondanks voor elkaar klaarstaat is uniek en was in de periode van lockdown nog 
eens goed te merken. Het was leuk als team retraites en symposia te bezoeken en in 2020 
op het nippertje nog samen een weekendje weg te gaan. Niels, wanneer je knie weer de 
oude is moeten we het maar eens hebben over een transfersom zodat je onze defensie kan 
komen versterken. Cees, bedankt dat je mij wil bijstaan als paranimf tijdens mijn verdediging. 
Met jouw vaderschapskwaliteiten aan mijn zijde hoef ik mij nergens zorgen over te maken. 
Ook wil ik mijn ANW-collega’s van de andere onderzoeksteams en het secretariaat bedanken. 
Ook de afdeling O&I van GGZ inGeest, in het bijzonder team veldwerk en Margie, Ton en de 
andere gastheren/-dames, voor de ondersteuning bij de vele metingen die wij in de Oldenal-
ler hebben mogen uitvoeren en voor de fijne ontvangst die wij en onze deelnemers konden 
verwachten. En de collega’s van ONWAR en Amsterdam Neuroscience voor alle uitstekend 
geregelde cursussen en symposia. Patricia, bedankt voor de kans om de GZ-opleiding te 
doen parallel aan mijn promotietraject. Ook dank aan de prettige en ontzettend leerzame 
samenwerking met collega’s van de polikliniek Ziekenhuispsychiatrie van Amsterdam UMC 
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locatie VUmc, en de polikliniek Angst & Depressie Haarlem van GGZ inGeest, in het bijzonder 
aan Marga Kuiper, Michel Reinders, Mechteld Baars en Willemijn Tybout. 
Tot slot, en minstens net zo belangrijk, wil ik mijn familie buiten het werkzame leven bedan-
ken voor de interesse in mijn werk, steun in stressvolle periodes en broodnodige afleiding. 
Allereerst Sterrenwijk ZA2: Hoekie, Leguaan, Ruub, Paultje, Mechtus, Basmaat, Markus, Njio, 
Knarfie, Toekan, D’André, Vinnie Shoeba, Wally, Roel, Bram, Vincent, Campie, Ellie, Jerry, Gijs, 
Huge, Len, Merijn, Sven. Al zo’n vijftien jaar mijn zaterdagfamilie. Ook al worden we oud, het 
blijft als vanouds. Zelfs met een kapotte knie was ik welkom – om te vlaggen. Voetbal blijft 
mijn alles en niet in de laatste plaats door jullie. Hoekie, supermooi dat je bij mijn ver- 
dediging aan mijn zijde zal staan! En Rein en Roel, dank voor de interessante gesprekken en 
discussies, de gezellige uitjes, de avonden gamen. Zelfs bij koude is de gevoelstemperatuur 
aangenaam. Ave! Bedankt aan familie Van Balkom, opdat we elkaar nog vaak mogen ont- 
moeten op de Mozartsingel, en familie Van Mastrigt. En uiteraard mijn nieuwe familie: Anja (en 
Lobke), Huub en Lenny, Luuk (UUU) en Mieke. Mooi om te zien hoe jullie in het leven staan, 
hoe jullie avonturen aangaan, onzekerheid niet ontlopen en enthousiast nieuwe ervaringen 
opdoen – ik kan daar nog veel van leren.
Lieve pap en mam, bedankt voor jullie onvoorwaardelijke steun. Welke stap ik ook neem, ik 
voel dat jullie me daarin steunen. En elke stap die ik neem, krijg ik meer bewondering voor 
alles wat jullie doen. Ik heb altijd de vrijheid gevoeld om nieuwe dingen te proberen en jullie 
stimulans heeft mij veel gebracht. Het is fijn met jullie te kunnen praten over wat ik doe, maar 
het is net zo fijn dat het hier niet altijd over hoeft te gaan en we ook gezellig kunnen praten 
en spelletjes spelen. Ik mag mij gelukkig prijzen met zulke ouders. Lieve Korin en Daan, jullie 
inspireren mij door jullie werk, als koppel en als persoon. Korin, heel gaaf dat je mijn kaft hebt 
willen maken – ik ben er supertrots op. Duizendmaal dank!
Lieve Anouk, bedankt voor de keren dat je dat je erbij was bij een presentatie, dat je mij 
steunde wanneer het even zwaar was, dat je mij verdroeg wanneer ik gestrest was, dat je 
een huishoudkaartje overnam wanneer ik laat thuiskwam. Wat de toekomst ook brengt, 
samen komt het wel goed. Ik voel dat je trots op me bent en andersom is dat ontegenzegge- 
lijk ook waar. Ik ben benieuwd naar ons volgende avontuur in Australië en ben heel blij dat jij 
straks als mijn vrouw aanwezig zal zijn bij mijn verdediging. 
Lieve Omama, het betekent veel voor me dat u dit boek nog in manuscriptvorm heeft kunnen 
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